loss	NN	B-NegReg	B-NegReg
-	:	I-NegReg	I-NegReg
of	IN	I-NegReg	I-NegReg
-	:	I-NegReg	I-NegReg
function	NN	I-NegReg	I-NegReg
mutations	NNS	B-Var	B-Var
DGAT1	NNP	B-Gene	B-Gene
congenital	JJ	B-Disease	O
diarrhea	NN	I-Disease	O
protein	NN	B-Disease	O
-	:	I-Disease	O
losing	NN	I-Disease	O
enteropathy	NN	I-Disease	O

Here	RB	O	O
we	PRP	O	O
identify	VBP	O	O
a	DT	O	O
previously	RB	O	O
unknown	JJ	O	O
DGAT1	NNP	O	O
mutation	NN	O	O
in	IN	O	O
identical	JJ	O	O
twins	NNS	O	O
of	IN	O	O
South	NNP	O	O
Asian	JJ	O	O
descent	NN	O	O
.	.	O	O

These	DT	O	O
male	JJ	O	O
patients	NNS	O	O
developed	VBD	O	O
watery	JJ	O	O
diarrhea	NN	O	O
shortly	RB	O	O
after	IN	O	O
birth	NN	O	O
,	,	O	O
with	IN	O	O
protein	JJ	O	O
-	:	O	O
losing	VBG	O	O
enteropathy	JJ	O	O
and	CC	O	O
failure	NN	O	O
to	TO	O	O
thrive	VB	O	O
.	.	O	O

Exome	NNP	O	O
sequencing	NN	O	O
revealed	VBD	O	O
a	DT	O	O
homozygous	JJ	O	O
recessive	JJ	O	O
mutation	NN	O	O
in	IN	O	O
DGAT1	NNP	O	O
,	,	O	O
c	NN	O	B-Var
.	.	O	I-Var
314	CD	O	I-Var
T	NNP	O	I-Var
C	NNP	O	O
,	,	O	O
p	NN	O	O
.	.	O	O
L105P	NNP	O	O
.	.	O	O

We	PRP	O	O
show	VBP	O	O
here	RB	O	O
that	IN	O	O
the	DT	O	O
p	NN	B-Var	B-Var
.	.	I-Var	I-Var
L105P	NNP	I-Var	I-Var
DGAT1	NNP	B-Gene	O
enzyme	NN	O	O
produced	VBN	O	O
from	IN	O	O
the	DT	O	O
mutant	JJ	B-Var	O
allele	NN	O	O
is	VBZ	O	O
less	RBR	B-NegReg	O
abundant	JJ	O	O
,	,	O	O
resulting	VBG	O	O
in	IN	O	O
partial	JJ	O	B-Gene
loss	NN	B-NegReg	B-NegReg
of	IN	O	O
TG	NNP	B-MPA	O
synthesis	NN	I-MPA	O
activity	NN	I-MPA	O
and	CC	O	O
decreased	JJ	B-NegReg	O
formation	NN	B-MPA	O
of	IN	I-MPA	O
lipid	JJ	I-MPA	O
droplets	NNS	I-MPA	O
in	IN	O	O
patient	JJ	O	O
-	:	O	O
derived	VBN	O	O
primary	JJ	O	O
dermal	JJ	O	O
fibroblasts	NNS	O	O
.	.	O	O
Thus	RB	O	O
,	,	O	O
in	IN	O	O
contrast	NN	O	O
with	IN	O	O
complete	JJ	O	O
loss	NN	O	O
-	:	O	O
of	IN	O	O
-	:	O	O
function	NN	O	O
alleles	NNS	O	O
of	IN	O	O
DGAT1	NNP	O	O
,	,	O	O
the	DT	O	O
p	NN	B-Var	B-Var
.	.	I-Var	I-Var
L105P	NNP	I-Var	I-Var
missense	NN	I-Var	O
allele	NN	O	O
partially	RB	O	O
reduces	VBZ	B-NegReg	B-NegReg
TG	NNP	B-MPA	B-MPA
synthesis	NN	I-MPA	I-MPA
activity	NN	I-MPA	I-MPA
and	CC	O	O
causes	VBZ	B-Reg	O
a	DT	O	O
less	RBR	B-MPA	O
severe	JJ	I-MPA	O
clinical	JJ	I-MPA	O
phenotype	NN	I-MPA	O
.	.	O	O
Our	PRP$	O	O
findings	NNS	O	O
add	VBP	O	O
to	TO	O	O
the	DT	O	O
growing	VBG	O	O
recognition	NN	O	O
of	IN	O	O
DGAT1	NNP	B-Gene	O
deficiency	NN	B-Var	O
as	IN	O	O
a	DT	O	O
cause	NN	B-Reg	O
of	IN	O	O
congenital	JJ	B-Disease	O
diarrhea	NN	I-Disease	O
with	IN	O	O
protein	JJ	B-Disease	O
-	:	I-Disease	O
losing	VBG	I-Disease	O
enteropathy	JJ	I-Disease	O
and	CC	O	O
indicate	VBP	O	O
that	IN	O	O
DGAT1	NNP	B-Gene	O
mutations	NNS	B-Var	O
result	VBP	B-Reg	O
in	IN	I-Reg	O
a	DT	O	O
spectrum	NN	B-Disease	O
of	IN	I-Disease	O
diseases	NNS	I-Disease	O

indel	NN	I-Var	O
mutation	NN	I-Var	O
CDH11	NNP	B-Gene	O
cause	NN	B-Reg	O
Elsahy	NNP	B-Disease	O
-	:	I-Disease	O
Waters	VBZ	I-Disease	O
Two	CD	I-Disease	O

Both	DT	O	O
had	VBD	O	O
glaucoma	NN	O	O
,	,	O	O
younger	JJR	O	O
one	CD	O	O
also	RB	O	O
had	VBD	O	O
cataracts	NNS	O	O
and	CC	O	O
phthisis	NN	O	O
bulbi	NN	O	O
.	.	O	O

Other	JJ	O	O
findings	NNS	O	O
included	VBD	O	O
bilateral	JJ	O	O
partial	JJ	O	O
cutaneous	JJ	O	O
syndactyly	NN	O	O
of	IN	O	O
2	CD	O	O
nd	NNS	O	O
and	CC	O	O
3	CD	O	O
rd	NN	O	O
fingers	NNS	O	O
,	,	O	O
history	NN	O	O
of	IN	O	O
impacted	JJ	O	O
teeth	NNS	O	O
with	IN	O	O
dentigerous	JJ	O	O
cyst	NN	O	O
in	IN	O	O
the	DT	O	O
elder	NN	O	O
one	CD	O	O
,	,	O	O
and	CC	O	O
intellectual	JJ	O	O
disability	NN	O	O
(	(	O	O
mild	JJ	O	O
and	CC	O	O
borderline	NN	O	O
)	)	O	O
.	.	O	O

The	DT	O	O
sisters	NNS	O	O
were	VBD	O	O
considered	VBN	O	O
to	TO	O	O
have	VB	O	O
Elsahy	NNP	O	O
-	:	O	O
Waters	VBZ	O	O
syndrome	JJ	O	O
.	.	O	O

In	IN	O	O
order	NN	O	O
to	TO	O	O
elucidate	VB	O	O
the	DT	O	O
underlying	JJ	O	O
molecular	JJ	O	O
cause	NN	O	O
,	,	O	O
sisters	NNS	O	O
and	CC	O	O
their	PRP$	O	O
healthy	JJ	O	O
parents	NNS	O	O
were	VBD	O	O
genotyped	VBN	O	O
by	IN	O	O
SNP	NNP	O	O
arrays	NNS	O	O
,	,	O	O
followed	VBN	O	O
by	IN	O	O
homozygosity	NN	O	O
mapping	NN	O	O
.	.	O	O

Homozygous	JJ	O	O
regions	NNS	O	O
were	VBD	O	O
further	RB	O	O
analyzed	VBN	O	O
by	IN	O	O
exome	JJ	O	O
sequencing	NN	O	O
in	IN	O	O
one	CD	O	O
affected	JJ	O	O
individual	NN	O	O
.	.	O	O

A	DT	O	O
homozygous	JJ	O	O
indel	NN	O	O
variant	NN	O	O
segregating	VBG	O	O
with	IN	O	O
the	DT	O	O
condition	NN	O	O
was	VBD	O	O
detected	VBN	O	O
in	IN	O	O
CDH11	NNP	O	O
(	(	O	O
c	NN	O	O
.	.	O	O
1116	CD	O	O
_	JJ	O	O
1117	CD	O	O
delinsGATCATCAG	NN	O	O
,	,	O	O
p	NN	O	O
.	.	O	O

(	(	O	O
Ile372MetfsTer9	NNP	O	O
))	NNP	O	O
,	,	O	O
which	WDT	O	O
was	VBD	O	O
then	RB	O	O
validated	VBN	O	O
by	IN	O	O
using	VBG	O	O
Sanger	NNP	O	O
sequencing	NN	O	O
.	.	O	O

CDH11	NNP	O	O
encodes	VBZ	O	O
cadherin	JJ	O	O
11	CD	O	O
(	(	O	O
osteo	SYM	O	O
-	:	O	O
cadherin	NN	O	O
)	)	O	O
that	WDT	O	O
regulates	VBZ	O	O
cell	VBP	O	O
-	:	O	O
cell	NN	O	O
adhesion	NN	O	O
,	,	O	O
cell	NN	O	O
polarization	NN	O	O
and	CC	O	O
migration	NN	O	O
,	,	O	O
as	RB	O	O
well	RB	O	O
as	IN	O	O
osteogenic	JJ	O	O
differentiation	NN	O	O
.	.	O	O

Further	JJ	O	O
experiments	NNS	O	O
revealed	VBD	O	O
that	IN	O	O
CDH11	NNP	O	O
expression	NN	O	O
was	VBD	O	O
decreased	VBN	O	O
in	IN	O	O
patient	JJ	O	O
-	:	O	O
derived	JJ	O	O
fibroblasts	NNS	O	O
as	IN	O	O
compared	VBN	O	O
to	TO	O	O
the	DT	O	O
heterozygous	JJ	O	O
parent	NN	O	O
and	CC	O	O
another	DT	O	O
healthy	JJ	O	O
donor	NN	O	O
.	.	O	O

Immunostaining	VBG	O	O
showed	VBD	O	O
absence	NN	O	O
of	IN	O	O
the	DT	O	O
protein	NN	O	O
expression	NN	O	O
in	IN	O	O
patient	JJ	O	O
fibroblasts	NNS	O	O
.	.	O	O

In	IN	O	O
addition	NN	O	O
,	,	O	O
cell	NN	B-CPA	B-CPA
proliferation	NN	I-CPA	I-CPA
rate	NN	I-CPA	I-CPA
was	VBD	O	O
slow	JJ	B-NegReg	O
and	CC	O	O
osteogenic	JJ	B-CPA	O
differentiation	NN	I-CPA	O
potential	NN	I-CPA	O
was	VBD	O	O
delayed	VBN	B-NegReg	O
.	.	O	O
We	PRP	O	O
consider	VBP	O	O
that	IN	O	O
this	DT	O	O
study	NN	O	O
reveals	VBZ	O	O
loss	NN	O	O
-	:	O	O
of	IN	O	O
-	:	O	O
function	NN	O	O
mutations	NNS	B-Var	O
in	IN	O	O
CDH11	NNP	B-Gene	O
as	IN	O	O
a	DT	O	O
probable	JJ	O	O
cause	NN	O	O
of	IN	O	O
this	DT	O	O
phenotype	NN	O	O
.	.	O	O
Next	JJ	O	O
generation	NN	O	O
sequencing	VBG	O	O
in	IN	O	O
further	JJ	O	O
patients	NNS	O	O
would	MD	O	O
both	DT	O	O
prove	VB	O	O
this	DT	O	O
gene	NN	O	O
as	IN	O	O
causative	JJ	O	O
,	,	O	O
and	CC	O	O
finely	RB	O	O
delineate	VB	O	O
this	DT	O	O
clinical	JJ	O	O
spectrum	NN	O	O
further	RBR	O	O
contributing	NN	O	O
in	IN	O	O
identification	NN	O	O
of	IN	O	O
other	JJ	O	O
possibly	RB	O	O
involved	VBN	O	O
gene	NN	O	O
(	(	O	O
s	JJ	O	O
)	)	O	O

Here	RB	O	O
we	PRP	O	O
investigate	VBP	O	O
the	DT	O	O
molecular	JJ	O	O
basis	NN	O	O
of	IN	O	O
sleep	JJ	O	O
need	NN	O	O
using	VBG	O	O
quantitative	JJ	O	O
phosphoproteomic	JJ	O	O
analysis	NN	O	O
of	IN	O	O
the	DT	O	O
sleep	JJ	O	O
-	:	O	O
deprived	VBN	O	O
and	CC	O	O
Sleepy	NNP	O	O
mouse	VBP	O	O
models	NNS	O	O
of	IN	O	O
increased	JJ	O	O
sleep	JJ	O	O
need	NN	O	O
.	.	O	O

Sleep	JJ	O	O
deprivation	NN	O	O
induces	NNS	O	B-Reg
cumulative	JJ	O	I-Reg
phosphorylation	NN	O	B-MPA
of	IN	O	O
the	DT	O	O
brain	NN	O	O
proteome	NN	O	O
,	,	O	O
which	WDT	O	O
dissipates	VBZ	O	O
during	IN	O	O
sleep	NN	O	O
.	.	O	O

Sleepy	NNP	O	O
mice	NN	O	O
,	,	O	O
owing	VBG	O	O
to	TO	O	O
a	DT	O	O
gain	NN	B-PosReg	O
-	:	I-PosReg	O
of	IN	I-PosReg	O
-	:	I-PosReg	O
function	NN	I-PosReg	O
mutation	NN	B-Var	O
in	IN	O	O
the	DT	O	O
Sik3	NNP	B-Gene	O
gene	NN	O	O
12	CD	O	O
,	,	O	O
have	VBP	O	O
a	DT	O	O
constitutively	RB	O	O
high	JJ	O	O
sleep	VBP	O	O
need	VBP	O	O
despite	IN	O	O
increased	VBN	O	O
sleep	NN	O	O
amount	NN	O	O
.	.	O	O
The	DT	O	O
brain	NN	B-Protein	O
proteome	NN	I-Protein	O
of	IN	O	O
these	DT	O	O
mice	NNS	O	O
exhibits	NNS	O	O
hyperphosphorylation	NN	B-MPA	O
,	,	O	O
similar	JJ	O	O
to	TO	O	O
that	DT	O	O
seen	VBN	O	O
in	IN	O	O
the	DT	O	O
brain	NN	O	O
of	IN	O	O
sleep	JJ	O	O
-	:	O	O
deprived	VBN	O	O
mice	NN	O	O
.	.	O	O
Comparison	NNP	O	O
of	IN	O	O
the	DT	O	O
two	CD	O	O
models	NNS	O	O
identifies	NNS	O	O
80	CD	O	O
mostly	RB	O	O
synaptic	JJ	O	O
sleep	NN	O	O
-	:	O	O
need	NN	O	O
-	:	O	O
index	NN	O	O
phosphoproteins	NNS	O	O
(	(	O	O
SNIPPs	NNP	O	O
)	)	O	O
,	,	O	O
in	IN	O	O
which	WDT	O	O
phosphorylation	NN	O	O
states	NNS	O	O
closely	RB	O	O
parallel	JJ	O	O
changes	NNS	O	O
of	IN	O	O
sleep	JJ	O	O
need	NN	O	O
.	.	O	O

SLEEPY	NNP	O	O
,	,	O	O
the	DT	O	O
mutant	JJ	B-Var	O
SIK3	NNP	B-Gene	O
protein	NN	B-Protein	O
,	,	O	O
preferentially	RB	B-PosReg	O
associates	VBZ	B-Interaction	O
with	IN	I-Interaction	O
and	CC	O	O
phosphorylates	NNS	B-MPA	O
SNIPPs	NNP	B-Protein	O
.	.	O	O
Inhibition	NN	O	O
of	IN	O	O
SIK3	NNP	O	B-MPA
activity	NN	O	I-MPA
reduces	VBZ	O	B-NegReg
phosphorylation	NN	O	B-MPA
of	IN	O	O
SNIPPs	NNP	O	O
and	CC	O	O
slow	JJ	O	O
wave	NN	O	O
activity	NN	O	O
during	IN	O	O
non	JJ	O	O
-	:	O	O
rapid	JJ	O	O
-	:	O	O
eye	NN	O	O
-	:	O	O
movement	NN	O	O
sleep	NN	O	O
,	,	O	O
the	DT	O	O
best	JJS	O	O
known	VBN	O	O
measurable	JJ	O	O
index	NN	O	O
of	IN	O	O
sleep	JJ	O	O
need	NN	O	O
,	,	O	O
in	IN	O	O
both	DT	O	O
Sleepy	NNP	O	O
mice	NN	O	O
and	CC	O	O
sleep	JJ	O	O
-	:	O	O
deprived	VBN	O	O
wild	JJ	O	O
-	:	O	O
type	NN	O	O
mice	NN	O	O
.	.	O	O

Our	PRP$	O	O
results	NNS	O	O
suggest	VBP	O	O
that	IN	O	O
phosphorylation	NN	O	O
of	IN	O	O
SNIPPs	NNP	O	O
accumulates	NNS	O	O
and	CC	O	O
dissipates	NNS	O	O
in	IN	O	O
relation	NN	O	O
to	TO	O	O
sleep	VB	O	O
need	NN	O	O
,	,	O	O
and	CC	O	O
therefore	RB	O	O
SNIPP	NNP	O	O
phosphorylation	NN	O	O
is	VBZ	O	O
a	DT	O	O
molecular	JJ	O	O
signature	NN	O	O
of	IN	O	O
sleep	JJ	O	O
need	NN	O	O
.	.	O	O

Whereas	IN	O	O
waking	VBG	O	O
encodes	NNS	O	O
memories	NNS	O	O
by	IN	O	O
potentiating	VBG	O	O
synapses	NNS	O	O
,	,	O	O
sleep	JJ	O	O
consolidates	NNS	O	O
memories	NNS	O	O
and	CC	O	O
restores	NNS	O	O
synaptic	JJ	O	O
homeostasis	NN	O	O
by	IN	O	O
globally	RB	O	O
downscaling	VBG	O	O
excitatory	NN	O	O
synapses4	SYM	O	O
-	:	O	O
6	CD	O	O
.	.	O	O

Thus	RB	O	O
,	,	O	O
the	DT	O	O
phosphorylation	NN	O	O
-	:	O	O
dephosphorylation	NN	O	O
cycle	NN	O	O
of	IN	O	O
SNIPPs	NNP	O	O
may	MD	O	O
represent	VB	O	O
a	DT	O	O
major	JJ	O	O
regulatory	JJ	O	O
mechanism	NN	O	O
that	WDT	O	O
underlies	VBZ	O	O
both	DT	O	O
synaptic	JJ	O	O
homeostasis	NN	O	O
and	CC	O	O
sleep	JJ	O	O
-	:	O	O
wake	NN	O	O
homeostasis	NN	O	O

apoptotic	JJ	B-Gene	O
genes	NNS	I-Gene	O
CASP9	NNP	I-Gene	O
implicated	VBD	I-Gene	O

Functional	JJ	O	O
studies	NNS	O	O
in	IN	O	O
fibroblasts	NNS	O	O
indicate	VBP	O	O
that	IN	O	O
these	DT	O	O
variants	NNS	B-Var	O
are	VBP	O	O
loss	NN	B-NegReg	O
-	:	I-NegReg	O
of	IN	I-NegReg	O
-	:	I-NegReg	O
function	NN	I-NegReg	O
,	,	O	O
as	IN	O	O
apoptosis	NN	B-CPA	O
is	VBZ	O	O
significantly	RB	O	O
reduced	VBN	B-NegReg	O
.	.	O	O
This	DT	O	O
is	VBZ	O	O
the	DT	O	O
first	JJ	O	O
report	NN	O	O
of	IN	O	O
variants	NNS	B-Var	O
in	IN	O	O
apoptotic	JJ	B-Gene	O
genes	NNS	I-Gene	O
contributing	VBG	B-Reg	O
to	TO	O	O
neural	JJ	B-Disease	O
tube	NN	I-Disease	O
defect	NN	I-Disease	O
risk	NN	O	O
in	IN	O	O
humans	NNS	O	O

BACKGROUND	NNS	O	O
:	:	O	O
Loss	NNP	B-NegReg	O
-	:	I-NegReg	O
of	IN	I-NegReg	O
-	:	I-NegReg	O
function	NN	I-NegReg	O
mutations	NNS	B-Var	O
in	IN	O	O
filaggrin	JJ	O	O
gene	NN	O	O
(	(	O	O
FLG	NNP	B-Gene	B-Gene
)	)	O	O
have	VBP	O	O
been	VBN	O	O
suggested	VBN	O	O
to	TO	O	O
increase	VB	O	B-PosReg
the	DT	O	O
susceptibility	NN	O	O
of	IN	O	O
skin	JJ	B-Disease	O
malignancies	NNS	I-Disease	O
due	JJ	O	O
to	TO	O	O
reduced	JJ	B-NegReg	B-NegReg
levels	NNS	B-MPA	O
of	IN	I-MPA	O
epidermal	JJ	I-MPA	O
filaggrin	NN	I-MPA	O
and	CC	O	O
its	PRP$	O	O
degradation	NN	B-MPA	O
products	NNS	I-MPA	O
,	,	O	O
urocanic	JJ	B-MPA	O
acid	NN	I-MPA	O
,	,	O	O
which	WDT	O	O
may	MD	O	O
be	VB	O	O
protective	JJ	O	O
against	IN	O	O
ultraviolet	JJ	O	O
irradiation	NN	O	O
.	.	O	O
OBJECTIVE	NN	O	O
:	:	O	O
We	PRP	O	O
aimed	VBD	O	O
to	TO	O	O
investigate	VB	O	O
the	DT	O	O
association	NN	O	O
between	IN	O	O
FLG	NNP	O	O
mutation	NN	O	O
status	NN	O	O
and	CC	O	O
the	DT	O	O
occurrence	NN	O	O
of	IN	O	O
malignant	JJ	O	O
melanoma	NN	O	O
(	(	O	O
MM	NNP	O	O
)	)	O	O
in	IN	O	O
Danish	JJ	O	O
adults	NNS	O	O
.	.	O	O

METHODS	NN	O	O
:	:	O	O
The	DT	O	O
prevalence	NN	O	O
of	IN	O	O
FLG	NNP	O	O
mutations	NNS	O	O
in	IN	O	O
a	DT	O	O
sample	NN	O	O
of	IN	O	O
MM	NNP	O	O
biopsies	NNS	O	O
was	VBD	O	O
compared	VBN	O	O
with	IN	O	O
a	DT	O	O
FLG	NNP	O	O
genotyped	VBD	O	O
cohort	NN	O	O
from	IN	O	O
two	CD	O	O
general	JJ	O	O
population	NN	O	O
studies	NNS	O	O
.	.	O	O

Pearson	NNP	O	O
's	POS	O	O
chi	NN	O	O
-	:	O	O
square	NN	O	O
and	CC	O	O
Fisher	NNP	O	O
's	POS	O	O
exact	JJ	O	O
tests	NNS	O	O
were	VBD	O	O
used	VBN	O	O
to	TO	O	O
compare	VB	O	O
the	DT	O	O
two	CD	O	O
groups	NNS	O	O
.	.	O	O

RESULTS	NN	O	O
:	:	O	O
A	DT	O	O
total	NN	O	O
of	IN	O	O
867	CD	O	O
MM	NNP	O	O
biopsies	NNS	O	O
and	CC	O	O
9965	CD	O	O
general	JJ	O	O
population	NN	O	O
controls	NNS	O	O
were	VBD	O	O
genotyped	VBN	O	O
,	,	O	O
respectively	RB	O	O
.	.	O	O

In	IN	O	O
the	DT	O	O
MM	NNP	O	O
sample	NN	O	O
2	CD	O	O
(	(	O	O
0.23%	CD	O	O
)	)	O	O
individuals	NNS	O	O
were	VBD	O	O
homozygous	JJ	O	O
and	CC	O	O
80	CD	O	O
(	(	O	O
9.4%	CD	O	O
)	)	O	O
heterozygous	JJ	O	O
mutation	NN	O	O
carriers	NNS	O	O
.	.	O	O

In	IN	O	O
the	DT	O	O
general	JJ	O	O
population	NN	O	O
controls	VBZ	O	O
the	DT	O	O
prevalence	NN	O	O
of	IN	O	O
FLG	NNP	O	O
mutations	NNS	O	O
was	VBD	O	O
18	CD	O	O
(	(	O	O
0.18%	CD	O	O
)	)	O	O
and	CC	O	O
835	CD	O	O
(	(	O	O
8.4%	CD	O	O
)	)	O	O
for	IN	O	O
homozygous	JJ	O	O
and	CC	O	O
heterozygous	JJ	O	O
mutations	NNS	O	O
,	,	O	O
respectively	RB	O	O
.	.	O	O

Fisher	NNP	O	O
's	POS	O	O
exact	JJ	O	O
test	NN	O	O
and	CC	O	O
Pearson	NNP	O	O
's	POS	O	O
chi	NN	O	O
square	JJ	O	O
test	NN	O	O
yielded	VBN	O	O
non	RB	O	O
-	:	O	O
significant	JJ	O	O
p	JJ	O	O
-	:	O	O
values	NNS	O	O
when	WRB	O	O
the	DT	O	O
groups	NNS	O	O
were	VBD	O	O
compared	VBN	O	O
.	.	O	O

CONCLUSION	NN	O	O
:	:	O	O
FLG	NNP	O	O
mutation	NN	O	O
was	VBD	O	O
not	RB	O	O
associated	VBN	O	O
with	IN	O	O
MM	NNP	O	O
in	IN	O	O
the	DT	O	O
studied	JJ	O	O
populations	NNS	O	O
.	.	O	O

This	DT	O	O
finding	NN	O	O
indicates	VBZ	O	O
that	IN	O	O
epidermal	JJ	O	O
deficiency	NN	O	O
of	IN	O	O
filaggrin	NN	O	O
and	CC	O	O
its	PRP$	O	O
degradation	NN	O	O
products	NNS	O	O
do	VBP	O	O
not	RB	O	O
influence	VB	O	O
the	DT	O	O
risk	NN	O	O
of	IN	O	O
MM	NNP	O	O
significantly	RB	O	O
.	.	O	O

This	DT	O	O
article	NN	O	O
is	VBZ	O	O
protected	VBN	O	O
by	IN	O	O
copyright	NN	O	O
.	.	O	O

All	DT	O	O
rights	NNS	O	O
reserved	VBN	O	O

Melanoma	NNP	O	B-Var
is	VBZ	O	O
the	DT	O	O
deadliest	JJS	O	O
skin	NN	O	O
cancer	NN	O	O
.	.	O	O

RACK1	NNP	O	O
(	(	O	O
Receptor	NNP	O	O
for	IN	O	O
activated	VBN	O	O
protein	NN	O	O
kinase	NNP	O	O
C	NNP	O	O
)	)	O	O
protein	NN	O	O
was	VBD	O	O
proposed	VBN	O	O
as	IN	O	O
a	DT	O	O
biological	JJ	O	O
marker	NN	O	O
of	IN	O	O
melanoma	NN	O	O
in	IN	O	O
human	JJ	O	O
and	CC	O	O
domestic	JJ	O	O
animal	NN	O	O
species	NNS	O	O
harboring	VBG	O	O
spontaneous	JJ	O	O
melanomas	NN	O	O
.	.	O	O

As	IN	O	O
a	DT	O	O
scaffold	JJ	O	O
protein	NN	O	O
,	,	O	O
RACK1	NNP	O	O
is	VBZ	O	O
able	JJ	O	O
to	TO	O	O
coordinate	VB	O	O
the	DT	O	O
interaction	NN	O	O
of	IN	O	O
key	JJ	O	O
signaling	VBG	O	O
molecules	NNS	O	O
implicated	VBN	O	O
in	IN	O	O
both	DT	O	O
physiological	JJ	O	O
cellular	JJ	O	O
functions	NNS	O	O
and	CC	O	O
tumorigenesis	NN	O	O
.	.	O	O

A	DT	O	O
role	NN	O	O
for	IN	O	O
RACK1	NNP	O	O
in	IN	O	O
rewiring	VBG	O	O
ERK	NNP	O	O
and	CC	O	O
JNK	NNP	O	O
signaling	VBG	O	O
pathways	NNS	O	O
in	IN	O	O
melanoma	NN	O	O
cell	NN	O	O
lines	NNS	O	O
had	VBD	O	O
been	VBN	O	O
proposed	VBN	O	O
.	.	O	O

Here	RB	O	O
,	,	O	O
we	PRP	O	O
used	VBD	O	O
a	DT	O	O
genetic	JJ	O	O
approach	NN	O	O
to	TO	O	O
test	VB	O	O
this	DT	O	O
hypothesis	NN	O	O
in	IN	O	O
vivo	NN	O	O
in	IN	O	O
the	DT	O	O
mouse	NN	O	O
.	.	O	O

We	PRP	O	O
show	VBP	O	O
that	IN	O	O
Rack1	NNP	B-Gene	O
knock	VB	B-Var	O
-	:	I-Var	O
down	RB	I-Var	O
in	IN	O	O
the	DT	O	O
mouse	NN	O	O
melanoma	NN	O	O
cell	NN	O	O
line	NN	O	O
B16	NNP	O	O
reduces	VBZ	B-NegReg	O
invasiveness	NN	B-MPA	O
and	CC	O	O
induces	NNS	B-Reg	O
cell	VBP	B-MPA	O
differentiation	NN	I-MPA	O
.	.	O	O
We	PRP	O	O
have	VBP	O	O
developed	VBN	O	O
the	DT	O	O
first	JJ	O	O
mouse	NN	O	O
model	NN	O	O
for	IN	O	O
RACK1	NNP	O	O
gain	NN	O	O
of	IN	O	O
function	NN	O	O
,	,	O	O
Tyr	NNP	O	O
:	:	O	O
:	:	O	O
Rack1	NNP	O	O
-	:	O	O
HA	NNP	O	O
transgenic	JJ	O	O
mice	NN	O	O
,	,	O	O
targeting	VBG	O	O
RACK1	NNP	O	O
to	TO	O	O
melanocytes	NNS	O	O
in	IN	O	O
vivo	NN	O	O
.	.	O	O

RACK1	NNP	O	O
overexpression	NN	O	O
was	VBD	O	O
not	RB	O	O
sufficient	JJ	O	O
to	TO	O	O
initiate	VB	O	O
melanomas	NNS	O	O
despite	IN	O	O
activated	VBN	O	O
ERK	NNP	O	O
and	CC	O	O
AKT	NNP	O	O
.	.	O	O

However	RB	O	O
,	,	O	O
in	IN	O	O
a	DT	O	O
context	NN	O	O
of	IN	O	O
melanoma	NN	O	O
predisposition	NN	O	O
,	,	O	O
RACK1	NNP	O	O
overexpression	NN	O	O
reduced	VBD	O	O
latency	NN	O	O
and	CC	O	O
increased	VBD	O	O
incidence	NN	O	O
and	CC	O	O
metastatic	JJ	O	O
rate	NN	O	O
.	.	O	O

In	IN	O	O
primary	JJ	O	O
melanoma	NN	O	O
cells	NNS	O	O
from	IN	O	O
Tyr	NN	O	O
:	:	O	O
:	:	O	O
Rack1	NNP	O	O
-	:	O	O
HA	NNP	O	O
,	,	O	O
Tyr	NNP	O	O
:	:	O	O
:	:	O	O
NRas	NNP	O	O
(	(	O	O
Q61K	NNP	O	O
)	)	O	O
mice	NN	O	O
,	,	O	O
activated	VBN	O	B-PosReg
JNK	NNP	O	B-MPA
(	(	O	I-MPA
c	SYM	O	I-MPA
-	:	O	I-MPA
Jun	NNP	O	I-MPA
N	NNP	O	O
-	:	O	O
terminal	JJ	O	O
kinase	NN	O	O
)	)	O	O
and	CC	O	O
activated	VBN	O	O
STAT3	NNP	O	O
(	(	O	O
signal	JJ	O	O
transducer	NN	O	O
and	CC	O	O
activator	NN	O	O
of	IN	O	O
transcription	NN	O	O
3	CD	O	O
)	)	O	O
acted	VBD	O	O
as	IN	O	O
RACK1	NNP	O	O
oncogenic	JJ	O	O
partners	NNS	O	O
in	IN	O	O
tumoral	JJ	O	O
progression	NN	O	O
.	.	O	O

A	DT	O	O
sequential	JJ	O	O
and	CC	O	O
coordinated	JJ	O	O
activation	NN	O	O
of	IN	O	O
ERK	NNP	O	O
,	,	O	O
JNK	NNP	O	O
and	CC	O	O
STAT3	NNP	O	O
with	IN	O	O
RACK1	NNP	O	O
is	VBZ	O	O
shown	VBN	O	O
to	TO	O	O
accelerate	VB	O	O
aggressive	JJ	O	O
melanoma	NN	O	B-CPA
development	NN	O	I-CPA
in	IN	O	O
vivo	NN	O	O

Nonetheless	RB	O	O
,	,	O	O
the	DT	O	O
Arabidopsis	NNP	O	O
genome	NN	O	O
encodes	NNS	O	O
nine	CD	O	O
PLCs	NNP	O	O
.	.	O	O

We	PRP	O	O
used	VBD	O	O
a	DT	O	O
reversed	JJ	O	O
-	:	O	O
genetic	JJ	O	O
approach	NN	O	O
to	TO	O	O
explore	VB	O	O
PLC	NNP	O	O
's	POS	O	O
function	NN	O	O
in	IN	O	O
Arabidopsis	NNP	O	O
,	,	O	O
and	CC	O	O
report	NN	O	O
here	RB	O	O
that	IN	O	O
PLC3	NNP	B-Gene	O
is	VBZ	O	O
required	VBN	O	O
for	IN	O	O
proper	JJ	O	O
root	NN	O	O
development	NN	O	O
,	,	O	O
seed	NN	O	O
germination	NN	O	O
and	CC	O	O
stomatal	JJ	O	O
opening	NN	O	O
.	.	O	O
Two	CD	O	O
independent	JJ	O	O
knock	NN	B-Var	O
-	:	I-Var	O
down	IN	I-Var	O
mutants	NNS	I-Var	O
,	,	O	O
plc3	SYM	O	O
-	:	O	O
2	CD	O	O
and	CC	O	O
plc3	VB	O	O
-	:	O	O
3	CD	O	O
,	,	O	O
were	VBD	O	O
found	VBN	O	O
to	TO	O	O
exhibit	VB	O	O
reduced	JJ	B-NegReg	O
lateral	JJ	B-CPA	O
root	NN	I-CPA	O
densities	NNS	I-CPA	O
by	IN	O	O
10	CD	O	O
-	:	O	O
20%	CD	O	O
.	.	O	O
Mutant	JJ	B-Var	O
seeds	NNS	O	O
germinated	VBD	B-CPA	O
more	RBR	O	O
slowly	RB	B-NegReg	O
but	CC	O	O
were	VBD	O	O
less	RBR	O	O
sensitive	JJ	O	O
to	TO	O	O
ABA	NNP	O	O
to	TO	O	O
prevent	VB	O	O
germination	NN	O	O
.	.	O	O
Guard	NNP	O	O
cells	NNS	O	O
of	IN	O	O
plc3	NN	O	O
were	VBD	O	O
also	RB	O	O
compromised	VBN	O	O
in	IN	O	O
ABA	NNP	O	O
-	:	O	O
dependent	JJ	O	O
stomatal	JJ	O	O
closure	NN	O	O
.	.	O	O

Promoter	NNP	O	O
-	:	O	O
-	:	O	O
glucuronidase	NN	O	O
(	(	O	O
GUS	NNP	O	O
)	)	O	O
analyses	VBZ	O	O
confirmed	VBN	O	O
PLC3	NNP	O	O
expression	NN	O	O
in	IN	O	O
guard	NN	O	O
cells	NNS	O	O
and	CC	O	O
germinating	VBG	O	O
seeds	NNS	O	O
,	,	O	O
and	CC	O	O
revealed	VBD	O	O
that	IN	O	O
the	DT	O	O
majority	NN	O	O
is	VBZ	O	O
expressed	VBN	O	O
in	IN	O	O
vascular	JJ	O	O
tissue	NN	O	O
,	,	O	O
most	RBS	O	O
probably	RB	O	O
phloem	JJ	O	O
companion	NN	O	O
cells	NNS	O	O
,	,	O	O
in	IN	O	O
roots	NNS	O	O
,	,	O	O
leaves	NNS	O	O
and	CC	O	O
flowers	NNS	O	O
.	.	O	O

In	IN	O	O
vivo	JJ	O	O
32	CD	O	O
Pi	NNP	O	O
labeling	VBG	O	O
revealed	VBD	O	O
that	IN	O	O
ABA	NNP	O	O
stimulated	VBD	O	O
the	DT	O	O
formation	NN	B-MPA	O
of	IN	I-MPA	O
PIP2	NNP	I-MPA	O
in	IN	O	O
germinating	VBG	O	O
seeds	NNS	O	O
and	CC	O	O
guard	NN	O	O
cell	NN	O	O
-	:	O	O
enriched	VBN	O	O
leaf	NN	O	O
peels	NNS	O	O
,	,	O	O
which	WDT	O	O
was	VBD	O	O
significantly	RB	O	O
reduced	VBN	B-NegReg	O
in	IN	O	O
plc3	NN	B-Gene	O
mutants	NNS	B-Var	O
.	.	O	O
Overexpression	NN	O	O
of	IN	O	O
PLC3	NNP	O	O
had	VBD	O	O
no	DT	O	O
effect	NN	O	O
on	IN	O	O
root	NN	O	O
system	NN	O	O
architecture	NN	O	O
or	CC	O	O
seed	NN	O	O
germination	NN	O	O
,	,	O	O
but	CC	O	O
increased	VBD	O	O
the	DT	O	O
plant	NN	O	O
's	POS	O	O
tolerance	NN	O	O
to	TO	O	O
drought	NN	O	O
.	.	O	O

Our	PRP$	O	O
results	NNS	O	O
provide	VBP	O	O
genetic	JJ	O	O
evidence	NN	O	O
for	IN	O	O
PLC	NNP	O	O
's	POS	O	O
involvement	NN	O	O
in	IN	O	O
plant	NN	O	O
development	NN	O	O
and	CC	O	O
ABA	NNP	O	O
signaling	NN	O	O
,	,	O	O
and	CC	O	O
confirm	NN	O	O
earlier	RBR	O	O
observations	NNS	O	O
that	WDT	O	O
overexpression	VBP	O	O
increases	NNS	O	O
drought	JJ	O	O
tolerance	NN	O	O
.	.	O	O

Potential	JJ	O	O
molecular	JJ	O	O
mechanisms	NN	O	O
for	IN	O	O
the	DT	O	O
above	JJ	O	O
observations	NNS	O	O
are	VBP	O	O
discussed	VBN	O	O

LMS	NNP	B-Disease	O
mutations	NNS	B-Var	O
in	IN	I-Var	O
exon	JJ	I-Var	O
33	CD	I-Var	O
NOTCH3	NNP	B-Gene	O
truncated	VBN	B-MPA	O
protein	NN	B-Protein	O
lacking	VBG	B-NegReg	O
sequences	NNS	B-MPA	O
for	IN	I-MPA	O
NOTCH3	NNP	I-MPA	O
degradation	NN	I-MPA	O
NOTCH3	NNP	B-Gene	O
gain	NN	B-PosReg	O
of	IN	I-PosReg	O
function	NN	I-PosReg	O

Notch3tm1	NNP	B-Var	O
.	.	I-Var	O
1	CD	I-Var	O
Ecan	JJ	I-Var	O
cancellous	JJ	B-CPA	O
and	CC	I-CPA	O
cortical	JJ	I-CPA	O
bone	NN	I-CPA	O
osteopenia	NN	B-NegReg	O
Microcomputed	VBN	O	O
tomography	NN	O	O
of	IN	O	O
these	DT	O	O
mutants	NNS	B-Var	O
revealed	VBD	O	O
a	DT	O	O
35	CD	O	O
-	:	O	O
60%	CD	O	O
decrease	NN	B-NegReg	O
in	IN	O	O
cancellous	JJ	B-CPA	O
bone	NN	I-CPA	O
volume	NN	I-CPA	O
associated	VBN	O	O
with	IN	O	O
a	DT	O	O
reduction	NN	B-NegReg	O
in	IN	O	O
trabecular	JJ	B-CPA	O
number	NN	I-CPA	O
and	CC	O	O
decreased	JJ	B-NegReg	B-NegReg
connectivity	NN	B-CPA	B-MPA
.	.	O	O
During	IN	O	O
maturation	NN	O	O
,	,	O	O
cancellous	JJ	O	O
and	CC	O	O
cortical	JJ	O	O
bones	NNS	O	O
were	VBD	O	O
restored	VBN	O	O
in	IN	O	O
female	NN	O	O
but	CC	O	O
not	RB	O	O
in	IN	O	O
male	JJ	O	O
mice	NN	O	O
,	,	O	O
which	WDT	O	O
exhibited	VBD	O	O
cancellous	JJ	O	O
bone	NN	O	O
osteopenia	NN	O	O
at	IN	O	O
4	CD	O	O
months	NNS	O	O
.	.	O	O

Cancellous	JJ	O	O
bone	NN	O	O
histomorphometry	NN	O	O
revealed	VBD	O	O
increased	VBN	O	O
osteoblast	NN	O	O
and	CC	O	O
osteocyte	JJ	O	O
numbers	NNS	O	O
and	CC	O	O
a	DT	O	O
modest	JJ	O	O
increase	NN	O	O
in	IN	O	O
osteoclast	JJ	O	O
surface	NN	O	O
and	CC	O	O
bone	NN	O	O
formation	NN	O	O
rate	NN	O	O
.	.	O	O

Notch3tm1	NNP	B-Var	O
.	.	I-Var	O
1	CD	I-Var	O
Ecan	JJ	I-Var	O
calvarial	JJ	B-CPA	O
osteoblasts	NNS	I-CPA	O
had	VBD	O	O
increased	VBN	B-PosReg	O
proliferation	NN	O	O
and	CC	O	O
increased	VBD	B-PosReg	O
bone	NN	B-Protein	O
-	:	I-Protein	O
carboxyglutamate	NN	I-Protein	O
protein	NN	I-Protein	O
(	(	I-Protein	O
Bglap	NNP	I-Protein	O
)	)	I-Protein	O
and	CC	O	O
TNF	NNP	B-Gene	O
superfamily	RB	I-Gene	O
member	NN	I-Gene	O
11	CD	I-Gene	O
(	(	I-Gene	O
Tnfsf11	NNP	I-Gene	O
)	)	I-Gene	O
mRNA	NN	B-MPA	O
levels	NNS	I-MPA	O
and	CC	O	O
lower	JJR	B-NegReg	B-NegReg
Tnfrsf11b	NNP	B-MPA	B-MPA
levels	NNS	I-MPA	I-MPA
.	.	O	O
Tnfsf11	NNP	O	O
mRNA	NN	O	O
was	VBD	O	O
increased	VBN	O	O
in	IN	O	O
osteocyte	JJ	O	O
-	:	O	O
rich	JJ	O	O
femora	NN	O	O
from	IN	O	O
Notch3tm1	NNP	O	O
.	.	O	O
1	CD	O	O
Ecan	JJ	O	O
mice	NN	O	O
.	.	O	O

Cultures	NNS	O	O
of	IN	O	O
bone	NN	O	O
marrow	NN	O	O
-	:	O	O
derived	VBN	O	O
macrophages	NNS	O	O
from	IN	O	O
Notch3tm1	NNP	O	O
.	.	O	O
1	CD	O	O
Ecan	JJ	O	O
mice	NN	O	O
revealed	VBD	O	O
increased	VBN	O	O
osteoclast	NN	O	O
formation	NN	O	O
,	,	O	O
particularly	RB	O	O
in	IN	O	O
cocultures	NNS	O	O
with	IN	O	O
osteoblasts	NNS	O	O
from	IN	O	O
Notch3tm1	NNP	O	O
.	.	O	O
1	CD	O	O
Ecan	JJ	O	O
mice	NN	O	O
.	.	O	O

In	IN	O	O
conclusion	NN	O	O
,	,	O	O
the	DT	O	O
Notch3tm1	NNP	B-Var	O
.	.	I-Var	O
1	CD	I-Var	O
Ecan	JJ	I-Var	O
mutation	NN	I-Var	O
causes	VBZ	O	O
osteopenia	RP	B-Disease	O
despite	IN	O	O
an	DT	O	O
increase	NN	B-PosReg	O
in	IN	O	O
osteoblast	JJ	B-CPA	O
proliferation	NN	I-CPA	O
and	CC	O	O
function	NN	B-CPA	O
and	CC	O	O
is	VBZ	O	O
associated	VBN	O	O
with	IN	O	O
enhanced	JJ	B-PosReg	O
Tnfsf11	NNP	B-Gene	O
expression	NN	B-MPA	O
in	IN	O	O
osteoblasts	NNS	O	O
and	CC	O	O
osteocytes	NNS	O	O

stimulation	NN	B-PosReg	O
G	NNP	B-Protein	B-MPA
protein	SYM	I-Protein	I-MPA
-	:	I-Protein	I-MPA
coupled	VBN	I-Protein	I-MPA
receptors	NNS	I-Protein	I-MPA
heterotrimeric	JJ	B-Protein	I-MPA
G	NNP	I-Protein	I-MPA
proteins	NNS	I-Protein	I-MPA
Alterations	NNS	B-Var	O
RGS	NNP	B-Protein	O
implicated	VBN	B-Reg	O
disease	NN	B-Disease	O
reducing	VBG	B-NegReg	O
inhibiting	VBG	B-NegReg	O
RGS	NNP	B-Protein	O
proteins	NNS	I-Protein	O
RGS4	NNP	B-Var	O
mutant	NN	I-Var	O
enhanced	VBD	B-PosReg	O
gain	VB	B-PosReg	O
-	:	I-PosReg	O
of	IN	I-PosReg	O
-	:	I-PosReg	O
function	NN	I-PosReg	O
yeast	SYM	B-Pathway	O
-	:	I-Pathway	O
based	VBN	I-Pathway	O
signalling	VBG	I-Pathway	O
pathway	NN	I-Pathway	O
Galpha	NNP	B-Protein	O
(	(	I-Protein	O
o1	NN	I-Protein	O
)	)	I-Protein	O
subunit	NN	I-Protein	O
contained	VBN	I-Protein	O
in	IN	I-Protein	O
an	DT	I-Protein	O
alpha	NN	I-Protein	O
(	(	I-Protein	O
2	CD	I-Protein	O
A	DT	I-Protein	O
)-	JJ	I-Protein	O
adrenoreceptor	NN	I-Protein	O
-	:	I-Protein	O
Galpha	NNP	I-Protein	O
(	(	I-Protein	O
o1	JJ	I-Protein	O
)(	NNP	I-Protein	O
C351I	NNP	I-Protein	O
)	)	I-Protein	O
fusion	NN	I-Protein	O
protein	NN	I-Protein	O
Mutational	JJ	O	O
analysis	NN	O	O
of	IN	O	O
serine	NN	O	O
30	CD	O	O
identified	VBD	O	O
a	DT	O	O
number	NN	O	O
of	IN	O	O
alternative	JJ	O	O
substitutions	NNS	O	O
that	WDT	O	O
result	VBP	O	O
in	IN	O	O
GOF	NNP	O	O
activity	NN	O	O
.	.	O	O

GOF	NNP	O	O
activity	NN	O	O
was	VBD	O	O
retained	VBN	O	O
upon	IN	O	O
transposition	NN	O	O
of	IN	O	O
the	DT	O	O
serine	NN	O	O
30	CD	O	O
-	:	O	O
cysteine	NN	O	O
mutation	NN	O	O
to	TO	O	O
the	DT	O	O
equivalent	JJ	O	O
serine	NN	O	O
residue	NN	O	O
in	IN	O	O
human	JJ	O	O
RGS16	NNP	O	O
.	.	O	O

As	IN	O	O
with	IN	O	O
previously	RB	O	O
identified	VBN	O	O
GOF	NNP	O	O
mutants	NNS	O	O
,	,	O	O
RGS4	NNP	B-Var	O
(	(	O	O
S30C	NNP	B-Var	O
S30F	NNP	B-Var	O
S30K	NNP	B-Var	O
)	)	O	O
demonstrate	NN	O	O
increased	VBD	B-PosReg	B-PosReg
steady	JJ	O	B-MPA
state	NN	O	I-MPA
protein	NN	B-MPA	I-MPA
levels	NNS	I-MPA	I-MPA
,	,	O	O
however	RB	O	O
these	DT	O	O
mutants	NNS	O	O
also	RB	O	O
demonstrate	VBP	O	O
enhanced	JJ	B-PosReg	O
GAP	NNP	B-MPA	O
activity	NN	I-MPA	O
through	IN	O	O
an	DT	O	O
additional	JJ	O	O
mechanism	NN	O	O
distinct	NN	O	O
from	IN	O	O
the	DT	O	O
increased	VBN	O	O
protein	NN	O	O
content	NN	O	O
.	.	O	O
The	DT	O	O
identification	NN	O	O
of	IN	O	O
human	JJ	O	O
RGS	NNP	O	O
mutants	NNS	O	O
with	IN	O	O
GOF	NNP	O	O
activity	NN	O	O
may	MD	O	O
provide	VB	O	O
novel	JJ	O	O
therapeutic	JJ	O	O
agents	NNS	O	O
for	IN	O	O
the	DT	O	O
treatment	NN	O	O
of	IN	O	O
signaling	VBG	O	O
-	:	O	O
based	VBN	O	O
diseases	NNS	O	O
and	CC	O	O
the	DT	O	O
ability	NN	O	O
to	TO	O	O
transpose	VB	O	O
these	DT	O	O
mutations	NNS	O	O
to	TO	O	O
other	JJ	O	O
human	JJ	O	O
RGS	NNP	O	O
proteins	NNS	O	O
extends	VBP	O	O
their	PRP$	O	O
application	NN	O	O
to	TO	O	O
multiple	VB	O	O
pathways	NNS	O	O

deletion	NN	B-Var	B-Var
TAS1R3	NNP	B-Gene	O
increased	VB	B-PosReg	O
cortical	JJ	B-CPA	O
bone	NN	I-CPA	O
mass	NN	I-CPA	O
Here	RB	O	O
,	,	O	O
we	PRP	O	O
independently	RB	O	O
corroborate	VBP	O	O
the	DT	O	O
increased	JJ	B-PosReg	O
thickness	NN	B-CPA	O
of	IN	I-CPA	O
cortical	JJ	I-CPA	O
bone	NN	I-CPA	O
in	IN	O	O
femurs	NNS	O	O
of	IN	O	O
20	CD	O	O
-	:	O	O
week	NN	O	O
-	:	O	O
old	JJ	O	O
male	JJ	O	O
Tas1R3	NNP	B-Gene	O
mutant	NN	B-Var	O
mice	NN	O	O
and	CC	O	O
confirm	NN	O	O
that	IN	O	O
Tas1R3	NNP	O	O
is	VBZ	O	O
expressed	VBN	O	O
in	IN	O	O
the	DT	O	O
bone	NN	O	O
environment	NN	O	O
.	.	O	O
Tas1R3	NNP	O	O
is	VBZ	O	O
expressed	VBN	O	O
in	IN	O	O
undifferentiated	JJ	O	O
bone	NN	O	O
marrow	NN	O	O
stromal	JJ	O	O
cells	NNS	O	O
(	(	O	O
BMSCs	NNP	O	O
)	)	O	O
in	IN	O	O
vitro	NN	O	O
and	CC	O	O
its	PRP$	O	O
expression	NN	O	O
is	VBZ	O	O
maintained	VBN	O	O
during	IN	O	O
BMP2	NNP	O	O
-	:	O	O
induced	VBD	O	O
osteogenic	JJ	O	O
differentiation	NN	O	O
.	.	O	O

However	RB	O	O
,	,	O	O
levels	NNS	O	O
of	IN	O	O
the	DT	O	O
bone	NN	O	O
formation	NN	O	O
marker	NN	O	O
procollagen	NN	O	O
type	NN	O	O
I	PRP	O	O
N	NNP	O	O
-	:	O	O
terminal	JJ	O	O
propeptide	NN	O	O
(	(	O	O
PINP	NNP	O	O
)	)	O	O
are	VBP	O	O
unchanged	JJ	O	O
in	IN	O	O
the	DT	O	O
serum	NN	O	O
of	IN	O	O
20	CD	O	O
-	:	O	O
week	NN	O	O
-	:	O	O
old	JJ	O	O
Tas1R3	NNP	O	O
mutant	NN	O	O
mice	NN	O	O
as	IN	O	O
compared	VBN	O	O
to	TO	O	O
controls	NNS	O	O
.	.	O	O

In	IN	O	O
contrast	NN	O	O
,	,	O	O
levels	NNS	B-MPA	O
of	IN	I-MPA	O
the	DT	I-MPA	O
bone	NN	I-MPA	O
resorption	NN	I-MPA	O
marker	NN	I-MPA	O
collagen	NN	I-MPA	B-MPA
type	NN	I-MPA	I-MPA
I	PRP	I-MPA	I-MPA
C	NNP	I-MPA	I-MPA
-	:	I-MPA	I-MPA
telopeptide	NN	I-MPA	I-MPA
are	VBP	O	O
reduced	VBN	B-NegReg	O
greater	JJR	O	O
than	IN	O	O
60%	CD	O	O
in	IN	O	O
Tas1R3	NNP	B-Gene	O
mutant	JJ	B-Var	O
mice	NN	O	O
.	.	O	O
Consistent	JJ	O	O
with	IN	O	O
this	DT	O	O
,	,	O	O
Tas1R3	NNP	O	O
and	CC	O	O
its	PRP$	O	O
putative	JJ	O	O
signaling	NN	O	O
partner	NN	O	O
Tas1R2	NNP	O	O
are	VBP	O	O
expressed	VBN	O	O
in	IN	O	O
primary	JJ	O	O
osteoclasts	NNS	O	O
and	CC	O	O
their	PRP$	O	O
expression	NN	O	O
levels	NNS	O	O
positively	RB	O	O
correlate	VBP	O	O
with	IN	O	O
differentiation	NN	O	O
status	NN	O	O
.	.	O	O

Collectively	RB	O	O
,	,	O	O
these	DT	O	O
findings	NNS	O	O
suggest	VBP	O	O
that	IN	O	O
high	JJ	B-PosReg	O
bone	NN	B-CPA	O
mass	NN	I-CPA	O
in	IN	O	O
Tas1R3	NNP	B-Gene	O
mutant	JJ	B-Var	O
mice	NN	O	O
is	VBZ	O	O
due	JJ	O	O
to	TO	O	O
uncoupled	JJ	O	O
bone	NN	O	O
remodeling	VBG	O	O
with	IN	O	O
reduced	VBN	B-NegReg	O
osteoclast	NN	B-CPA	O
function	NN	I-CPA	O
and	CC	O	O
provide	VB	O	O
rationale	NN	O	O
for	IN	O	O
future	JJ	O	O
experiments	NNS	O	O
examining	VBG	O	O
the	DT	O	O
cell	NN	O	O
-	:	O	O
type	NN	O	O
-	:	O	O
dependent	JJ	O	O
role	NN	O	O
for	IN	O	O
TAS1R	NNP	O	O
family	NN	O	O
members	NNS	O	O
in	IN	O	O
nutrient	JJ	O	O
sensing	NN	O	O
in	IN	O	O
postnatal	JJ	O	O
bone	NN	O	O
remodeling	NN	O	O

diabetes	NNS	B-Disease	B-Gene
gain	NN	B-PosReg	B-PosReg
-	:	I-PosReg	I-PosReg
of	IN	I-PosReg	I-PosReg
-	:	I-PosReg	I-PosReg
function	NN	I-PosReg	I-PosReg
mutation	NN	B-Var	B-Var
ABCC8	NNP	B-Gene	B-Gene
Gain	NNP	B-PosReg	B-PosReg
-	:	I-PosReg	I-PosReg
of	IN	I-PosReg	I-PosReg
-	:	I-PosReg	I-PosReg
function	NN	I-PosReg	I-PosReg
ABCC8	NNP	B-Gene	B-Gene
mutations	NNS	B-Var	B-Var
cause	VB	B-Reg	B-Reg
neonatal	JJ	B-Disease	B-Disease
diabetes	NNS	I-Disease	O
mellitus	NNS	I-Disease	O
maturity	NN	B-Disease	O
-	:	I-Disease	O
onset	NN	I-Disease	O
diabetes	NNS	I-Disease	O
However	RB	O	O
,	,	O	O
the	DT	O	O
intrafamilial	JJ	O	O
heterogeneous	JJ	O	O
nature	NN	O	O
of	IN	O	O
diabetes	NNS	O	O
caused	VBN	O	O
by	IN	O	O
the	DT	O	O
ABCC8	NNP	O	O
mutation	NN	O	O
is	VBZ	O	O
not	RB	O	O
fully	RB	O	O
understood	JJ	O	O
to	TO	O	O
date	NN	O	O
.	.	O	O

To	TO	O	O
clarify	VB	O	O
the	DT	O	O
intrafamilial	JJ	O	O
heterogeneous	JJ	O	O
nature	NN	O	O
of	IN	O	O
monogenetic	JJ	O	O
diabetes	NNS	O	O
,	,	O	O
we	PRP	O	O
conducted	VBD	O	O
a	DT	O	O
case	NN	O	O
study	NN	O	O
on	IN	O	O
a	DT	O	O
family	NN	O	O
with	IN	O	O
ABCC8	NNP	O	O
mutations	NNS	O	O
.	.	O	O

We	PRP	O	O
investigated	VBD	O	O
eight	CD	O	O
family	NN	O	O
members	NNS	O	O
,	,	O	O
including	VBG	O	O
a	DT	O	O
neonatal	JJ	O	O
diabetes	NN	O	O
patient	NN	O	O
,	,	O	O
based	VBN	O	O
on	IN	O	O
metabolic	JJ	O	O
features	NNS	O	O
and	CC	O	O
genetic	JJ	O	O
analysis	NN	O	O
.	.	O	O

All	DT	O	O
coding	VBG	O	O
exons	NNS	O	O
and	CC	O	O
exon	SYM	O	O
-	:	O	O
intron	NN	O	O
boundaries	NNS	O	O
of	IN	O	O
the	DT	O	O
KCNJ11	NNP	O	O
,	,	O	O
ABCC8	NNP	O	O
,	,	O	O
GCK	NNP	O	O
,	,	O	O
HNF1A	NNP	O	O
,	,	O	O
and	CC	O	O
HNF4A	NNP	O	O
genes	NNS	O	O
were	VBD	O	O
amplified	VBN	O	O
from	IN	O	O
genomic	JJ	O	O
DNA	NN	O	O
and	CC	O	O
directly	RB	O	O
sequenced	VBN	O	O
.	.	O	O

Five	CD	O	O
gene	NN	O	O
mutation	NN	O	O
carriers	NNS	O	O
with	IN	O	O
ABCC8	NNP	O	O
(	(	O	O
c	NN	O	B-Var
.	.	O	I-Var
1819	CD	O	I-Var
G	NNP	O	I-Var
A	NNP	O	I-Var
p	NN	O	O
.	.	O	O
V607M	NNP	O	O
)	)	O	O
were	VBD	O	O
identified	VBN	O	O
in	IN	O	O
this	DT	O	O
family	NN	O	O
,	,	O	O
and	CC	O	O
the	DT	O	O
onset	NN	O	O
and	CC	O	O
severity	NN	O	O
of	IN	O	O
diabetes	NNS	O	O
progressively	RB	O	O
worsened	VBD	O	O
across	IN	O	O
the	DT	O	O
three	CD	O	O
generations	NNS	O	O
.	.	O	O

Each	DT	O	O
of	IN	O	O
the	DT	O	O
ABCC8	NNP	O	O
gene	NN	O	O
mutation	NN	O	O
carrier	NN	O	O
family	NN	O	O
members	NNS	O	O
were	VBD	O	O
diagnosed	VBN	O	O
with	IN	O	O
diabetes	NNS	O	O
as	IN	O	O
follows	VBZ	O	O
:	:	O	O
the	DT	O	O
grandfather	NN	O	O
with	IN	O	O
type	JJ	O	O
2	CD	O	O
diabetes	NNS	O	O
at	IN	O	O
35	CD	O	O
years	NNS	O	O
of	IN	O	O
age	NN	O	O
,	,	O	O
the	DT	O	O
aunt	NN	O	O
with	IN	O	O
slowly	RB	O	O
-	:	O	O
progressive	JJ	O	O
insulin	NN	O	O
-	:	O	O
dependent	NN	O	O
diabetes	VBZ	O	O
at	IN	O	O
18	CD	O	O
years	NNS	O	O
of	IN	O	O
age	NN	O	O
,	,	O	O
the	DT	O	O
mother	NN	O	O
with	IN	O	O
ketosis	NN	O	O
-	:	O	O
onset	NN	O	O
insulin	NN	O	O
-	:	O	O
dependent	NN	O	O
diabetes	VBZ	O	O
at	IN	O	O
14	CD	O	O
years	NNS	O	O
of	IN	O	O
age	NN	O	O
,	,	O	O
the	DT	O	O
sister	NN	O	O
with	IN	O	O
impaired	JJ	O	O
glucose	JJ	O	O
tolerance	NN	O	O
at	IN	O	O
9	CD	O	O
years	NNS	O	O
of	IN	O	O
age	NN	O	O
,	,	O	O
and	CC	O	O
the	DT	O	O
proband	NN	O	O
with	IN	O	O
transient	JJ	O	O
neonatal	JJ	O	O
diabetes	NNS	O	O
at	IN	O	O
birth	NN	O	O
.	.	O	O

The	DT	O	O
present	JJ	O	O
study	NN	O	O
shows	VBZ	O	O
the	DT	O	O
heterogeneous	JJ	O	O
nature	NN	O	O
of	IN	O	O
diabetes	NNS	O	O
in	IN	O	O
a	DT	O	O
family	NN	O	O
with	IN	O	O
a	DT	O	O
gain	NN	O	O
-	:	O	O
of	IN	O	O
-	:	O	O
function	NN	O	O
mutation	NN	O	O
in	IN	O	O
the	DT	O	O
ABCC8	NNP	O	O
gene	NN	O	O

The	DT	O	O
tyrosine	NN	O	O
phosphatase	NN	O	O
Shp2	NNP	O	O
has	VBZ	O	O
emerged	VBN	O	O
as	IN	O	O
a	DT	O	O
major	JJ	O	O
regulator	NN	O	O
of	IN	O	O
receptor	NN	O	O
tyrosine	NN	O	O
kinase	NN	O	O
(	(	O	O
RTK	NNP	O	O
)	)	O	O
and	CC	O	O
cytokine	JJ	O	O
receptor	NN	O	O
signaling	NN	O	O
.	.	O	O

In	IN	O	O
the	DT	O	O
last	JJ	O	O
decade	NN	O	O
,	,	O	O
germline	JJ	O	O
mutations	NNS	O	O
in	IN	O	O
the	DT	O	O
human	JJ	O	O
PTPN11	NNP	O	O
gene	NN	O	O
,	,	O	O
encoding	VBG	O	O
Shp2	NNP	O	O
,	,	O	O
were	VBD	O	O
linked	VBN	O	O
to	TO	O	O
Noonan	NNP	O	O
(	(	O	O
NS	NNP	O	O
)	)	O	O
and	CC	O	O
LEOPARD	NNP	O	O
syndromes	NNS	O	O
,	,	O	O
two	CD	O	O
multisymptomatic	JJ	O	O
developmental	NN	O	O
disorders	NNS	O	O
that	WDT	O	O
are	VBP	O	O
characterized	VBN	O	O
by	IN	O	O
short	JJ	O	O
stature	NN	O	O
,	,	O	O
craniofacial	JJ	O	O
defects	NNS	O	O
,	,	O	O
cardiac	JJ	O	O
defects	NNS	O	O
,	,	O	O
and	CC	O	O
mental	JJ	O	O
retardation	NN	O	O
.	.	O	O

Somatic	JJ	O	O
Shp2	NNP	B-Gene	O
mutations	NNS	B-Var	O
are	VBP	O	O
also	RB	O	O
associated	VBN	B-Reg	O
with	IN	O	O
several	JJ	O	O
types	NNS	O	O
of	IN	O	O
human	JJ	O	O
malignancies	NNS	O	O
,	,	O	O
such	JJ	O	O
as	IN	O	O
the	DT	O	O
most	RBS	O	O
common	JJ	O	O
juvenile	NN	B-Disease	O
leukemia	NN	I-Disease	O
,	,	O	O
juvenile	JJ	B-Disease	B-Disease
myelomonocytic	JJ	I-Disease	I-Disease
leukemia	NN	I-Disease	I-Disease
(	(	O	O
JMML	NNP	O	O
)	)	O	O
.	.	O	O
Whereas	NNP	O	O
NS	NNP	B-Disease	O
and	CC	O	O
JMML	NNP	B-Disease	O
are	VBP	O	O
caused	VBN	O	O
by	IN	O	O
gain	NN	B-PosReg	O
-	:	I-PosReg	O
of	IN	I-PosReg	O
-	:	I-PosReg	O
function	NN	I-PosReg	O
(	(	O	O
GOF	NNP	O	O
)	)	O	O
mutations	NNS	B-Var	B-Var
of	IN	O	O
Shp2	NNP	B-Gene	O
,	,	O	O
loss	NN	B-NegReg	O
-	:	I-NegReg	O
of	IN	I-NegReg	O
-	:	I-NegReg	O
function	NN	I-NegReg	O
(	(	O	O
LOF	NNP	O	O
)	)	O	O
mutations	NNS	B-Var	B-Var
are	VBP	O	O
thought	VBN	O	O
to	TO	O	O
be	VB	O	O
associated	VBN	O	O
with	IN	O	O
LEOPARD	NNP	B-Disease	O
syndrome	NN	I-Disease	O
.	.	O	O
Animal	NNP	O	O
models	NNS	O	O
that	IN	O	O
carry	VBP	O	O
conditional	JJ	O	O
LOF	NNP	O	O
and	CC	O	O
GOF	NNP	O	O
mutations	NNS	O	O
have	VBP	O	O
allowed	VBN	O	O
a	DT	O	O
better	RBR	O	O
understanding	NN	O	O
of	IN	O	O
the	DT	O	O
mechanism	NN	O	O
of	IN	O	O
Shp2	NNP	O	O
function	NN	O	O
in	IN	O	O
disease	NN	O	O
,	,	O	O
and	CC	O	O
shed	VBD	O	O
light	NN	O	O
on	IN	O	O
the	DT	O	O
role	NN	O	O
of	IN	O	O
Shp2	NNP	O	O
in	IN	O	O
signaling	VBG	O	O
pathways	NNS	O	O
that	WDT	O	O
control	VBP	O	O
decisive	JJ	O	O
events	NNS	O	O
during	IN	O	O
embryonic	JJ	O	O
development	NN	O	O
or	CC	O	O
during	IN	O	O
cellular	JJ	O	O
transformation	NN	O	B-MPA
tumorigenesis	NN	O	I-MPA

p53	NN	B-Gene	B-Var
mutation	NN	B-Var	B-Var
associated	VBN	B-Reg	B-Reg
aggressive	JJ	B-Disease	B-Disease
nonendometrioid	JJ	I-Disease	I-Disease
cancer	NN	I-Disease	I-Disease

METHODS	NN	O	O
:	:	O	O
To	TO	O	O
clarify	VB	O	O
the	DT	O	O
relationship	NN	O	O
between	IN	O	O
expression	NN	O	O
of	IN	O	O
p53	NN	O	O
GOF	NNP	O	O
mutation	NN	O	O
(	(	O	O
p53	JJ	O	O
-	:	O	O
R175H	NN	O	O
)	)	O	O
and	CC	O	O
invasive	JJ	O	O
potential	NN	O	O
of	IN	O	O
human	JJ	O	O
endometrial	JJ	O	O
cancer	NN	O	O
KLE	NNP	O	O
cells	NNS	O	O
,	,	O	O
we	PRP	O	O
tested	VBD	B-Reg	O
the	DT	O	O
consequences	NNS	O	O
of	IN	O	O
up	IN	B-PosReg	O
-	:	I-PosReg	O
regulation	NN	I-PosReg	O
and	CC	O	O
down	IN	B-NegReg	O
-	:	I-NegReg	O
regulation	NN	I-NegReg	O
of	IN	O	O
p53	NN	O	O
-	:	O	O
R175H	NN	O	O
in	IN	O	O
KLE	NNP	O	O
cells	NNS	O	O
by	IN	O	O
inducing	VBG	B-Reg	O
p53	NN	B-Protein	O
-	:	I-Protein	O
R175H	NNP	I-Protein	O
expression	NN	I-Protein	O
vector	NN	I-Protein	O
or	CC	O	O
suppressing	VBG	B-NegReg	O
the	DT	O	O
p53	NN	B-Gene	O
gene	NN	I-Gene	O
with	IN	O	O
short	JJ	O	O
hairpin	NN	O	O
RNA	NNP	O	O
.	.	O	O
RESULTS	NNS	O	O
:	:	O	O
We	PRP	O	O
found	VBD	O	O
that	IN	O	O
forced	VBN	O	O
over	IN	B-PosReg	O
-	:	I-PosReg	O
expression	NN	I-PosReg	O
of	IN	O	O
p53	NN	B-Protein	O
-	:	I-Protein	O
R175H	NNP	I-Protein	O
significantly	RB	O	O
promoted	VBD	B-PosReg	B-PosReg
cell	NN	B-CPA	B-CPA
migration	NN	I-CPA	I-CPA
and	CC	I-CPA	O
invasion	NN	I-CPA	O
,	,	O	O
and	CC	O	O
induced	JJ	O	O
activation	NN	B-PosReg	O
of	IN	O	O
the	DT	O	O
epidermal	JJ	B-Pathway	O
growth	NN	I-Pathway	O
factor	NN	I-Pathway	O
receptor	NN	I-Pathway	O
(	(	I-Pathway	O
EGFR	NNP	I-Pathway	O
)	)	I-Pathway	O
phosphatidylinositol	VBD	I-Pathway	O
3	CD	I-Pathway	O
-	:	I-Pathway	O
kinase	NN	I-Pathway	O
(	(	I-Pathway	O
PI3K	NNP	I-Pathway	O
)	)	I-Pathway	O
AKT	NNP	I-Pathway	O
pathway	NN	I-Pathway	O
.	.	O	O
Conversely	RB	O	O
,	,	O	O
suppression	NN	B-NegReg	O
of	IN	O	O
p53	NN	B-Protein	O
-	:	I-Protein	O
R175H	NN	I-Protein	O
with	IN	O	O
short	JJ	B-Gene	O
hairpin	NN	I-Gene	O
RNA	NNP	I-Gene	O
significantly	RB	O	O
inhibited	VBD	B-NegReg	B-NegReg
cell	NN	B-CPA	B-CPA
migration	NN	I-CPA	I-CPA
and	CC	I-CPA	O
invasion	NN	I-CPA	O
,	,	O	O
and	CC	O	O
resulted	VBD	O	O
in	IN	O	O
attenuation	NN	B-NegReg	O
of	IN	O	O
EGFR	NNP	B-Pathway	O
PI3K	NNP	I-Pathway	O
AKT	NNP	I-Pathway	O
pathway	NN	I-Pathway	O
.	.	I-Pathway	O
CONCLUSION	NN	O	O
:	:	O	O
These	DT	O	O
findings	NNS	O	O
show	VBP	O	O
for	IN	O	O
the	DT	O	O
first	JJ	O	O
time	NN	O	O
that	WDT	O	O
elevated	VBD	B-PosReg	O
expression	NN	B-MPA	O
of	IN	O	O
p53	NN	B-Gene	O
-	:	O	O
R175H	NNP	B-Var	O
mutant	NN	O	O
may	MD	O	O
exert	VB	O	O
gain	VB	B-PosReg	B-PosReg
-	:	O	I-PosReg
of	IN	O	I-PosReg
-	:	O	I-PosReg
function	NN	B-MPA	I-PosReg
activity	NN	I-MPA	B-MPA
to	TO	O	O
activate	VB	B-PosReg	O
the	DT	O	O
EGFR	NNP	B-Pathway	O
PI3K	NNP	I-Pathway	O
AKT	NNP	I-Pathway	O
pathway	NN	I-Pathway	O
and	CC	O	O
thus	RB	O	O
may	MD	O	O
contribute	VB	B-Reg	O
to	TO	O	O
the	DT	O	O
invasive	JJ	O	O
phenotype	NN	O	O
in	IN	O	O
endometrial	JJ	B-Disease	B-Disease
cancer	NN	I-Disease	I-Disease

NR5A1	NNP	B-Gene	O
,	,	I-Disease	O
disorders	NNS	I-Disease	O
sex	NN	I-Disease	O
development	NN	I-Disease	O
loss	NN	B-NegReg	B-NegReg
of	IN	I-NegReg	I-NegReg
function	NN	I-NegReg	I-NegReg
mutations	NNS	B-Var	B-Var

PATIENT	NNP	O	O
(	(	O	O
S	NNP	O	O
)	)	O	O
:	:	O	O
Six	CD	O	O
46	CD	O	O
,	,	O	O
XY	NNP	O	O
DSD	NNP	O	O
patients	NNS	O	O
.	.	O	O

INTERVENTION	NNP	O	O
(	(	O	O
S	NNP	O	O
)	)	O	O
:	:	O	O
None	NN	O	O
.	.	O	O

MAIN	NNP	O	O
OUTCOME	NNP	O	O
MEASURE	NNP	O	O
(	(	O	O
S	NNP	O	O
)	)	O	O
:	:	O	O
Sanger	NN	O	O
sequencing	NN	O	O
and	CC	O	O
multiplex	JJ	O	O
ligation	NN	O	O
-	:	O	O
dependent	JJ	O	O
probe	NN	O	O
amplification	NN	O	O
analysis	NN	O	O
to	TO	O	O
identify	VB	O	O
the	DT	O	O
mutations	NNS	O	O
or	CC	O	O
deletions	NNS	O	O
duplications	NNS	O	O
of	IN	O	O
the	DT	O	O
NR5A1	NNP	O	O
gene	NN	O	O
.	.	O	O

Functional	JJ	O	O
studies	NNS	O	O
by	IN	O	O
transactivation	NN	O	O
assays	NNS	O	O
to	TO	O	O
predict	VB	O	O
the	DT	O	O
impact	NN	O	O
of	IN	O	O
mutations	NNS	O	O
on	IN	O	O
molecular	JJ	O	O
function	NN	O	O
.	.	O	O

RESULT	NNP	O	O
(	(	O	O
S	NNP	O	O
)	)	O	O
:	:	O	O
NR5A1	JJ	B-Gene	O
exons	NNS	O	O
sequencing	VBG	O	O
identified	VBN	B-Reg	O
in	IN	I-Reg	O
six	CD	O	O
46	CD	B-Disease	O
,	,	I-Disease	O
XY	NNP	I-Disease	O
DSD	NNP	I-Disease	O
patients	NNS	O	O
six	CD	O	O
novel	JJ	O	O
mutations	NNS	O	O
:	:	O	O
p	NN	B-Var	B-Var
.	.	I-Var	I-Var
T40R	NNP	I-Var	I-Var
,	,	O	O
p	NN	B-Var	B-Var
.	.	I-Var	I-Var
T47C	NNP	I-Var	I-Var
,	,	O	O
p	NN	B-Var	B-Var
.	.	I-Var	I-Var
G328W	NNP	I-Var	I-Var
,	,	O	O
p	NN	B-Var	B-Var
.	.	I-Var	I-Var
A351E	NNP	I-Var	I-Var
,	,	O	O
p	NN	B-Var	B-Var
.	.	I-Var	I-Var
R427W	NNP	I-Var	I-Var
,	,	O	O
and	CC	O	O
p	NN	B-Var	B-Var
.	.	I-Var	I-Var
Q460R	NNP	I-Var	I-Var
.	.	O	O
Five	CD	O	O
missense	JJ	O	O
variants	NNS	O	O
were	VBD	O	O
heterozygous	JJ	O	O
,	,	O	O
and	CC	O	O
one	CD	O	O
was	VBD	O	O
homozygous	JJ	O	O
(	(	O	O
p	NN	O	B-Var
.	.	O	I-Var
R427W	NNP	O	I-Var
)	)	O	O
.	.	O	O

Functional	JJ	O	O
analysis	NN	O	O
revealed	VBD	O	O
a	DT	O	O
significant	JJ	O	O
loss	NN	B-NegReg	B-NegReg
of	IN	O	O
DNA	NNP	B-Interaction	O
-	:	I-Interaction	O
binding	NN	I-Interaction	O
and	CC	O	O
transactivation	NN	B-MPA	O
ability	NN	O	O
for	IN	O	O
all	DT	O	O
variants	NNS	O	O
,	,	O	O
except	IN	O	O
for	IN	O	O
p	NN	O	B-Var
.	.	O	I-Var
Q460R	NNP	O	I-Var
,	,	O	O
which	WDT	O	O
showed	VBD	O	O
a	DT	O	O
modest	JJ	O	O
reduced	VBN	O	B-NegReg
activity	NN	O	B-MPA
compared	VBN	O	O
with	IN	O	O
that	DT	O	O
of	IN	O	O
the	DT	O	O
wild	JJ	O	O
-	:	O	O
type	NN	O	O
protein	NN	O	O
.	.	O	O
Phenotypes	NNS	O	O
associated	VBN	O	O
with	IN	O	O
these	DT	O	O
mutations	NNS	O	O
varied	VBD	O	O
from	IN	O	O
males	NNS	O	O
with	IN	O	O
spontaneous	JJ	O	O
puberty	NN	O	O
,	,	O	O
substantial	JJ	O	O
T	NNP	O	O
production	NN	O	O
,	,	O	O
and	CC	O	O
possible	JJ	O	O
fertility	NN	O	O
,	,	O	O
to	TO	O	O
females	NNS	O	O
with	IN	O	O
and	CC	O	O
without	IN	O	O
m	JJ	O	O
llerian	JJ	O	O
structures	NNS	O	O
and	CC	O	O
primary	JJ	O	O
amenorrhea	NN	O	O
.	.	O	O

CONCLUSION	NNP	O	O
(	(	O	O
S	NNP	O	O
)	)	O	O
:	:	O	O
We	PRP	O	O
describe	VBP	O	O
six	CD	O	O
novel	JJ	O	O
mutations	NNS	B-Var	O
in	IN	O	O
NR5A1	NNP	B-Gene	O
gene	NN	O	O
and	CC	O	O
showed	VBD	O	O
that	IN	O	O
they	PRP	O	O
might	MD	O	O
affect	VB	B-Reg	O
protein	NN	B-MPA	O
structure	NN	I-MPA	O
,	,	O	O
therefore	RB	O	O
compromising	VBG	B-NegReg	O
seriously	RB	O	O
the	DT	O	O
SF	NNP	B-MPA	O
-	:	I-MPA	O
1	CD	I-MPA	O
role	NN	O	O
in	IN	O	O
regulating	VBG	O	O
gonadal	NN	B-CPA	O
development	NN	I-CPA	O
.	.	O	O
Clinically	RB	O	O
,	,	O	O
we	PRP	O	O
suggest	VBP	O	O
that	IN	O	O
NR5A1	NNP	O	O
analysis	NN	O	O
should	MD	O	O
be	VB	O	O
performed	VBN	O	O
whenever	WRB	O	O
atypical	JJ	O	O
sex	NN	O	O
organs	NNS	O	O
are	VBP	O	O
evidenced	VBN	O	O
or	CC	O	O
there	EX	O	O
is	VBZ	O	O
an	DT	O	O
abnormal	JJ	O	O
sexual	JJ	O	O
development	NN	O	O
,	,	O	O
to	TO	O	O
have	VB	O	O
proper	JJ	O	O
diagnosis	NN	O	O
and	CC	O	O
better	JJR	O	O
management	NN	O	O
of	IN	O	O
patients	NNS	O	O

The	DT	O	O
most	RBS	O	O
frequent	JJ	O	O
LoF	NNP	B-NegReg	O
mutation	NN	B-Var	O
in	IN	O	O
human	JJ	O	O
cancers	NNS	O	O
is	VBZ	O	O
Adenomatous	JJ	B-Gene	O
polyposis	NN	I-Gene	O
coli	NN	I-Gene	O
(	(	O	O
APC	NNP	O	O
)	)	O	O
,	,	O	O
causing	VBG	O	O
aberrant	JJ	O	O
activation	NN	B-PosReg	O
of	IN	O	O
the	DT	O	O
Wnt	NNP	B-Pathway	O
pathway	NN	I-Pathway	O
.	.	O	O
In	IN	O	O
nearly	RB	O	O
all	DT	O	O
colon	NN	B-Disease	O
cancer	NN	I-Disease	O
tumors	NNS	I-Disease	O
,	,	O	O
the	DT	O	O
APC	NNP	B-Protein	O
protein	NN	I-Protein	O
is	VBZ	O	O
truncated	VBN	O	O
,	,	O	O
but	CC	O	O
still	RB	O	O
retains	VBZ	B-NegReg	B-MPA
partial	JJ	I-NegReg	I-MPA
binding	NN	B-Interaction	I-MPA
abilities	NNS	B-MPA	I-MPA
.	.	O	O
OBJECTIVE	NNP	O	O
METHODS	NNP	O	O
:	:	O	O
Here	RB	O	O
,	,	O	O
we	PRP	O	O
tested	VBD	O	O
the	DT	O	O
hypothesis	NN	O	O
that	WDT	O	O
extracellular	JJ	O	O
inhibitors	NNS	O	O
of	IN	O	O
the	DT	O	O
Wnt	NNP	O	O
pathway	NN	O	O
,	,	O	O
although	IN	O	O
acting	VBG	O	O
upstream	NN	O	O
of	IN	O	O
the	DT	O	O
APC	NNP	O	O
mutation	NN	O	O
,	,	O	O
can	MD	O	O
restore	VB	O	O
normal	JJ	O	O
levels	NNS	O	O
of	IN	O	O
pathway	NN	O	O
activity	NN	O	O
in	IN	O	O
colon	NN	O	O
cancer	NN	O	O
cells	NNS	O	O
.	.	O	O

To	TO	O	O
this	DT	O	O
end	NN	O	O
,	,	O	O
we	PRP	O	O
developed	VBD	O	O
and	CC	O	O
simulated	VBD	O	O
a	DT	O	O
mathematical	JJ	O	O
model	NN	O	O
for	IN	O	O
the	DT	O	O
Wnt	NNP	O	O
pathway	NN	O	O
in	IN	O	O
different	JJ	O	O
APC	NNP	O	O
mutants	NNS	O	O
,	,	O	O
with	IN	O	O
or	CC	O	O
without	IN	O	O
the	DT	O	O
effects	NNS	O	O
of	IN	O	O
the	DT	O	O
extracellular	JJ	O	O
inhibitors	NNS	O	O
,	,	O	O
Secreted	NNP	O	O
Frizzled	NNP	O	O
-	:	O	O
Related	VBN	O	O
Protein1	NNP	O	O
(	(	O	O
sFRP1	NN	O	O
)	)	O	O
and	CC	O	O
Dickhopf1	NNP	O	O
(	(	O	O
Dkk1	NNP	O	O
)	)	O	O
.	.	O	O

We	PRP	O	O
compared	VBN	O	O
our	PRP$	O	O
model	NN	O	O
predictions	NNS	O	O
to	TO	O	O
experimental	VB	O	O
data	NNS	O	O
in	IN	O	O
the	DT	O	O
literature	NN	O	O
.	.	O	O

RESULTS	NN	O	O
:	:	O	O
Our	PRP$	O	O
model	NN	O	O
accurately	RB	O	O
predicts	VBZ	O	O
T	NNP	O	O
-	:	O	O
cell	NN	O	O
factor	NN	O	O
(	(	O	O
TCF	NNP	O	O
)	)	O	O
activity	NN	O	O
in	IN	O	O
mutant	JJ	O	O
cells	NNS	O	O
that	WDT	O	O
vary	VBP	O	O
in	IN	O	O
APC	NNP	O	O
mutation	NN	O	O
.	.	O	O

Model	NNP	O	O
simulations	NNS	O	O
suggest	VBP	O	O
that	IN	O	O
both	DT	O	O
sFRP1	NNS	O	O
and	CC	O	O
DKK1	NNP	O	O
can	MD	O	O
reduce	VB	O	O
TCF	NNP	O	O
activity	NN	O	O
in	IN	O	O
APC1638N	NNP	O	O
1572	CD	O	O
T	NNP	O	O
and	CC	O	O
Apcmin	NNP	O	O
min	NN	O	O
mutants	NNS	O	O
,	,	O	O
but	CC	O	O
restoration	NN	O	O
of	IN	O	O
normal	JJ	O	B-MPA
activity	NN	O	I-MPA
levels	NNS	O	I-MPA
is	VBZ	O	O
possible	JJ	O	O
only	RB	O	O
in	IN	O	O
the	DT	O	O
former	JJ	O	O
.	.	O	O

When	WRB	O	O
applied	VBN	O	O
in	IN	O	O
combination	NN	O	O
,	,	O	O
synergism	NN	O	O
between	IN	O	O
the	DT	O	O
two	CD	O	O
inhibitors	NNS	O	O
can	MD	O	O
reduce	VB	O	O
their	PRP$	O	O
effective	JJ	O	O
doses	NNS	O	O
to	TO	O	O
one	CD	O	O
-	:	O	O
fourth	JJ	O	O
of	IN	O	O
the	DT	O	O
doses	NNS	O	O
required	VBN	O	O
under	IN	O	O
single	JJ	O	O
inhibitor	NN	O	O
application	NN	O	O
.	.	O	O

Overall	JJ	O	O
,	,	O	O
re	VB	O	O
-	:	O	O
establishment	NN	O	O
of	IN	O	O
normal	JJ	O	O
Wnt	NNP	O	O
pathway	NN	O	O
activity	NN	O	O
is	VBZ	O	O
predicted	VBN	O	O
for	IN	O	O
every	DT	O	O
APC	NNP	O	O
mutant	NN	O	O
in	IN	O	O
whom	WP	O	O
TCF	NNP	O	O
activity	NN	O	O
is	VBZ	O	O
increased	VBN	O	O
by	IN	O	O
up	IN	O	O
to	TO	O	O
11	CD	O	O
fold	NN	O	O
.	.	O	O

CONCLUSIONS	NN	O	O
:	:	O	O
Our	PRP$	O	O
work	NN	O	O
suggests	VBZ	O	O
that	IN	O	O
extracellular	JJ	O	O
inhibitors	NNS	O	O
can	MD	O	O
effectively	RB	O	O
restore	VB	O	O
normal	JJ	O	O
Wnt	NNP	O	O
pathway	NN	O	O
activity	NN	O	O
in	IN	O	O
APC	NNP	O	O
-	:	O	O
truncated	VBD	O	O
cancer	NN	O	O
cells	NNS	O	O
,	,	O	O
even	RB	O	O
though	IN	O	O
these	DT	O	O
LoF	NNP	O	O
mutations	NNS	O	O
occur	VBP	O	O
downstream	NN	O	O
of	IN	O	O
the	DT	O	O
inhibitory	JJ	O	O
action	NN	O	O
.	.	O	O

The	DT	O	O
insufficient	JJ	O	O
activity	NN	O	O
of	IN	O	O
the	DT	O	O
truncated	JJ	O	O
APC	NNP	O	O
can	MD	O	O
be	VB	O	O
quantitatively	RB	O	O
balanced	VBN	O	O
by	IN	O	O
the	DT	O	O
upstream	JJ	O	O
intervention	NN	O	O
.	.	O	O

This	DT	O	O
new	JJ	O	O
concept	NN	O	O
of	IN	O	O
upstream	JJ	O	O
intervention	NN	O	O
to	TO	O	O
control	VB	O	O
the	DT	O	O
effects	NNS	O	O
of	IN	O	O
downstream	NN	O	O
mutations	NNS	O	O
may	MD	O	O
be	VB	O	O
considered	VBN	O	O
also	RB	O	O
for	IN	O	O
other	JJ	O	O
partial	JJ	O	O
LoF	NNP	O	B-NegReg
mutations	NNS	O	B-Var
in	IN	O	O
other	JJ	O	O
signaling	VBG	O	O
pathways	NNS	O	O

METHODS	NNS	O	O
:	:	O	O
We	PRP	O	O
used	VBD	O	O
whole	JJ	O	O
-	:	O	O
exome	NN	O	O
sequencing	NN	O	O
in	IN	O	O
43	CD	O	O
sporadic	JJ	O	O
cases	NNS	O	O
affected	VBD	O	O
with	IN	O	O
myelomeningocele	NN	O	O
or	CC	O	O
anencephaly	NN	O	O
and	CC	O	O
their	PRP$	O	O
unaffected	JJ	O	O
parents	NNS	O	O
to	TO	O	O
identify	VB	O	O
DNMs	NNP	O	O
in	IN	O	O
their	PRP$	O	O
exomes	NNS	O	O
.	.	O	O

RESULTS	NNS	O	O
:	:	O	O
We	PRP	O	O
identified	VBD	O	O
42	CD	O	O
coding	VBG	O	O
DNMs	NNP	O	O
in	IN	O	O
25	CD	O	O
cases	NNS	O	O
,	,	O	O
of	IN	O	O
which	WDT	O	O
6	CD	O	O
were	VBD	O	O
loss	NN	O	O
of	IN	O	O
function	NN	O	O
(	(	O	O
LoF	NNP	O	O
)	)	O	O
showing	VBG	O	O
a	DT	O	O
higher	JJR	O	B-PosReg
rate	NN	O	O
of	IN	O	O
LoF	NNP	O	O
DNM	NNP	O	O
in	IN	O	O
our	PRP$	O	O
cohort	NN	O	O
compared	VBN	O	O
with	IN	O	O
control	NN	O	O
cohorts	NNS	O	O
.	.	O	O

Notably	RB	O	O
,	,	O	O
we	PRP	O	O
identified	VBD	O	O
two	CD	O	O
protein	SYM	B-Protein	O
-	:	O	O
truncating	VBG	B-NegReg	O
DNMs	NNP	B-Var	O
in	IN	O	O
two	CD	O	O
independent	JJ	O	O
cases	NNS	O	O
in	IN	O	O
SHROOM3	NNP	B-Gene	O
,	,	O	O
previously	RB	O	O
associated	VBN	O	O
with	IN	O	O
NTDs	NNP	O	O
only	RB	O	O
in	IN	O	O
animal	JJ	O	O
models	NNS	O	O
.	.	O	O
We	PRP	O	O
have	VBP	O	O
demonstrated	VBN	O	O
a	DT	O	O
significant	JJ	O	O
enrichment	NN	O	O
of	IN	O	O
LoF	NNP	B-NegReg	O
DNMs	NNP	B-Var	O
in	IN	O	O
this	DT	O	O
gene	NN	O	O
in	IN	O	O
NTDs	NNP	B-Disease	O
compared	VBN	O	O
with	IN	O	O
the	DT	O	O
gene	NN	O	O
specific	JJ	O	O
DNM	NNP	O	O
rate	NN	O	O
and	CC	O	O
to	TO	O	O
the	DT	O	O
DNM	NNP	O	O
rate	NN	O	O
estimated	VBN	O	O
from	IN	O	O
control	NN	O	O
cohorts	NNS	O	O
.	.	O	O
We	PRP	O	O
also	RB	O	O
identified	VBD	O	O
one	CD	O	O
nonsense	NN	O	O
DNM	NNP	O	O
in	IN	O	O
PAX3	NNP	O	O
and	CC	O	O
two	CD	O	O
potentially	RB	O	O
causative	JJ	O	O
missense	NN	O	O
DNMs	NNP	O	O
in	IN	O	O
GRHL3	NNP	O	O
and	CC	O	O
PTPRS	NNP	O	O
.	.	O	O

CONCLUSIONS	NN	O	O
:	:	O	O
Our	PRP$	O	O
study	NN	O	O
demonstrates	VBZ	O	O
an	DT	O	O
important	JJ	O	O
role	NN	O	O
of	IN	O	O
LoF	NNP	B-NegReg	O
DNMs	NNP	B-Var	O
in	IN	O	O
the	DT	O	O
development	NN	O	O
of	IN	O	O
NTDs	NNP	B-Disease	O
and	CC	O	O
strongly	RB	O	O
implicates	VBZ	O	O
SHROOM3	NNP	B-Gene	O
in	IN	O	O
its	PRP$	O	O
aetiology	NN	O	O

About	IN	O	O
90%	CD	O	O
of	IN	O	O
these	DT	O	O
mutations	NNS	O	B-Var
encode	VBP	O	B-Gene
missense	NN	O	B-Var
mutant	NN	O	I-Var
proteins	VBZ	O	O
that	IN	O	O
span	VBP	O	O
190	CD	O	O
different	JJ	O	O
codons	NNS	O	O
localized	VBN	O	O
in	IN	O	O
the	DT	O	O
DNA	NNP	O	O
-	:	O	O
binding	VBG	O	O
domain	NN	O	O
of	IN	O	O
the	DT	O	O
gene	NN	O	O
and	CC	O	O
protein	NN	O	O
.	.	O	O

These	DT	O	O
mutations	NNS	B-Var	B-Var
produce	VBP	O	B-PosReg
a	DT	O	O
protein	NN	O	O
with	IN	O	O
a	DT	O	O
reduced	JJ	O	B-NegReg
capacity	NN	O	B-MPA
to	TO	O	O
bind	VB	O	B-Interaction
to	TO	O	O
a	DT	O	O
specific	JJ	O	O
DNA	NNP	O	O
sequence	NN	O	O
that	WDT	O	O
regulates	VBZ	B-Reg	O
the	DT	O	O
p53	NN	B-Pathway	O
transcriptional	JJ	I-Pathway	O
pathway	NN	I-Pathway	O
.	.	O	O
Eight	CD	O	O
of	IN	O	O
these	DT	O	O
mutations	NNS	O	B-Var
are	VBP	O	O
localized	VBN	O	O
in	IN	O	O
codons	NNS	O	O
that	WDT	O	O
account	VBP	O	O
for	IN	O	O
28%	CD	O	O
of	IN	O	O
the	DT	O	O
total	JJ	O	O
p53	NN	O	O
mutations	NNS	O	O
and	CC	O	O
these	DT	O	O
alleles	NNS	O	O
appear	VBP	O	O
to	TO	O	O
be	VB	O	O
selected	VBN	O	O
for	IN	O	O
preferentially	RB	O	O
in	IN	O	O
human	JJ	O	O
cancers	NNS	O	O
of	IN	O	O
many	JJ	O	O
tissue	NN	O	O
types	NNS	O	O
.	.	O	O

This	DT	O	O
article	NN	O	O
explores	VBZ	O	O
the	DT	O	O
question	NN	O	O
Why	WRB	O	O
are	VBP	O	O
there	RB	O	O
hotspot	JJ	O	O
mutations	NNS	O	O
in	IN	O	O
the	DT	O	O
p53	NN	O	O
gene	NN	O	O
in	IN	O	O
human	JJ	O	O
cancers	NNS	O	O
?	.	O	O

Four	CD	O	O
possible	JJ	O	O
reasons	NNS	O	O
for	IN	O	O
this	DT	O	O
are	VBP	O	O
considered	VBN	O	O
;	:	O	O
(	(	O	O
1	CD	O	O
)	)	O	O
the	DT	O	O
hotspot	NN	O	O
mutant	JJ	B-Var	O
alleles	NNS	O	O
produce	VBP	O	O
a	DT	O	O
protein	NN	O	O
that	WDT	O	O
has	VBZ	O	O
a	DT	O	O
highly	RB	O	O
altered	JJ	B-Reg	O
structure	NN	B-MPA	O
,	,	O	O
(	(	O	O
2	CD	O	O
)	)	O	O
environmental	JJ	O	O
mutagens	NNS	O	O
produce	VBP	O	O
allele	JJ	O	O
-	:	O	O
specific	JJ	O	O
changes	NNS	O	O
in	IN	O	O
the	DT	O	O
p53	NN	O	O
gene	NN	O	O
,	,	O	O
(	(	O	O
3	CD	O	O
)	)	O	O
these	DT	O	O
mutations	NNS	O	B-Var
arise	VBP	O	B-Gene
at	IN	O	O
selected	VBN	O	O
sites	NNS	O	O
in	IN	O	O
the	DT	O	O
gene	NN	O	O
due	JJ	O	O
to	TO	O	O
a	DT	O	O
specific	JJ	O	O
DNA	NNP	O	O
sequence	NN	O	O
,	,	O	O
such	JJ	O	O
as	IN	O	O
a	DT	O	O
methylated	JJ	O	O
cytosine	NN	O	O
residue	NN	O	O
in	IN	O	O
a	DT	O	O
CpG	NNP	O	O
dinucleotide	NN	O	O
,	,	O	O
which	WDT	O	O
has	VBZ	O	O
a	DT	O	O
higher	JJR	O	B-PosReg
mutation	NN	O	B-Var
rate	NN	O	O
changing	VBG	O	O
C	NNP	O	O
to	TO	O	O
T	NNP	O	O
nucleotides	NNS	O	O
,	,	O	O
(	(	O	O
4	CD	O	O
)	)	O	O
along	IN	O	O
with	IN	O	O
the	DT	O	O
observed	JJ	O	O
change	NN	O	O
in	IN	O	O
mutant	JJ	O	B-Var
p53	NN	O	B-Gene
proteins	NNS	O	B-Protein
,	,	O	O
which	WDT	O	O
produce	VBP	O	O
a	DT	O	O
loss	NN	O	O
of	IN	O	O
function	NN	O	O
(	(	O	O
DNA	NNP	O	O
binding	NN	O	O
and	CC	O	O
transcription	NN	O	O
)	)	O	O
,	,	O	O
some	DT	O	O
mutant	JJ	B-Var	O
proteins	NNS	B-Protein	O
have	VBP	O	O
an	DT	O	O
allele	JJ	O	O
-	:	O	O
specific	JJ	O	O
gain	NN	B-PosReg	O
of	IN	I-PosReg	O
function	NN	I-PosReg	O
that	WDT	O	O
promotes	VBZ	O	O
cancer	NN	B-Disease	O
.	.	O	O
Evidence	NN	O	O
is	VBZ	O	O
presented	VBN	O	O
that	IN	O	O
demonstrates	VBZ	O	O
the	DT	O	O
first	JJ	O	O
three	CD	O	O
possibilities	NNS	O	O
all	DT	O	O
contribute	VBP	O	O
some	DT	O	O
property	NN	O	O
to	TO	O	O
this	DT	O	O
list	NN	O	O
of	IN	O	O
hotspot	NN	O	O
mutations	NNS	O	O
.	.	O	O

The	DT	O	O
fourth	JJ	O	O
possibility	NN	O	O
remains	VBZ	O	O
to	TO	O	O
be	VB	O	O
tested	VBN	O	O

Pointed	NNP	O	O
(	(	O	O
Pnt	NNP	O	O
)	)	O	O
is	VBZ	O	O
a	DT	O	O
transcriptional	JJ	O	O
activator	NN	O	O
that	IN	O	O
functions	NNS	O	O
downstream	NN	O	O
of	IN	O	O
the	DT	O	O
highly	RB	O	O
conserved	JJ	O	O
Receptor	NNP	O	O
Tyrosine	NNP	O	O
Kinase	NNP	O	O
(	(	O	O
RTK	NNP	O	O
)	)	O	O
signaling	VBG	O	O
pathway	NN	O	O
.	.	O	O

Pnt	NNP	O	O
is	VBZ	O	O
an	DT	O	O
ETS	NNP	O	O
family	NN	O	O
transcription	NN	O	O
factor	NN	O	O
and	CC	O	O
encodes	NNS	O	O
for	IN	O	O
two	CD	O	O
proteins	NNS	O	O
,	,	O	O
PntP1	NNP	O	O
and	CC	O	O
PntP2	NNP	O	O
.	.	O	O

However	RB	O	O
,	,	O	O
while	IN	O	O
PntP1	NNP	O	O
is	VBZ	O	O
constitutively	RB	O	O
active	JJ	O	O
,	,	O	O
PntP2	NNP	O	O
is	VBZ	O	O
only	RB	O	O
active	JJ	O	O
after	IN	O	O
being	VBG	O	O
phosphorylated	VBN	O	O
by	IN	O	O
MAPK	NNP	O	O
in	IN	O	O
the	DT	O	O
RTK	NNP	O	O
pathway	NN	O	O
.	.	O	O

As	IN	O	O
mutations	NNS	B-Var	O
in	IN	O	O
pnt	NN	B-Gene	O
perturb	IN	B-Reg	O
the	DT	O	O
development	NN	B-CPA	O
of	IN	I-CPA	O
several	JJ	I-CPA	O
tissues	NNS	I-CPA	O
,	,	O	O
we	PRP	O	O
wanted	VBD	O	O
to	TO	O	O
examine	VB	O	O
the	DT	O	O
effect	NN	O	O
and	CC	O	O
efficacy	NN	O	O
of	IN	O	O
using	VBG	O	O
RNAi	NNP	O	O
to	TO	O	O
target	VB	O	O
Pnt	NNP	O	O
.	.	O	O
We	PRP	O	O
have	VBP	O	O
expressed	VBN	O	O
pnt	JJ	O	O
RNAi	NNP	O	O
in	IN	O	O
the	DT	O	O
eyes	NNS	O	O
,	,	O	O
oocyte	NN	O	O
,	,	O	O
and	CC	O	O
heart	NN	O	O
cells	NNS	O	O
using	VBG	O	O
three	CD	O	O
different	JJ	O	O
RNAi	NNP	O	O
lines	NNS	O	O
:	:	O	O
Valium20	NNP	O	O
,	,	O	O
Valium10	NNP	O	O
,	,	O	O
and	CC	O	O
VDRC	NNP	O	O
.	.	O	O

Valium20	NNP	O	O
is	VBZ	O	O
distinct	JJ	O	O
since	IN	O	O
it	PRP	O	O
generates	VBZ	O	O
a	DT	O	O
short	JJ	O	O
hairpin	NN	O	O
RNA	NNP	O	O
(	(	O	O
shRNA	NN	O	O
)	)	O	O
,	,	O	O
while	IN	O	O
Valium10	NNP	O	O
and	CC	O	O
VDRC	NNP	O	O
produce	VBP	O	O
long	JJ	O	O
hairpin	NN	O	O
dsRNA	NN	O	O
.	.	O	O

We	PRP	O	O
found	VBD	O	O
that	IN	O	O
for	IN	O	O
each	DT	O	O
tissue	NN	O	O
examined	VBD	O	O
Valium20	NNP	O	O
exhibited	VBD	O	O
the	DT	O	O
strongest	JJS	O	O
phenotype	NN	O	O
while	IN	O	O
the	DT	O	O
Valium10	NNP	O	O
and	CC	O	O
VDRC	NNP	O	O
lines	NNS	O	O
produced	VBD	O	O
varying	VBG	O	O
levels	NNS	O	O
of	IN	O	O
severity	NN	O	O
and	CC	O	O
that	IN	O	O
the	DT	O	O
long	JJ	O	O
hairpin	NN	O	O
RNA	NNP	O	O
produced	VBN	O	O
by	IN	O	O
the	DT	O	O
Valium10	NNP	O	O
and	CC	O	O
VDRC	NNP	O	O
lines	NNS	O	O
are	VBP	O	O
unable	JJ	O	B-NegReg
to	TO	O	O
effectively	RB	O	O
knockdown	VB	O	O
pnt	NN	O	O
in	IN	O	O
embryonic	JJ	O	O
tissues	NNS	O	O

RIG	NNP	B-Gene	O
-	:	I-Gene	O
I	PRP	I-Gene	O
C268F	NNP	B-Var	O
E373A	NNP	B-Var	O
impaired	JJ	B-NegReg	B-NegReg
ATPase	NNP	B-Protein	B-MPA
activity	NN	B-MPA	I-MPA
hyperactive	JJ	B-PosReg	I-MPA
signaling	NN	B-MPA	I-MPA

Cap1	NNP	O	O
-	:	O	O
RNA	NN	O	O
compromises	VBZ	O	O
its	PRP$	O	O
ability	NN	O	O
to	TO	O	O
stabilize	VB	O	O
RIG	NNP	O	O
-	:	O	O
I	PRP	O	O
helicase	VBP	O	O
and	CC	O	O
blunts	NNS	O	O
caspase	VB	O	O
activation	NN	O	O
and	CC	O	O
recruitment	NN	O	O
domains	NNS	O	O
(	(	O	O
CARD	NNP	O	O
)	)	O	O
partial	JJ	O	O
opening	NN	O	O
by	IN	O	O
threefold	NN	O	O
.	.	O	O

RIG	NNP	B-Gene	O
-	:	I-Gene	O
I	PRP	I-Gene	O
H830A	VBP	B-Var	O
mutation	NN	I-Var	O
restores	NNS	B-PosReg	O
Cap1	NNP	B-Protein	O
-	:	I-Protein	O
helicase	NN	I-Protein	O
engagement	NN	B-MPA	O
as	RB	O	O
well	RB	O	O
as	IN	O	O
CARDs	NNP	B-MPA	O
partial	JJ	I-MPA	O
opening	NN	I-MPA	O
event	NN	I-MPA	O
to	TO	O	O
a	DT	O	O
level	NN	O	O
comparable	JJ	O	O
to	TO	O	O
that	DT	O	O
of	IN	O	O
5	CD	O	O
ppp	NN	O	O
.	.	O	O
However	RB	O	O
,	,	O	O
E373A	NNP	B-Var	O
RIG	NNP	B-Gene	O
-	:	I-Gene	O
I	PRP	I-Gene	O
locks	VBP	O	O
the	DT	O	O
receptor	NN	O	O
in	IN	O	O
an	DT	O	O
ATP	NNP	O	O
-	:	O	O
bound	NN	O	O
state	NN	O	O
,	,	O	O
resulting	VBG	O	O
in	IN	O	O
enhanced	VBN	B-PosReg	O
Cap1	NNP	B-Protein	O
-	:	I-Protein	O
helicase	NN	I-Protein	O
engagement	NN	B-MPA	O
and	CC	O	O
a	DT	O	O
sequential	JJ	B-MPA	O
CARDs	NNP	I-MPA	O
stimulation	NN	I-MPA	O
.	.	O	O
C268F	NNP	B-Var	O
mutation	NN	I-Var	O
renders	VBZ	O	O
a	DT	O	O
more	RBR	B-PosReg	O
tethered	JJ	B-MPA	O
ring	NN	I-MPA	O
architecture	NN	I-MPA	O
and	CC	O	O
results	NNS	B-Reg	O
in	IN	I-Reg	O
constitutive	JJ	B-MPA	O
CARDs	NNP	I-MPA	O
signaling	NN	I-MPA	O
in	IN	O	O
an	DT	O	O
ATP	NNP	O	O
-	:	O	O
independent	JJ	O	O
manner	NN	O	O

-	:	I-Gene	I-PosReg
of	IN	I-NegReg	I-PosReg
-	:	I-NegReg	I-PosReg
Function	NN	I-NegReg	I-PosReg
Mutations	NNS	B-Var	B-Var
Loss	NNP	B-NegReg	B-NegReg
-	:	I-NegReg	I-NegReg
of	IN	I-NegReg	I-NegReg
-	:	I-NegReg	I-NegReg
function	NN	I-NegReg	I-NegReg
mutations	NNS	B-Var	B-Var
APOC3	NNP	B-Gene	B-Gene
low	JJ	B-NegReg	B-NegReg
remnant	NN	B-MPA	B-MPA
cholesterol	NN	I-MPA	I-MPA
levels	NNS	I-MPA	I-MPA

We	PRP	O	O
tested	VBD	O	O
to	TO	O	O
what	WP	O	O
extent	VB	O	O
the	DT	O	O
low	JJ	O	O
risk	NN	O	O
of	IN	O	O
IVD	NNP	O	O
in	IN	O	O
APOC3	NNP	O	O
loss	NN	O	O
-	:	O	O
of	IN	O	O
-	:	O	O
function	NN	O	O
heterozygotes	NNS	O	O
is	VBZ	O	O
mediated	VBN	O	O
by	IN	O	O
low	JJ	O	O
plasma	NN	O	O
remnant	NN	O	O
cholesterol	NN	O	O
and	CC	O	O
LDL	NNP	O	O
-	:	O	O
C.	NNP	O	O

APPROACH	NN	O	O
AND	CC	O	O
RESULTS	NNP	O	O
:	:	O	O
In	IN	O	O
APOC3	NNP	O	O
loss	NN	O	O
-	:	O	O
of	IN	O	O
-	:	O	O
function	NN	O	O
heterozygotes	VBZ	O	O
versus	IN	O	O
noncarriers	NNS	O	O
,	,	O	O
we	PRP	O	O
first	RB	O	O
determined	VBD	O	O
remnant	JJ	O	O
cholesterol	NN	O	O
and	CC	O	O
LDL	NNP	O	B-MPA
-	:	O	I-MPA
C	NN	O	I-MPA
levels	NNS	O	I-MPA
in	IN	O	O
meta	NN	O	O
-	:	O	O
analyses	NNS	O	O
of	IN	O	O
137	CD	O	O
895	CD	O	O
individuals	NNS	O	O
.	.	O	O

Second	JJ	O	O
,	,	O	O
we	PRP	O	O
determined	VBD	O	O
whether	IN	O	O
the	DT	O	O
association	NN	O	O
with	IN	O	O
LDL	NNP	O	O
-	:	O	O
C	NNP	O	O
was	VBD	O	O
masked	VBN	O	O
by	IN	O	O
lipid	JJ	O	O
-	:	O	O
lowering	VBG	O	O
therapy	NN	O	O
.	.	O	O

Finally	RB	O	O
,	,	O	O
using	VBG	O	O
mediation	NN	O	O
analysis	NN	O	O
,	,	O	O
we	PRP	O	O
determined	VBD	O	O
the	DT	O	O
fraction	NN	O	O
of	IN	O	O
the	DT	O	O
low	JJ	O	O
risk	NN	O	O
of	IN	O	O
IVD	NNP	O	O
and	CC	O	O
ischemic	JJ	O	O
heart	NN	O	O
disease	NN	O	O
mediated	VBN	O	O
by	IN	O	O
remnant	JJ	O	O
cholesterol	NN	O	O
and	CC	O	O
LDL	NNP	O	O
-	:	O	O
C.	NNP	O	O

In	IN	O	O
meta	SYM	O	O
-	:	O	O
analyses	NNS	O	O
,	,	O	O
remnant	JJ	O	O
cholesterol	NN	O	O
was	VBD	O	O
43%	CD	O	O
lower	JJR	O	O
(	(	O	O
95%	CD	O	O
confidence	NN	O	O
interval	NN	O	O
,	,	O	O
40%	CD	O	O
-	:	O	O
47%	CD	O	O
)	)	O	O
,	,	O	O
and	CC	O	O
LDL	NNP	O	O
-	:	O	O
C	NNP	O	O
was	VBD	O	O
4%	CD	O	O
lower	JJR	O	O
(	(	O	O
1%	CD	O	O
-	:	O	O
6%	CD	O	O
)	)	O	O
in	IN	O	O
loss	NN	O	O
-	:	O	O
of	IN	O	O
-	:	O	O
function	NN	O	O
heterozygotes	NNS	O	O
(	(	O	O
n	JJ	O	O
776	CD	O	O
)	)	O	O
versus	NN	O	O
noncarriers	NNS	O	O
.	.	O	O

In	IN	O	O
the	DT	O	O
general	JJ	O	O
population	NN	O	O
,	,	O	O
LDL	NNP	O	O
-	:	O	O
C	NNP	O	O
was	VBD	O	O
3%	CD	O	O
lower	JJR	O	O
in	IN	O	O
loss	NN	O	O
-	:	O	O
of	IN	O	O
-	:	O	O
function	NN	O	O
heterozygotes	VBZ	O	O
versus	IN	O	O
noncarriers	NNS	O	O
,	,	O	O
4%	CD	O	O
lower	JJR	O	O
when	WRB	O	O
correcting	VBG	O	O
for	IN	O	O
lipid	JJ	O	O
-	:	O	O
lowering	VBG	O	O
therapy	NN	O	O
,	,	O	O
and	CC	O	O
3%	CD	O	O
lower	JJR	O	O
in	IN	O	O
untreated	JJ	O	O
individuals	NNS	O	O
(	(	O	O
P	NNP	O	O
values	NNS	O	O
,	,	O	O
0.06	CD	O	O
-	:	O	O
0.008	CD	O	O
)	)	O	O
.	.	O	O

Remnant	NNP	O	O
cholesterol	NN	O	O
mediated	VBD	O	O
37%	CD	O	O
of	IN	O	O
the	DT	O	O
observed	JJ	O	O
41%	CD	O	O
lower	JJR	O	O
risk	NN	O	O
of	IN	O	O
IVD	NNP	O	O
and	CC	O	O
54%	CD	O	O
of	IN	O	O
the	DT	O	O
observed	JJ	O	O
36%	CD	O	O
lower	JJR	O	O
risk	NN	O	O
of	IN	O	O
ischemic	JJ	O	O
heart	NN	O	O
disease	NN	O	O
;	:	O	O
corresponding	VBG	O	O
values	NNS	O	O
mediated	VBN	O	O
by	IN	O	O
LDL	NNP	O	O
-	:	O	O
C	NNP	O	O
were	VBD	O	O
1%	CD	O	O
and	CC	O	O
2%	CD	O	O
.	.	O	O

CONCLUSIONS	NN	O	O
:	:	O	O
The	DT	O	O
low	JJ	O	O
risk	NN	O	O
of	IN	O	O
IVD	NNP	O	O
observed	VBD	O	O
in	IN	O	O
APOC3	NNP	B-Gene	O
loss	NN	B-NegReg	O
-	:	I-NegReg	O
of	IN	I-NegReg	O
-	:	I-NegReg	O
function	NN	I-NegReg	O
heterozygotes	NNS	O	O
is	VBZ	O	O
mainly	RB	O	O
mediated	VBN	O	O
by	IN	O	O
the	DT	O	O
associated	VBN	O	O
low	JJ	B-NegReg	O
remnant	NN	B-MPA	O
cholesterol	NN	I-MPA	O
and	CC	O	O
not	RB	O	O
by	IN	O	O
low	JJ	O	O
LDL	NNP	O	O
-	:	O	O
C.	NNP	O	O
Furthermore	RB	O	O
,	,	O	O
the	DT	O	O
contribution	NN	O	O
of	IN	O	O
LDL	NNP	O	O
-	:	O	O
C	NN	O	O
to	TO	O	O
IVD	NNP	O	O
risk	NN	O	O
was	VBD	O	O
not	RB	O	O
masked	VBN	O	O
by	IN	O	O
lipid	JJ	O	O
-	:	O	O
lowering	VBG	O	O
therapy	NN	O	O
.	.	O	O

This	DT	O	O
suggests	VBZ	O	O
APOC3	NNP	O	O
and	CC	O	O
remnant	VB	O	O
cholesterol	NN	O	O
as	IN	O	O
important	JJ	O	O
new	JJ	O	O
targets	NNS	O	O
for	IN	O	O
reducing	VBG	O	O
cardiovascular	JJ	O	O
risk	NN	O	O

BACKGROUND	NN	O	O
:	:	O	O
PAI	NNP	B-Gene	O
-	:	I-Gene	O
1	CD	I-Gene	O
gain	NN	O	O
-	:	O	O
of	IN	O	O
-	:	O	O
function	NN	O	O
variants	NNS	B-Var	B-Var
promote	VBP	B-PosReg	B-PosReg
airway	JJ	B-CPA	B-MPA
fibrosis	NN	I-CPA	I-MPA
and	CC	O	O
are	VBP	O	O
associated	VBN	B-Reg	O
with	IN	I-Reg	O
asthma	NNS	B-Disease	O
and	CC	O	O
with	IN	O	O
worse	JJR	O	O
lung	NN	O	O
function	NN	O	O
in	IN	O	O
subjects	NNS	O	O
with	IN	O	O
asthma	NN	O	O
.	.	O	O
OBJECTIVE	NN	O	O
:	:	O	O
We	PRP	O	O
sought	VBD	O	O
to	TO	O	O
determine	VB	O	O
whether	IN	O	O
the	DT	O	O
association	NN	O	O
of	IN	O	O
a	DT	O	O
gain	NN	O	O
-	:	O	O
of	IN	O	O
-	:	O	O
function	NN	O	O
polymorphism	NN	O	O
in	IN	O	O
plasminogen	NN	O	O
activator	NN	O	O
inhibitor	NN	O	O
-	:	O	O
1	CD	O	O
(	(	O	O
PAI	NNP	O	O
-	:	O	O
1	CD	O	O
)	)	O	O
with	IN	O	O
airway	JJ	O	O
obstruction	NN	O	O
is	VBZ	O	O
modified	VBN	O	O
by	IN	O	O
asthma	NN	O	O
status	NN	O	O
,	,	O	O
and	CC	O	O
whether	IN	O	O
any	DT	O	O
genotype	JJ	O	O
effect	NN	O	O
persists	NNS	O	O
after	IN	O	O
accounting	VBG	O	O
for	IN	O	O
common	JJ	O	O
exposures	NNS	O	O
that	WDT	O	O
increase	VBP	O	B-PosReg
PAI	NNP	O	B-MPA
-	:	O	I-MPA
1	CD	O	I-MPA
level	NN	O	I-MPA
.	.	O	O

METHODS	NNS	O	O
:	:	O	O
We	PRP	O	O
studied	VBD	O	O
2070	CD	O	O
Latino	NNP	O	O
children	NNS	O	O
(	(	O	O
8	CD	O	O
-	:	O	O
21	CD	O	O
y	NN	O	O
)	)	O	O
with	IN	O	O
genotypic	NN	O	O
and	CC	O	O
pulmonary	JJ	O	O
function	NN	O	O
data	NNS	O	O
from	IN	O	O
the	DT	O	O
GALA	NNP	O	O
II	NNP	O	O
cohort	NN	O	O
.	.	O	O

We	PRP	O	O
estimated	VBD	O	O
the	DT	O	O
relationship	NN	O	O
of	IN	O	O
the	DT	O	O
PAI	NNP	O	O
-	:	O	O
1	CD	O	O
risk	NN	O	O
allele	NN	O	O
with	IN	O	O
FEV1	NNP	O	O
FVC	NNP	O	O
by	IN	O	O
multivariate	NN	O	O
linear	JJ	O	O
regression	NN	O	O
,	,	O	O
stratified	VBN	O	O
by	IN	O	O
asthma	NN	O	O
status	NN	O	O
.	.	O	O

We	PRP	O	O
examined	VBD	O	O
the	DT	O	O
association	NN	O	O
of	IN	O	O
the	DT	O	O
polymorphism	NN	O	O
with	IN	O	O
asthma	NN	O	O
and	CC	O	O
airway	JJ	O	O
obstruction	NN	O	O
within	IN	O	O
asthmatics	NNS	O	O
via	IN	O	O
multivariate	NN	O	O
logistic	JJ	O	O
regression	NN	O	O
.	.	O	O

We	PRP	O	O
replicated	VBD	O	O
associations	NNS	O	O
in	IN	O	O
the	DT	O	O
SAPPHIRE	NNP	O	O
cohort	NN	O	O
of	IN	O	O
African	JJ	O	O
Americans	NNPS	O	O
(	(	O	O
n	JJ	O	O
1056	CD	O	O
)	)	O	O
.	.	O	O

Secondary	JJ	O	O
analysis	NN	O	O
included	VBD	O	O
the	DT	O	O
effect	NN	O	O
of	IN	O	O
the	DT	O	O
at	IN	O	O
-	:	O	O
risk	NN	O	O
polymorphism	NN	O	O
on	IN	O	O
postbronchodilator	NN	O	O
lung	NN	O	O
function	NN	O	O
.	.	O	O

RESULTS	NN	O	O
:	:	O	O
There	EX	O	O
was	VBD	O	O
an	DT	O	O
interaction	NN	O	O
between	IN	O	O
asthma	NN	O	O
status	NN	O	O
and	CC	O	O
the	DT	O	O
PAI	NNP	O	O
-	:	O	O
1	CD	O	O
polymorphism	NN	O	O
on	IN	O	O
FEV1	NNP	O	O
FVC	NNP	O	O
(	(	O	O
P	NNP	O	B-Var
.	.	O	I-Var
03	CD	O	I-Var
)	)	O	O
.	.	O	O

The	DT	O	O
gain	NN	O	O
-	:	O	O
of	IN	O	O
-	:	O	O
function	NN	O	O
variants	NNS	O	O
,	,	O	O
genotypes	NNS	O	O
(	(	O	O
AA	NNP	O	O
AG	NNP	O	O
)	)	O	O
,	,	O	O
were	VBD	O	O
associated	VBN	O	B-Reg
with	IN	O	O
lower	JJR	O	O
FEV1	NNP	O	O
FVC	NNP	O	O
in	IN	O	O
subjects	NNS	O	O
with	IN	O	O
asthma	NN	O	O
(	(	O	O
-	:	O	O
1.25	CD	O	O
,	,	O	O
CI	NNP	O	O
:	:	O	O
-	:	O	O
2.14	CD	O	O
,	,	O	O
-	:	O	O
0.35	CD	O	O
,	,	O	O
P	NNP	O	B-Var
.	.	O	I-Var
006	CD	O	I-Var
)	)	O	O
,	,	O	O
but	CC	O	O
not	RB	O	O
in	IN	O	O
controls	NNS	O	O
.	.	O	O

Subjects	NNS	O	O
with	IN	O	O
asthma	NN	O	O
and	CC	O	O
the	DT	O	O
AA	NNP	O	O
AG	NNP	O	O
genotypes	NNS	O	O
had	VBD	O	O
a	DT	O	O
5%	CD	O	O
decrease	NN	O	O
in	IN	O	O
FEV1	NNP	O	O
FVC	NNP	O	O
(	(	O	O
P	NNP	O	B-Var
.	.	O	I-Var
001	CD	O	I-Var
)	)	O	O
.	.	O	O

In	IN	O	O
asthmatics	NNS	O	O
,	,	O	O
the	DT	O	O
risk	NN	O	O
genotype	NN	O	O
(	(	O	O
AA	NNP	O	O
AG	NNP	O	O
)	)	O	O
was	VBD	O	O
associated	VBN	O	O
with	IN	O	O
a	DT	O	O
39%	CD	O	O
increase	NN	O	O
in	IN	O	O
risk	NN	O	O
of	IN	O	O
clinically	RB	O	O
relevant	JJ	O	O
airway	NN	O	O
obstruction	NN	O	O
(	(	O	O
OR	CC	O	O
1.39	CD	O	O
,	,	O	O
CI	NNP	O	O
:	:	O	O
1.01	CD	O	O
,	,	O	O
1.92	CD	O	O
,	,	O	O
P	NNP	O	B-Var
.	.	O	I-Var
04	CD	O	I-Var
)	)	O	O
.	.	O	O

These	DT	O	O
associations	NNS	O	O
persisted	VBD	O	O
after	IN	O	O
exclusion	NN	O	O
of	IN	O	O
factors	NNS	O	O
that	IN	O	O
increase	NN	O	O
PAI	NNP	O	O
-	:	O	O
1	CD	O	O
including	VBG	O	O
tobacco	NN	O	O
exposure	NN	O	O
and	CC	O	O
obesity	NN	O	O
.	.	O	O

CONCLUSIONS	NNP	O	O
AND	NNP	O	O
CLINICAL	NNP	O	O
RELEVANCE	NNP	O	O
:	:	O	O
The	DT	O	O
decrease	NN	O	O
in	IN	O	O
the	DT	O	O
FEV1	NNP	O	O
FVC	NNP	O	O
ratio	NN	O	O
associated	VBN	O	O
with	IN	O	O
the	DT	O	O
risk	NN	O	O
genotype	NN	O	O
was	VBD	O	O
modified	VBN	O	O
by	IN	O	O
asthma	NN	O	O
status	NN	O	O
.	.	O	O

The	DT	O	O
genotype	NN	O	O
increased	VBD	O	O
the	DT	O	O
odds	NNS	O	O
of	IN	O	O
airway	JJ	O	O
obstruction	NN	O	O
by	IN	O	O
75%	CD	O	O
within	IN	O	O
asthmatics	NNS	O	O
only	RB	O	O
.	.	O	O

As	IN	O	O
exposures	NNS	O	O
known	VBN	O	O
to	TO	O	O
increase	VB	O	B-PosReg
PAI	NNP	O	B-MPA
-	:	O	I-MPA
1	CD	O	I-MPA
levels	NNS	O	I-MPA
did	VBD	O	O
not	RB	O	O
mitigate	VB	O	O
this	DT	O	O
association	NN	O	O
,	,	O	O
PAI	NNP	O	O
-	:	O	O
1	CD	O	O
may	MD	O	O
contribute	VB	O	O
to	TO	O	O
airway	VB	O	O
obstruction	NN	O	O
in	IN	O	O
the	DT	O	O
context	NN	O	O
of	IN	O	O
chronic	JJ	O	O
asthmatic	JJ	O	O
airway	NN	O	O
inflammation	NN	O	O

Post	NNP	O	O
-	:	O	O
zygotic	JJ	O	O
activating	NN	O	O
mutations	NNS	O	O
in	IN	O	O
PIK3CA	NNP	O	O
and	CC	O	O
other	JJ	O	O
genes	NNS	O	O
encoding	VBG	O	O
members	NNS	O	O
of	IN	O	O
PI3K	NNP	O	O
-	:	O	O
AKT	NNP	O	O
-	:	O	O
mTOR	NN	O	O
pathway	NN	O	O
have	VBP	O	O
been	VBN	O	O
found	VBN	O	O
in	IN	O	O
various	JJ	O	O
overgrowth	NN	O	O
syndromes	NNS	O	O
that	WDT	O	O
have	VBP	O	O
been	VBN	O	O
grouped	VBN	O	O
together	RB	O	O
as	IN	O	O
PIK3CA	NNP	O	O
-	:	O	O
related	JJ	O	O
overgrowth	NN	O	O
spectrum	NN	O	O
(	(	O	O
PROS	NNP	O	O
)	)	O	O
.	.	O	O

We	PRP	O	O
report	VBP	O	O
a	DT	O	O
female	JJ	O	O
patient	NN	O	O
with	IN	O	O
gait	JJ	O	O
disturbance	NN	O	O
,	,	O	O
leg	NN	O	O
pain	NN	O	O
,	,	O	O
isolated	VBD	O	O
macrodactyly	NN	O	O
of	IN	O	O
the	DT	O	O
foot	NN	O	O
,	,	O	O
and	CC	O	O
mild	JJ	O	O
intellectual	JJ	O	O
disability	NN	O	O
.	.	O	O

Imaging	NN	O	O
of	IN	O	O
the	DT	O	O
lower	JJR	O	O
limb	NN	O	O
showed	VBD	O	O
a	DT	O	O
lipoblastoma	NN	O	O
of	IN	O	O
the	DT	O	O
right	JJ	O	O
thigh	NN	O	O
.	.	O	O

A	DT	O	O
mosaic	NN	O	O
gain	NN	B-PosReg	O
-	:	I-PosReg	O
of	IN	I-PosReg	O
-	:	I-PosReg	O
function	NN	I-PosReg	O
mutation	NN	O	O
in	IN	O	O
the	DT	O	O
catalytic	JJ	O	O
domain	NN	O	O
of	IN	O	O
PIK3CA	NNP	B-Gene	O
(	(	O	O
c	NN	B-Var	O
.	.	I-Var	O
3140	CD	I-Var	O
A	NNP	I-Var	O
G	NNP	I-Var	O
;	:	O	O
p	NN	B-Var	B-Var
.	.	I-Var	I-Var
His1047Arg	NNP	I-Var	I-Var
)	)	O	O
was	VBD	O	O
detected	VBN	O	O
in	IN	O	O
the	DT	O	O
adipose	JJ	O	O
tissue	NN	O	O
and	CC	O	O
in	IN	O	O
skin	NN	O	O
cultured	VBN	O	O
fibroblasts	NNS	O	O
from	IN	O	O
the	DT	O	O
macrodactyly	NN	O	O
but	CC	O	O
not	RB	O	O
in	IN	O	O
blood	NN	O	O
.	.	O	O
The	DT	O	O
leg	NN	O	O
pain	NN	O	O
and	CC	O	O
the	DT	O	O
severe	JJ	O	O
walking	NN	O	O
disturbance	NN	O	O
improved	VBD	O	O
slightly	RB	O	O
over	IN	O	O
time	NN	O	O
and	CC	O	O
serial	JJ	O	O
MRI	NNP	O	O
of	IN	O	O
the	DT	O	O
lower	JJR	O	O
limbs	NN	O	O
suggested	VBD	O	O
that	IN	O	O
the	DT	O	O
size	NN	O	O
of	IN	O	O
the	DT	O	O
lipoblastoma	NN	O	O
relative	NN	O	O
to	TO	O	O
the	DT	O	O
lower	JJR	O	O
limb	NN	O	O
muscles	NNS	O	O
or	CC	O	O
to	TO	O	O
the	DT	O	O
whole	JJ	O	O
lower	JJR	O	O
limb	NN	O	O
was	VBD	O	O
unchanged	JJ	O	O
as	IN	O	O
consequence	NN	O	O
of	IN	O	O
limb	NN	O	O
growth	NN	O	O
.	.	O	O

This	DT	O	O
case	NN	O	O
report	NN	O	O
illustrates	VBZ	O	O
that	IN	O	O
pain	NN	O	O
and	CC	O	O
gait	NN	O	O
disturbance	NN	O	O
can	MD	O	O
be	VB	O	O
features	NNS	O	O
of	IN	O	O
PROS	NNP	O	O
and	CC	O	O
highlights	NNS	O	O
the	DT	O	O
need	NN	O	O
of	IN	O	O
better	JJR	O	O
knowledge	NN	O	O
about	IN	O	O
the	DT	O	O
natural	JJ	O	O
history	NN	O	O
of	IN	O	O
the	DT	O	O
disease	NN	O	O

gain	NN	B-PosReg	I-Gene
-	:	I-PosReg	I-PosReg
-	:	I-PosReg	I-PosReg
function	NN	I-PosReg	I-PosReg
promotes	NNS	I-Var	B-CPA
CAC	NNP	I-Gene	I-CPA
tumorigenesis	NN	I-PosReg	I-CPA
and	CC	I-Disease	O
induces	NNS	I-CPA	O
EMT	NNP	I-PosReg	O
via	IN	I-CPA	O
Wnt	NNP	B-Pathway	O
-	:	I-Pathway	O
catenin	NN	I-Pathway	O
signaling	VBG	I-Pathway	O
pathway	NN	I-Pathway	O

mutation	NN	B-Var	B-Var
SHP2	NNP	B-Gene	B-Disease
highest	JJS	B-Reg	I-Disease
colorectal	JJ	B-Disease	I-Disease
cancer	NN	I-Disease	I-Disease

The	DT	O	O
Wnt	NNP	O	O
-	:	O	O
catenin	NN	O	O
(	(	O	O
CTNNB1	NNP	O	O
)	)	O	O
signaling	VBG	O	O
pathway	NN	O	O
is	VBZ	O	O
crucial	JJ	O	O
for	IN	O	O
CRC	NNP	O	O
,	,	O	O
and	CC	O	O
excessive	JJ	O	O
activation	NN	O	O
of	IN	O	O
this	DT	O	O
pathway	NN	O	O
has	VBZ	O	O
been	VBN	O	O
observed	VBN	O	O
in	IN	O	O
several	JJ	O	O
tumors	NNS	O	O
.	.	O	O

We	PRP	O	O
used	VBD	O	O
Ptpn11E76K	NNP	O	O
conditional	JJ	O	O
knock	NN	O	O
-	:	O	O
in	IN	O	O
mice	NN	O	O
to	TO	O	O
study	VB	O	O
this	DT	O	O
GOF	NNP	O	O
mutation	NN	O	O
in	IN	O	O
colitis	NN	O	O
-	:	O	O
associated	VBN	O	O
CRC	NNP	O	O
(	(	O	O
CAC	NNP	O	O
)	)	O	O
and	CC	O	O
used	VBD	O	O
the	DT	O	O
CRC	NNP	O	O
cell	NN	O	O
lines	NNS	O	O
HT29	NNP	O	O
and	CC	O	O
HCT116	NNP	O	O
to	TO	O	O
determine	VB	O	O
the	DT	O	O
relationship	NN	O	O
between	IN	O	O
SHP2	NNP	O	O
and	CC	O	O
Wnt	NNP	O	O
-	:	O	O
catenin	NN	O	O
signaling	NN	O	O
.	.	O	O

Ptpn11E76K	NNP	B-Gene	O
conditional	JJ	I-Gene	O
knock	NN	I-Var	O
-	:	O	O
in	IN	O	O
mice	NN	O	O
exhibited	VBN	O	O
aggravated	JJ	B-PosReg	O
inflammation	NN	B-CPA	O
and	CC	O	O
increased	VBD	B-PosReg	B-PosReg
CAC	NNP	B-Disease	B-MPA
tumorigenesis	NN	B-CPA	I-MPA
.	.	O	O
In	IN	O	O
vitro	NN	O	O
,	,	O	O
SHP2E76K	NNP	B-Gene	O
and	CC	I-Gene	O
SHP2WT	NNP	I-Var	O
promoted	VBD	B-PosReg	O
malignant	JJ	B-CPA	O
biological	JJ	I-CPA	O
behaviors	NNS	I-CPA	O
of	IN	I-CPA	O
CRC	NNP	I-CPA	O
cells	NNS	I-CPA	O
and	CC	O	O
induced	JJ	B-PosReg	O
epithelial	JJ	B-CPA	O
-	:	I-CPA	O
mesenchymal	JJ	I-CPA	O
transition	NN	I-CPA	O
(	(	I-CPA	O
EMT	NNP	I-CPA	O
)	)	I-CPA	O
via	IN	O	O
the	DT	O	O
Wnt	NNP	O	O
-	:	O	O
catenin	NN	O	O
signaling	VBG	O	O
pathway	NN	O	O
.	.	O	O
Together	RB	O	O
,	,	O	O
our	PRP$	O	O
results	NNS	O	O
showed	VBD	O	O
that	IN	O	O
SHP2E76K	NNP	B-Gene	O
acts	VBZ	I-Gene	O
as	IN	I-Var	O
an	DT	O	O
oncogene	NN	O	O
that	WDT	O	O
promotes	VBZ	B-PosReg	O
the	DT	O	O
tumorigenesis	NN	B-CPA	O
and	CC	O	O
metastasis	NN	B-CPA	O
of	IN	O	O
CRC	NNP	B-Disease	O

Mutations	NNS	B-Var	B-Var
SHP	NNP	B-Gene	B-Gene
-	:	I-Gene	O
2	CD	I-Gene	O
phosphatase	NN	B-Enzyme	O
hyperactivation	NN	B-PosReg	O
catalytic	JJ	B-MPA	B-CPA
activity	NN	I-MPA	I-CPA
human	JJ	B-Disease	I-CPA
leukemias	NN	I-Disease	I-CPA
juvenile	JJ	B-Disease	B-Disease
myelomonocytic	JJ	I-Disease	I-Disease
leukemia	NN	I-Disease	I-Disease

GOF	NNP	O	O
mutant	NN	O	O
SHP	NNP	O	O
-	:	O	O
2	CD	O	O
must	MD	O	O
have	VB	O	O
gained	VBN	O	O
additional	JJ	O	O
capacities	NNS	O	O
.	.	O	O

To	TO	O	O
test	VB	O	O
this	DT	O	O
possibility	NN	O	O
,	,	O	O
we	PRP	O	O
investigated	VBD	O	O
effects	NNS	O	O
of	IN	O	O
a	DT	O	O
GOF	NNP	O	O
mutation	NN	O	O
of	IN	O	O
SHP	NNP	O	O
-	:	O	O
2	CD	O	O
(	(	O	O
SHP	NNP	O	O
-	:	O	O
2	CD	O	O
E76K	NNP	O	O
)	)	O	O
on	IN	O	O
hematopoietic	JJ	O	O
cell	NN	O	O
function	NN	O	O
and	CC	O	O
IL	NNP	O	O
-	:	O	O
3	CD	O	O
signal	JJ	O	O
transduction	NN	O	O
by	IN	O	O
comparing	VBG	O	O
with	IN	O	O
those	DT	O	O
of	IN	O	O
overexpressed	JJ	O	O
WT	NNP	O	O
SHP	NNP	O	O
-	:	O	O
2	CD	O	O
.	.	O	O

Our	PRP$	O	O
results	NNS	O	O
showed	VBD	O	O
that	IN	O	O
SHP	NNP	B-Gene	O
-	:	I-Gene	O
2	CD	I-Gene	O
E76K	NNP	B-Var	O
mutation	NN	I-Var	O
caused	VBD	O	O
myeloproliferative	JJ	B-Disease	O
disease	NN	I-Disease	O
in	IN	I-Disease	O
mice	NN	I-Disease	O
,	,	O	O
while	IN	O	O
overexpression	NN	O	O
of	IN	O	O
WT	NNP	O	O
SHP	NNP	O	O
-	:	O	O
2	CD	O	O
decreased	VBN	O	O
hematopoietic	JJ	O	O
potential	NN	O	O
of	IN	O	O
the	DT	O	O
transduced	JJ	O	O
cells	NNS	O	O
in	IN	O	O
recipient	NN	O	O
animals	NNS	O	O
.	.	O	O
The	DT	O	O
E76K	NNP	B-Var	O
mutation	NN	I-Var	O
in	IN	I-Var	O
the	DT	I-Var	O
N	NNP	I-Var	O
-	:	I-Var	O
terminal	JJ	I-Var	O
Src	NNP	I-Var	O
homology	NN	I-Var	O
2	CD	I-Var	O
domain	NN	I-Var	O
increased	VBD	B-PosReg	B-PosReg
interactions	NNS	B-Interaction	B-Interaction
of	IN	O	O
mutant	JJ	B-Var	O
SHP	NNP	B-Gene	O
-	:	I-Gene	O
2	CD	I-Gene	O
with	IN	O	O
Grb2	NNP	B-Protein	O
,	,	O	O
Gab2	NNP	O	O
,	,	O	O
and	CC	O	O
p85	NN	O	O
,	,	O	O
leading	VBG	O	O
to	TO	O	O
hyperactivation	NN	B-PosReg	O
of	IN	O	O
IL	NNP	B-Pathway	O
-	:	I-Pathway	O
3	CD	I-Pathway	O
-	:	I-Pathway	O
induced	VBN	I-Pathway	O
Erk	NNP	I-Pathway	O
and	CC	I-Pathway	O
phosphatidylinositol	$	I-Pathway	O
3	CD	I-Pathway	O
-	:	I-Pathway	O
kinase	NN	I-Pathway	O
(	(	I-Pathway	O
PI3K	NNP	I-Pathway	O
)	)	I-Pathway	O
pathways	VBZ	I-Pathway	O
.	.	O	O
In	IN	O	O
addition	NN	O	O
,	,	O	O
despite	IN	O	O
the	DT	O	O
substantial	JJ	O	O
increase	NN	B-PosReg	O
in	IN	O	O
the	DT	O	O
catalytic	JJ	B-MPA	O
activity	NN	I-MPA	O
,	,	O	O
dephosphorylation	NN	B-MPA	O
of	IN	I-MPA	O
STAT5	NNP	I-MPA	O
by	IN	O	O
SHP	NNP	B-Gene	O
-	:	I-Gene	O
2	CD	I-Gene	O
E76K	NNP	B-Var	O
was	VBD	O	O
dampened	VBN	B-NegReg	O
.	.	O	O
Furthermore	RB	O	O
,	,	O	O
catalytically	RB	B-Var	O
inactive	JJ	I-Var	O
SHP	NNP	I-Var	O
-	:	I-Var	O
2	CD	I-Var	O
E76K	NNP	I-Var	O
with	IN	I-Var	O
an	DT	I-Var	O
additional	JJ	I-Var	O
C459S	NNP	I-Var	O
mutation	NN	I-Var	O
retained	VBD	O	O
the	DT	O	O
capability	NN	O	O
to	TO	O	O
increase	VB	B-PosReg	B-PosReg
the	DT	O	O
interaction	NN	B-Interaction	O
with	IN	O	O
Gab2	NNP	B-Protein	O
and	CC	O	O
to	TO	O	O
enhance	VB	B-PosReg	O
the	DT	O	O
activation	NN	B-Pathway	O
of	IN	I-Pathway	O
the	DT	I-Pathway	O
PI3K	NNP	I-Pathway	O
pathway	NN	I-Pathway	O
.	.	O	O
Taken	VBN	O	O
together	RB	O	O
,	,	O	O
these	DT	O	O
studies	NNS	O	O
suggest	VBP	O	O
that	IN	O	O
in	IN	O	O
addition	NN	O	O
to	TO	O	O
the	DT	O	O
elevated	VBN	O	B-PosReg
catalytic	JJ	O	B-MPA
activity	NN	O	I-MPA
,	,	O	O
fundamental	JJ	O	O
changes	NNS	O	O
in	IN	O	O
physical	JJ	O	O
and	CC	O	O
functional	JJ	O	O
interactions	NNS	O	O
between	IN	O	O
GOF	NNP	O	O
mutant	NNP	O	O
SHP	NNP	O	O
-	:	O	O
2	CD	O	O
and	CC	O	O
signaling	VBG	O	O
partners	NNS	O	O
also	RB	O	O
play	VBP	O	O
an	DT	O	O
important	JJ	O	O
role	NN	O	O
in	IN	O	O
SHP	NNP	O	O
-	:	O	O
2	CD	O	O
-	:	O	O
related	VBN	O	O
leukemigenesis	NN	O	O

-	:	I-Var	O
allelic	JJ	I-Var	O
in	IN	I-Var	O
COCH	NNP	B-Gene	O
cause	NN	B-Reg	O
autosomal	JJ	B-Disease	O
recessive	JJ	I-Disease	O
prelingual	JJ	I-Disease	O
hearing	NN	I-Disease	O
impairment	NN	I-Disease	O

Here	RB	O	O
,	,	O	O
we	PRP	O	O
describe	VBP	O	O
two	CD	O	O
brothers	NNS	O	O
with	IN	O	O
congenital	JJ	O	O
prelingual	JJ	O	O
deafness	NN	O	O
and	CC	O	O
a	DT	O	O
homozygous	JJ	O	O
nonsense	NN	O	O
c	NN	B-Var	B-Var
.	.	I-Var	I-Var
292	CD	I-Var	I-Var
C	NNP	I-Var	I-Var
T	NNP	I-Var	I-Var
(	(	I-Var	O
p	NN	I-Var	B-Var
.	.	I-Var	I-Var
Arg98	NNP	I-Var	I-Var
)	)	I-Var	O
COCH	NNP	B-Gene	O
variant	NN	O	O
,	,	O	O
suggesting	VBG	O	O
a	DT	O	O
loss	NN	B-NegReg	O
-	:	I-NegReg	O
of	IN	I-NegReg	O
-	:	I-NegReg	O
function	NN	I-NegReg	O
effect	NN	O	O
.	.	O	O
Vestibular	JJ	B-Disease	O
dysfunction	NN	I-Disease	O
starting	VBG	O	O
in	IN	O	O
the	DT	O	O
first	JJ	O	O
decade	NN	O	O
was	VBD	O	O
observed	VBN	O	O
in	IN	O	O
the	DT	O	O
older	JJR	O	O
patient	NN	O	O
.	.	O	O
The	DT	O	O
heterozygous	JJ	O	O
parents	NNS	O	O
and	CC	O	O
sibling	VBG	O	O
have	VBP	O	O
normal	JJ	O	O
hearing	NN	O	O
and	CC	O	O
vestibular	JJ	O	O
function	NN	O	O
,	,	O	O
except	IN	O	O
for	IN	O	O
the	DT	O	O
mother	NN	O	O
,	,	O	O
who	WP	O	O
shows	VBZ	O	O
vestibular	JJ	O	O
hyporeflexia	NN	O	O
and	CC	O	O
abnormal	JJ	O	O
smooth	JJ	O	O
pursuit	NN	O	O
tests	NNS	O	O
,	,	O	O
most	JJS	O	O
likely	JJ	O	O
due	JJ	O	O
to	TO	O	O
concomitant	JJ	O	O
disease	NN	O	O
.	.	O	O

This	DT	O	O
is	VBZ	O	O
the	DT	O	O
first	JJ	O	O
report	NN	O	O
of	IN	O	O
autosomal	JJ	O	O
recessive	JJ	O	O
inheritance	NN	O	O
of	IN	O	O
cochlea	NN	O	O
-	:	O	O
vestibular	JJ	O	O
dysfunction	NN	O	O
caused	VBN	O	O
by	IN	O	O
a	DT	O	O
pathogenic	JJ	O	O
variant	NN	O	O
in	IN	O	O
the	DT	O	O
COCH	NNP	O	O
gene	NN	O	O
.	.	O	O

An	DT	O	O
earlier	JJR	O	O
onset	NN	O	O
of	IN	O	O
hearing	VBG	O	O
impairment	NN	O	O
and	CC	O	O
vestibular	JJ	O	O
dysfunction	NN	O	O
compared	VBN	O	O
to	TO	O	O
the	DT	O	O
dominant	JJ	O	O
hearing	NN	O	O
loss	NN	O	O
causing	VBG	O	O
COCH	NNP	O	O
variants	NNS	O	O
is	VBZ	O	O
observed	VBN	O	O

Young	NN	O	O
individuals	NNS	O	O
with	IN	O	O
AF	NNP	O	O
have	VBP	O	O
a	DT	O	O
strong	JJ	O	O
genetic	JJ	O	O
association	NN	O	O
with	IN	O	O
the	DT	O	O
disease	NN	O	O
,	,	O	O
but	CC	O	O
the	DT	O	O
mechanisms	NNS	O	O
remain	VBP	O	O
incompletely	RB	O	O
understood	JJ	O	O
.	.	O	O

Objective	NN	O	O
:	:	O	O
To	TO	O	O
perform	VB	O	O
large	JJ	O	O
-	:	O	O
scale	NN	O	O
whole	JJ	O	O
-	:	O	O
genome	NN	O	O
sequencing	NN	O	O
to	TO	O	O
identify	VB	O	O
genetic	JJ	O	O
variants	NNS	O	O
related	VBN	O	O
to	TO	O	O
AF	NNP	O	O
.	.	O	O

Design	NNP	O	O
,	,	O	O
Setting	NNP	O	O
,	,	O	O
and	CC	O	O
Participants	NNS	O	O
:	:	O	O
The	DT	O	O
National	NNP	O	O
Heart	NNP	O	O
,	,	O	O
Lung	NNP	O	O
,	,	O	O
and	CC	O	O
Blood	NNP	O	O
Institute	NNP	O	O
's	POS	O	O
Trans	NNP	O	O
-	:	O	O
Omics	NNS	O	O
for	IN	O	O
Precision	NNP	O	O
Medicine	NNP	O	O
Program	NNP	O	O
includes	VBZ	O	O
longitudinal	JJ	O	O
and	CC	O	O
cohort	JJ	O	O
studies	NNS	O	O
that	WDT	O	O
underwent	VBP	O	O
high	JJ	O	O
-	:	O	O
depth	NN	O	O
whole	JJ	O	O
-	:	O	O
genome	NN	O	O
sequencing	NN	O	O
between	IN	O	O
2014	CD	O	O
and	CC	O	O
2017	CD	O	O
in	IN	O	O
18	CD	O	O
526	CD	O	O
individuals	NNS	O	O
from	IN	O	O
the	DT	O	O
United	NNP	O	O
States	NNPS	O	O
,	,	O	O
Mexico	NNP	O	O
,	,	O	O
Puerto	NNP	O	O
Rico	NNP	O	O
,	,	O	O
Costa	NNP	O	O
Rica	NNP	O	O
,	,	O	O
Barbados	NNP	O	O
,	,	O	O
and	CC	O	O
Samoa	NNP	O	O
.	.	O	O

This	DT	O	O
case	NN	O	O
-	:	O	O
control	NN	O	O
study	NN	O	O
included	VBD	O	O
2781	CD	O	O
patients	NNS	O	O
with	IN	O	O
early	JJ	O	B-Disease
-	:	O	I-Disease
onset	NN	O	I-Disease
AF	NNP	O	O
from	IN	O	O
9	CD	O	O
studies	NNS	O	O
and	CC	O	O
identified	JJ	O	O
4959	CD	O	O
controls	NNS	O	O
of	IN	O	O
European	JJ	O	O
ancestry	NN	O	O
from	IN	O	O
the	DT	O	O
remaining	VBG	O	O
participants	NNS	O	O
.	.	O	O

Results	NNS	O	O
were	VBD	O	O
replicated	VBN	O	O
in	IN	O	O
the	DT	O	O
UK	NNP	O	O
Biobank	NNP	O	O
(	(	O	O
346	CD	O	O
546	CD	O	O
participants	NNS	O	O
)	)	O	O
and	CC	O	O
the	DT	O	O
MyCode	NNP	O	O
Study	NNP	O	O
(	(	O	O
42	CD	O	O
782	CD	O	O
participants	NNS	O	O
)	)	O	O
.	.	O	O

Exposures	NNS	O	O
:	:	O	O
Loss	NNP	O	O
-	:	O	O
of	IN	O	O
-	:	O	O
function	NN	O	O
(	(	O	O
LOF	NNP	O	O
)	)	O	O
variants	NNS	O	B-Var
in	IN	O	O
genes	NNS	O	O
at	IN	O	O
AF	NNP	O	O
loci	NN	O	O
and	CC	O	O
common	JJ	O	O
genetic	JJ	O	O
variation	NN	O	O
across	IN	O	O
the	DT	O	O
whole	JJ	O	O
genome	NN	O	O
.	.	O	O

Main	NNP	O	O
Outcomes	NNP	O	O
and	CC	O	O
Measures	NNS	O	O
:	:	O	O
Early	JJ	O	O
-	:	O	O
onset	NN	O	O
AF	NNP	O	O
(	(	O	O
defined	VBN	O	O
as	IN	O	O
AF	NNP	O	O
onset	NN	O	O
in	IN	O	O
persons	NNS	O	O
66	CD	O	O
years	NNS	O	O
of	IN	O	O
age	NN	O	O
)	)	O	O
.	.	O	O

Due	JJ	O	O
to	TO	O	O
multiple	JJ	O	O
testing	NN	O	O
,	,	O	O
the	DT	O	O
significance	NN	O	O
threshold	NN	O	O
for	IN	O	O
the	DT	O	O
rare	JJ	O	O
variant	JJ	O	O
analysis	NN	O	O
was	VBD	O	O
P	NNP	O	B-MPA
4.55	CD	O	I-MPA
10	CD	O	I-MPA
-	:	O	I-MPA
3	CD	O	I-MPA
.	.	O	O

Results	NNS	O	O
:	:	O	O
Among	IN	O	O
2781	CD	O	O
participants	NNS	O	O
with	IN	O	O
early	JJ	O	B-Disease
-	:	O	I-Disease
onset	NN	O	I-Disease
AF	NNP	O	I-Disease
(	(	O	O
the	DT	O	O
case	NN	O	O
group	NN	O	O
)	)	O	O
,	,	O	O
72.1%	CD	O	O
were	VBD	O	O
men	NNS	O	O
,	,	O	O
and	CC	O	O
the	DT	O	O
mean	NN	O	O
(	(	O	O
SD	NNP	O	O
)	)	O	O
age	NN	O	O
of	IN	O	O
AF	NNP	O	O
onset	NN	O	O
was	VBD	O	O
48.7	CD	O	O
(	(	O	O
10.2	CD	O	O
)	)	O	O
years	NNS	O	O
.	.	O	O

Participants	NNS	O	O
underwent	JJ	O	O
whole	JJ	O	O
-	:	O	O
genome	NN	O	O
sequencing	NN	O	O
at	IN	O	O
a	DT	O	O
mean	JJ	O	O
depth	NN	O	O
of	IN	O	O
37.8	CD	O	O
fold	NN	O	O
and	CC	O	O
mean	JJ	O	O
genome	JJ	O	O
coverage	NN	O	O
of	IN	O	O
99.1%	CD	O	O
.	.	O	O

At	IN	O	O
least	JJS	O	O
1	CD	O	O
LOF	NNP	O	O
variant	NN	O	O
in	IN	O	O
TTN	NNP	O	O
,	,	O	O
the	DT	O	O
gene	NN	O	O
encoding	VBG	O	O
the	DT	O	O
sarcomeric	JJ	O	O
protein	NN	O	O
titin	NN	O	O
,	,	O	O
was	VBD	O	O
present	JJ	O	O
in	IN	O	O
2.1%	CD	O	O
of	IN	O	O
case	NN	O	O
participants	NNS	O	O
compared	VBN	O	O
with	IN	O	O
1.1%	CD	O	O
in	IN	O	O
control	NN	O	O
participants	NNS	O	O
(	(	O	O
odds	NNS	O	O
ratio	VBP	O	O
[	CD	O	O
OR	NNP	O	O
]	NNP	O	O
,	,	O	O
1.76	CD	O	O
[	NN	O	O
95%	CD	O	O
CI	NNP	O	O
,	,	O	O
1.04	CD	O	O
-	:	O	O
2.97	CD	O	O
])	NN	O	O
.	.	O	O

The	DT	O	O
proportion	NN	O	O
of	IN	O	O
individuals	NNS	O	O
with	IN	O	O
early	JJ	B-Disease	B-Disease
-	:	I-Disease	I-Disease
onset	NN	I-Disease	I-Disease
AF	NNP	I-Disease	O
who	WP	O	O
carried	VBD	O	O
a	DT	O	O
LOF	NNP	B-PosReg	O
variant	NN	B-Var	O
in	IN	O	O
TTN	NNP	B-Gene	O
increased	VBD	B-PosReg	O
with	IN	O	O
an	DT	O	O
earlier	JJR	O	O
age	NN	O	O
of	IN	O	O
AF	NNP	O	O
onset	FW	O	O
(	(	O	O
P	NNP	O	O
value	NN	O	O
for	IN	O	O
trend	NN	O	O
,	,	O	O
4.92	CD	O	O
10	CD	O	O
-	:	O	O
4	CD	O	O
)	)	O	O
,	,	O	O
and	CC	O	O
6.5%	CD	O	O
of	IN	O	O
individuals	NNS	O	O
with	IN	O	O
AF	NNP	O	O
onset	VBP	O	O
prior	RB	O	O
to	TO	O	O
age	NN	O	O
30	CD	O	O
carried	VBD	O	O
a	DT	O	O
TTN	NNP	O	O
LOF	NNP	O	O
variant	NN	O	O
(	(	O	O
OR	NNP	O	O
,	,	O	O
5.94	CD	O	O
[	NN	O	O
95%	CD	O	O
CI	NNP	O	O
,	,	O	O
2.64	CD	O	O
-	:	O	O
13.35	CD	O	O
]	NN	O	O
;	:	O	O
P	NNP	O	O
1.65	CD	O	O
10	CD	O	O
-	:	O	O
5	CD	O	O
)	)	O	O
.	.	O	O
The	DT	O	O
association	NN	O	O
between	IN	O	O
TTN	NNP	O	O
LOF	NNP	O	O
variants	NNS	O	O
and	CC	O	O
AF	NNP	O	O
was	VBD	O	O
replicated	VBN	O	O
in	IN	O	O
an	DT	O	O
independent	JJ	O	O
study	NN	O	O
of	IN	O	O
1582	CD	O	O
patients	NNS	O	O
with	IN	O	O
early	JJ	O	B-Disease
-	:	O	I-Disease
onset	NN	O	I-Disease
AF	NNP	O	I-Disease
(	(	O	O
cases	NNS	O	O
)	)	O	O
and	CC	O	O
41	CD	O	O
200	CD	O	O
control	NN	O	O
participants	NNS	O	O
(	(	O	O
OR	NNP	O	O
,	,	O	O
2.16	CD	O	O
[	NN	O	O
95%	CD	O	O
CI	NNP	O	O
,	,	O	O
1.19	CD	O	O
-	:	O	O
3.92	CD	O	O
]	NN	O	O
;	:	O	O
P	NNP	O	B-Var
.	.	O	I-Var
01	CD	O	I-Var
)	)	O	O
.	.	O	O

Conclusions	NNS	O	O
and	CC	O	O
Relevance	NN	O	O
:	:	O	O
In	IN	O	O
a	DT	O	O
case	NN	O	O
-	:	O	O
control	NN	O	O
study	NN	O	O
,	,	O	O
there	EX	O	O
was	VBD	O	O
a	DT	O	O
statistically	RB	O	O
significant	JJ	B-Reg	O
association	NN	I-Reg	O
between	IN	O	O
an	DT	O	O
LOF	NNP	B-NegReg	O
variant	NN	B-Var	O
in	IN	O	O
the	DT	O	O
TTN	NNP	B-Gene	O
gene	NN	O	O
and	CC	O	O
early	JJ	B-Disease	O
-	:	I-Disease	O
onset	NN	I-Disease	O
AF	NNP	I-Disease	O
,	,	O	O
with	IN	O	O
the	DT	O	O
variant	JJ	O	O
present	NN	O	O
in	IN	O	O
a	DT	O	O
small	JJ	O	O
percentage	NN	O	O
of	IN	O	O
participants	NNS	O	O
with	IN	O	O
early	JJ	O	B-Disease
-	:	O	I-Disease
onset	NN	O	I-Disease
AF	NNP	O	I-Disease
(	(	O	O
the	DT	O	O
case	NN	O	O
group	NN	O	O
)	)	O	O
.	.	O	O
Further	JJ	O	O
research	NN	O	O
is	VBZ	O	O
necessary	JJ	O	O
to	TO	O	O
understand	VB	O	O
whether	IN	O	O
this	DT	O	O
is	VBZ	O	O
a	DT	O	O
causal	NN	O	O
relationship	NN	O	O

function	NN	I-PosReg	O
TMEM16E	NNP	B-Gene	O
scrambling	VBG	B-MPA	O
activity	NN	I-MPA	B-MPA
mutation	NN	B-Var	B-Var
gnathodiaphyseal	JJ	B-Disease	B-Disease
dysplasia	NN	I-Disease	I-Disease
Mutations	NNS	B-Var	B-Var
TMEM16E	NNP	B-Gene	B-Gene
associated	VBN	B-Reg	B-Reg
bone	NN	B-Disease	B-Disease
disease	NN	I-Disease	I-Disease
gnathodiaphyseal	NN	B-Disease	B-Disease
dysplasia	NN	I-Disease	I-Disease
muscle	NN	B-Disease	I-Disease
dystrophies	NNS	I-Disease	I-Disease
However	RB	O	O
,	,	O	O
the	DT	O	O
physiological	JJ	O	O
function	NN	O	O
of	IN	O	O
TMEM16E	NNP	O	O
has	VBZ	O	O
remained	VBN	O	O
unclear	JJ	O	O
.	.	O	O

We	PRP	O	O
show	VBP	O	O
here	RB	O	O
that	IN	O	O
human	JJ	O	O
TMEM16E	NNP	O	O
,	,	O	O
when	WRB	O	O
overexpressed	VBN	O	O
in	IN	O	O
mammalian	JJ	O	O
cell	NN	O	O
lines	NNS	O	O
,	,	O	O
displayed	VBN	O	O
partial	JJ	O	B-NegReg
plasma	NN	O	B-MPA
membrane	NN	O	I-MPA
localization	NN	O	I-MPA
and	CC	O	O
gave	VBD	O	O
rise	NN	O	O
to	TO	O	O
phospholipid	VB	O	O
scrambling	VBG	O	O
(	(	O	O
PLS	NNP	O	O
)	)	O	O
as	RB	O	O
well	RB	O	O
as	IN	O	O
non	JJ	O	O
-	:	O	O
selective	JJ	O	O
ionic	JJ	O	O
currents	NNS	O	O
with	IN	O	O
slow	JJ	O	O
time	NN	O	O
-	:	O	O
dependent	JJ	O	O
activation	NN	O	O
at	IN	O	O
highly	RB	O	O
depolarized	VBN	O	O
membrane	NN	O	O
potentials	NNS	O	O
.	.	O	O

While	IN	O	O
the	DT	O	O
activity	NN	O	O
of	IN	O	O
wild	JJ	O	O
-	:	O	O
type	NN	O	O
TMEM16E	NNP	O	O
depended	VBD	O	O
on	IN	O	O
elevated	VBN	O	B-PosReg
cytosolic	JJ	O	B-MPA
Ca2	NNP	O	I-MPA
levels	NNS	O	I-MPA
,	,	O	O
a	DT	O	O
mutant	JJ	O	O
form	NN	O	O
carrying	VBG	O	O
the	DT	O	O
GDD	NNP	O	O
-	:	O	O
causing	VBG	O	O
T513I	NNP	O	O
substitution	NN	O	O
showed	VBD	O	O
PLS	NNP	O	O
and	CC	O	O
large	JJ	O	O
time	NN	O	O
-	:	O	O
dependent	JJ	O	O
ion	NN	O	O
currents	NNS	O	O
even	RB	O	O
at	IN	O	O
low	JJ	O	O
cytosolic	JJ	O	O
Ca2	NNP	O	O
concentrations	NNS	O	O
.	.	O	O

Contrarily	RB	O	O
,	,	O	O
mutation	NN	O	O
of	IN	O	O
the	DT	O	O
homologous	JJ	O	O
position	NN	O	O
in	IN	O	O
the	DT	O	O
Ca2	NNP	O	O
-	:	O	O
activated	VBD	O	O
Cl	NNP	O	O
-	:	O	O
channel	NN	O	O
TMEM16B	NNP	O	O
paralog	NN	O	O
hardly	RB	O	O
affected	VBD	O	O
its	PRP$	O	O
function	NN	O	O
.	.	O	O

In	IN	O	O
summary	JJ	O	O
,	,	O	O
these	DT	O	O
data	NNS	O	O
provide	VBP	O	O
the	DT	O	O
first	JJ	O	O
direct	JJ	O	O
demonstration	NN	O	O
of	IN	O	O
Ca2	NNP	O	O
-	:	O	O
dependent	JJ	O	O
PLS	NNP	O	O
activity	NN	O	O
for	IN	O	O
TMEM16E	NNP	O	O
and	CC	O	O
suggest	VBP	O	O
a	DT	O	O
gain	NN	O	O
-	:	O	O
of	IN	O	O
-	:	O	O
function	NN	O	O
phenotype	NN	O	O
related	VBN	O	O
to	TO	O	O
a	DT	O	O
GDD	NNP	O	O
mutation	NN	O	O

Macrolactonization	NN	O	O
of	IN	O	O
natural	JJ	O	O
product	NN	O	O
analogs	NNS	O	O
presents	VBZ	O	O
a	DT	O	O
significant	JJ	O	O
challenge	NN	O	O
to	TO	O	O
both	DT	O	O
biosynthetic	JJ	O	O
assembly	NN	O	O
and	CC	O	O
synthetic	JJ	O	O
chemistry	NN	O	O
.	.	O	O

In	IN	O	O
the	DT	O	O
preceding	VBG	O	O
paper	NN	O	O
,	,	O	O
we	PRP	O	O
identified	VBD	O	O
a	DT	O	O
thioesterase	NN	O	O
(	(	O	O
TE	NNP	O	O
)	)	O	O
domain	VBP	O	O
catalytic	JJ	O	O
bottleneck	NN	O	O
in	IN	O	O
the	DT	O	O
processing	NN	O	O
of	IN	O	O
un	JJ	O	O
-	:	O	O
natural	JJ	O	O
substrates	NNS	O	O
in	IN	O	O
the	DT	O	O
pikromycin	NN	O	O
(	(	O	O
Pik	NNP	O	O
)	)	O	O
system	NN	O	O
,	,	O	O
preventing	VBG	O	B-NegReg
the	DT	O	O
formation	NN	O	O
of	IN	O	O
epimerized	JJ	O	O
macrolactones	NNS	O	O
.	.	O	O

Here	RB	O	O
,	,	O	O
we	PRP	O	O
perform	VBP	O	O
molecular	JJ	O	O
dynamics	NNS	O	O
(	(	O	O
MD	NNP	O	O
)	)	O	O
simulations	NNS	O	O
showing	VBG	O	O
the	DT	O	O
epimerized	JJ	O	O
hexaketide	NN	O	O
was	VBD	O	O
accommodated	VBN	O	O
within	IN	O	O
the	DT	O	O
Pik	NNP	O	O
TE	NNP	O	O
active	JJ	O	O
site	NN	O	O
;	:	O	O
however	RB	O	O
,	,	O	O
intrinsic	JJ	O	O
conformational	JJ	O	O
preferences	NNS	O	O
of	IN	O	O
the	DT	O	O
substrate	NN	O	O
resulted	VBD	O	O
in	IN	O	O
predominately	RB	O	O
unproductive	JJ	O	O
conformations	NNS	O	O
,	,	O	O
in	IN	O	O
agreement	NN	O	O
with	IN	O	O
the	DT	O	O
observed	JJ	O	O
hydrolysis	NN	O	O
.	.	O	O

Accordingly	RB	O	O
,	,	O	O
we	PRP	O	O
engineered	VBD	O	O
the	DT	O	O
stereospecific	NN	O	O
Pik	NNP	O	O
TE	NNP	O	O
to	TO	O	O
yield	VB	O	O
a	DT	O	O
variant	NN	O	O
(	(	O	O
TES148C	NNP	O	O
)	)	O	O
with	IN	O	O
improved	VBN	O	O
reaction	NN	O	O
kinetics	NNS	O	O
and	CC	O	O
gain	VB	O	O
-	:	O	O
of	IN	O	O
-	:	O	O
function	NN	O	O
processing	NN	O	O
of	IN	O	O
an	DT	O	O
unnatural	JJ	O	O
,	,	O	O
epimerized	JJ	O	O
hexaketide	NN	O	O
.	.	O	O

Quantum	NNP	O	O
mechanical	JJ	O	O
(	(	O	O
QM	NNP	O	O
)	)	O	O
comparison	NN	O	O
of	IN	O	O
model	NN	O	O
TES148C	NNP	O	O
and	CC	O	O
TEWT	NNP	O	O
reaction	NN	O	O
coordinate	NN	O	O
diagrams	NNS	O	O
revealed	VBD	O	O
a	DT	O	O
change	NN	O	O
in	IN	O	O
mechanism	NN	O	O
from	IN	O	O
a	DT	O	O
stepwise	NN	O	O
addition	NN	O	O
-	:	O	O
elimination	NN	O	O
(	(	O	O
TEWT	NNP	O	O
)	)	O	O
to	TO	O	O
a	DT	O	O
lower	JJR	O	O
energy	NN	O	O
concerted	VBD	O	O
acyl	JJ	O	O
substitution	NN	O	O
(	(	O	O
TES148C	NNP	O	O
)	)	O	O
,	,	O	O
accounting	VBG	O	O
for	IN	O	O
the	DT	O	O
gain	NN	O	O
-	:	O	O
of	IN	O	O
-	:	O	O
function	NN	O	O
and	CC	O	O
improved	VBN	O	O
reaction	NN	O	O
kinetics	NNS	O	O
.	.	O	O

Finally	RB	O	O
,	,	O	O
we	PRP	O	O
introduced	VBD	O	O
the	DT	O	O
S148C	NNP	B-Var	O
mutation	NN	O	O
into	IN	O	O
a	DT	O	O
polyketide	JJ	O	O
synthase	NN	O	O
module	NN	O	O
(	(	O	O
PikAIII	NNP	O	O
-	:	O	O
TE	NN	O	O
)	)	O	O
to	TO	O	O
impart	VB	O	O
increased	JJ	B-PosReg	O
substrate	NN	B-MPA	O
flexibility	NN	I-MPA	O
,	,	O	O
enabling	VBG	B-PosReg	O
the	DT	O	O
production	NN	B-MPA	O
of	IN	I-MPA	O
diastereomeric	JJ	I-MPA	O
macrolactones	NNS	I-MPA	O

-	:	I-NegReg	I-NegReg
-	:	I-NegReg	I-NegReg
function	NN	I-NegReg	I-NegReg
IKZF1	NNP	B-Gene	B-Disease
deletions	NNS	B-Var	I-Disease
acute	JJ	B-Disease	I-Disease
lymphoblastic	JJ	I-Disease	I-Disease
leukemia	NN	I-Disease	I-Disease

deletions	NNS	B-Var	O
functionally	RB	B-MPA	O
inactivated	VBN	I-MPA	O
allele	NN	I-MPA	O
loss	NN	B-NegReg	O
-	:	I-NegReg	O
of	IN	I-NegReg	O
-	:	I-NegReg	O
function	NN	I-NegReg	O
dominant	JJ	B-NegReg	O
-	:	I-NegReg	O
negative	JJ	I-NegReg	O
isoforms	NNS	B-MPA	O
The	DT	O	O
prognostic	JJ	O	O
impact	NN	O	O
of	IN	O	O
these	DT	O	O
alterations	NNS	O	O
especially	RB	O	O
in	IN	O	O
adult	JJ	O	B-Disease
acute	JJ	O	I-Disease
lymphoblastic	JJ	O	I-Disease
leukemia	NN	O	I-Disease
is	VBZ	O	O
not	RB	O	O
well	RB	O	O
defined	VBN	O	O
.	.	O	O

We	PRP	O	O
analyzed	VBD	O	O
482	CD	O	O
well	RB	O	O
-	:	O	O
characterized	VBN	O	O
cases	NNS	O	O
of	IN	O	O
adult	NN	O	O
BCR	NNP	O	O
-	:	O	O
ABL	NNP	O	O
-	:	O	O
negative	JJ	O	O
B	NNP	O	O
-	:	O	O
precursor	NN	O	O
acute	JJ	O	O
lymphoblastic	JJ	O	O
leukemia	NN	O	O
uniformly	RB	O	O
treated	VBN	O	O
in	IN	O	O
the	DT	O	O
framework	NN	O	O
of	IN	O	O
the	DT	O	O
GMALL	NNP	O	O
studies	NNS	O	O
and	CC	O	O
detected	VBD	O	O
IKZF1	NNP	O	O
alterations	NNS	O	O
in	IN	O	O
128	CD	O	O
cases	NNS	O	O
(	(	O	O
27%	CD	O	O
)	)	O	O
.	.	O	O

In	IN	O	O
20%	CD	O	O
,	,	O	O
the	DT	O	O
IKZF1	NNP	O	O
alteration	NN	O	O
was	VBD	O	O
present	JJ	O	O
in	IN	O	O
a	DT	O	O
large	JJ	O	O
fraction	NN	O	O
of	IN	O	O
leukemic	JJ	O	O
cells	NNS	O	O
(	(	O	O
"	JJ	O	O
high	JJ	O	O
deletion	NN	O	O
load	NN	O	O
"	NNP	O	O
)	)	O	O
while	IN	O	O
in	IN	O	O
7%	CD	O	O
it	PRP	O	O
was	VBD	O	O
detected	VBN	O	O
only	RB	O	O
in	IN	O	O
small	JJ	O	O
subclones	NNS	O	O
(	(	O	O
"	JJ	O	O
low	JJ	O	O
deletion	NN	O	O
load	NN	O	O
"	NN	O	O
)	)	O	O
.	.	O	O

Some	DT	O	O
patients	NNS	O	O
showed	VBD	O	O
more	JJR	O	O
than	IN	O	O
one	CD	O	O
IKZF1	NNP	O	O
alteration	NN	O	O
(	(	O	O
8%	CD	O	O
)	)	O	O
.	.	O	O

Patients	NNS	O	O
exhibiting	VBG	O	O
a	DT	O	O
loss	NN	O	O
-	:	O	O
of	IN	O	O
-	:	O	O
function	NN	O	O
isoform	NN	O	O
with	IN	O	O
high	JJ	B-Var	O
deletion	NN	I-Var	O
load	NN	I-Var	O
had	VBD	O	O
a	DT	O	O
shorter	NN	B-NegReg	O
overall	JJ	B-MPA	O
survival	NN	I-MPA	O
(	(	O	O
OS	NNP	O	O
at	IN	O	O
5	CD	O	O
years	NNS	O	O
28%	CD	O	O
vs	NN	O	O
.	.	O	O
59%	CD	O	O
,	,	O	O
p	RB	O	O
0.0001	CD	O	O
)	)	O	O
,	,	O	O
also	RB	O	O
significant	JJ	O	O
in	IN	O	O
a	DT	O	O
subgroup	JJ	O	O
analysis	NN	O	O
of	IN	O	O
standard	JJ	O	O
risk	NN	O	O
patients	NNS	O	O
according	VBG	O	O
to	TO	O	O
GMALL	NNP	O	O
classification	NN	O	O
(	(	O	O
OS	NNP	O	O
at	IN	O	O
5	CD	O	O
years	NNS	O	O
37%	CD	O	O
vs	NN	O	O
.	.	O	O

68%	CD	O	O
,	,	O	O
p	RB	O	O
0.0002	CD	O	O
)	)	O	O
.	.	O	O

Low	JJ	O	B-NegReg
deletion	NN	O	B-Var
load	NN	O	O
or	CC	O	O
dominant	JJ	O	O
-	:	O	O
negative	JJ	O	O
IKZF1	NNP	O	O
alterations	NNS	O	O
had	VBD	O	O
no	DT	O	O
prognostic	JJ	O	O
impact	NN	O	O
.	.	O	O

The	DT	O	O
results	NNS	O	O
thus	RB	O	O
suggest	VBP	O	O
that	IN	O	O
there	EX	O	O
is	VBZ	O	O
a	DT	O	O
clear	JJ	O	O
distinction	NN	O	O
between	IN	O	O
loss	NN	O	O
-	:	O	O
of	IN	O	O
-	:	O	O
function	NN	O	O
and	CC	O	O
dominant	JJ	O	O
-	:	O	O
negative	JJ	O	O
IKZF1	NNP	O	O
deletions	NNS	O	O
.	.	O	O

Affected	JJ	O	O
patients	NNS	O	O
should	MD	O	O
thus	RB	O	O
be	VB	O	O
monitored	VBN	O	O
for	IN	O	O
minimal	JJ	O	O
residual	JJ	O	O
disease	NN	O	O
carefully	RB	O	O
to	TO	O	O
detect	VB	O	O
incipient	JJ	O	O
relapses	NNS	O	O
at	IN	O	O
an	DT	O	O
early	JJ	O	O
stage	NN	O	O
and	CC	O	O
they	PRP	O	O
are	VBP	O	O
potential	JJ	O	O
candidates	NNS	O	O
for	IN	O	O
alternative	JJ	O	O
or	CC	O	O
intensified	JJ	O	O
treatment	NN	O	O
regimes	NNS	O	O
.	.	O	O

Registered	VBN	O	O
at	IN	O	O
http	NN	O	O
:	:	O	O
www	NN	O	O
.	.	O	O
clinicaltrials	NNS	O	O
.	.	O	O
gov	NN	O	O
:	:	O	O
NCT00199056	NNP	O	O
,	,	O	O
NCT00198991	NNP	O	O

SYNGAP1	NNP	B-Gene	O
loss	NN	B-NegReg	O
-	:	I-NegReg	O
of	IN	I-NegReg	O
-	:	I-NegReg	O
function	NN	I-NegReg	O
variants	NNS	B-Var	O
are	VBP	O	O
causally	RB	O	O
associated	VBN	O	O
with	IN	O	O
intellectual	JJ	B-Disease	O
disability	NN	I-Disease	O
,	,	O	O
severe	JJ	B-Disease	O
epilepsy	NN	I-Disease	O
,	,	O	O
autism	NN	B-Disease	O
spectrum	NN	I-Disease	O
disorder	NN	I-Disease	O
and	CC	O	O
schizophrenia	NN	B-Disease	O
.	.	O	O
While	IN	O	O
there	EX	O	O
are	VBP	O	O
hundreds	NNS	O	O
of	IN	O	O
genetic	JJ	O	O
risk	NN	O	O
factors	NNS	O	O
for	IN	O	O
neurodevelopmental	JJ	O	O
disorders	NNS	O	O
(	(	O	O
NDDs	NNP	O	O
)	)	O	O
,	,	O	O
this	DT	O	O
gene	NN	O	O
is	VBZ	O	O
somewhat	RB	O	O
unique	JJ	O	O
because	IN	O	O
of	IN	O	O
the	DT	O	O
frequency	NN	O	O
and	CC	O	O
penetrance	NN	O	O
of	IN	O	O
loss	NN	O	O
-	:	O	O
of	IN	O	O
-	:	O	O
function	NN	O	O
variants	NNS	O	O
found	VBN	O	O
in	IN	O	O
patients	NNS	O	O
combined	VBN	O	O
with	IN	O	O
the	DT	O	O
range	NN	O	O
of	IN	O	O
brain	NN	O	O
disorders	NNS	O	O
associated	VBN	O	O
with	IN	O	O
SYNGAP1	NNP	O	O
pathogenicity	NN	O	O
.	.	O	O

These	DT	O	O
clinical	JJ	O	O
findings	NNS	O	O
indicate	VBP	O	O
that	IN	O	O
SYNGAP1	NNP	O	O
regulates	VBZ	O	O
fundamental	JJ	O	O
neurodevelopmental	JJ	O	O
processes	NNS	O	O
that	WDT	O	O
are	VBP	O	O
necessary	JJ	O	O
for	IN	O	O
brain	NN	O	O
development	NN	O	O
.	.	O	O

Here	RB	O	O
,	,	O	O
we	PRP	O	O
describe	VBP	O	O
four	CD	O	O
phenotypic	NN	O	O
domains	NNS	O	O
that	WDT	O	O
are	VBP	O	O
controlled	VBN	O	O
by	IN	O	O
Syngap1	NNP	O	O
expression	NN	O	O
across	IN	O	O
vertebrate	NN	O	O
species	NNS	O	O
.	.	O	O

Two	CD	O	O
domains	NNS	O	O
,	,	O	O
the	DT	O	O
maturation	NN	O	O
of	IN	O	O
cognitive	JJ	O	O
functions	NNS	O	O
and	CC	O	O
maintenance	NN	O	O
of	IN	O	O
excitatory	JJ	O	B-MPA
-	:	O	I-MPA
inhibitory	NN	O	I-MPA
balance	NN	O	I-MPA
,	,	O	O
are	VBP	O	O
defined	VBN	O	O
exclusively	RB	O	O
through	IN	O	O
a	DT	O	O
review	NN	O	O
of	IN	O	O
the	DT	O	O
current	JJ	O	O
literature	NN	O	O
.	.	O	O

Two	CD	O	O
additional	JJ	O	O
domains	NNS	O	O
are	VBP	O	O
defined	VBN	O	O
by	IN	O	O
integrating	VBG	O	O
the	DT	O	O
current	JJ	O	O
literature	NN	O	O
with	IN	O	O
new	JJ	O	O
data	NNS	O	O
indicating	NN	O	O
that	IN	O	O
SYNGAP1	NNP	O	O
Syngap1	NNP	O	O
regulates	VBZ	O	O
innate	JJ	O	O
survival	NN	O	O
behaviors	NNS	O	O
and	CC	O	O
brain	NN	O	O
structure	NN	O	O
.	.	O	O

These	DT	O	O
four	CD	O	O
phenotypic	NN	O	O
domains	NNS	O	O
are	VBP	O	O
commonly	RB	O	O
disrupted	VBN	O	O
in	IN	O	O
NDDs	NNP	O	O
,	,	O	O
suggesting	VBG	O	O
that	IN	O	O
a	DT	O	O
deeper	JJR	O	O
understanding	NN	O	O
of	IN	O	O
developmental	JJ	O	O
Syngap1	NNP	O	O
functions	NNS	O	O
will	MD	O	O
be	VB	O	O
generalizable	JJ	O	O
to	TO	O	O
other	JJ	O	O
NDDs	NNP	O	O
of	IN	O	O
known	VBN	O	O
or	CC	O	O
unknown	JJ	O	O
etiology	NN	O	O
.	.	O	O

Therefore	RB	O	O
,	,	O	O
we	PRP	O	O
discuss	VBP	O	O
the	DT	O	O
known	VBN	O	O
molecular	NN	O	O
and	CC	O	O
cellular	JJ	O	O
functions	NNS	O	O
of	IN	O	O
Syngap1	NNP	O	O
and	CC	O	O
consider	VB	O	O
how	WRB	O	O
these	DT	O	O
functions	NNS	O	O
may	MD	O	O
contribute	VB	O	O
to	TO	O	O
the	DT	O	O
emergence	NN	O	O
of	IN	O	O
disease	NN	O	O
-	:	O	O
relevant	JJ	O	O
phenotypes	NNS	O	O
.	.	O	O

Finally	RB	O	O
,	,	O	O
we	PRP	O	O
identify	VBP	O	O
major	JJ	O	O
unexplored	JJ	O	O
areas	NNS	O	O
of	IN	O	O
Syngap1	NNP	O	O
neurobiology	NN	O	O
and	CC	O	O
discuss	VB	O	O
how	WRB	O	O
a	DT	O	O
deeper	JJR	O	O
understanding	NN	O	O
of	IN	O	O
this	DT	O	O
gene	NN	O	O
may	MD	O	O
uncover	VB	O	O
general	JJ	O	O
principles	NNS	O	O
of	IN	O	O
NDD	NNP	O	O
pathobiology	NN	O	O

INTRODUCTION	NN	O	O
:	:	O	O
Progranulin	NNP	O	O
(	(	O	O
PGRN	NNP	O	O
)	)	O	O
is	VBZ	O	O
an	DT	O	O
acrosomal	JJ	O	O
glycoprotein	NN	O	O
that	WDT	O	O
is	VBZ	O	O
synthesized	VBN	O	O
during	IN	O	O
spermatogenesis	NN	O	O
.	.	O	O

It	PRP	O	O
is	VBZ	O	O
overexpressed	VBN	O	O
in	IN	O	O
tumors	NNS	O	O
and	CC	O	O
has	VBZ	O	O
anti	VBN	O	O
-	:	O	O
inflammatory	NN	O	O
properties	NNS	O	O
.	.	O	O

The	DT	O	O
protein	NN	O	O
may	MD	O	O
be	VB	O	O
cleaved	VBN	O	O
into	IN	O	O
granulins	NNS	O	O
which	WDT	O	O
display	VBP	O	O
pro	FW	O	O
-	:	O	O
inflammatory	NN	O	O
properties	NNS	O	O
.	.	O	O

In	IN	O	O
2006	CD	O	O
,	,	O	O
mutations	NNS	B-Var	O
in	IN	O	O
progranulin	JJ	O	O
gene	NN	O	O
(	(	O	O
GRN	NNP	B-Gene	B-Gene
)	)	O	O
that	WDT	O	O
cause	VBP	O	O
haploinsufficiency	NN	O	O
were	VBD	O	O
found	VBN	O	O
in	IN	O	O
familial	JJ	O	O
cases	NNS	B-Reg	O
of	IN	O	O
frontotemporal	JJ	B-Disease	O
dementia	NN	I-Disease	O
(	(	O	O
FTD	NNP	O	O
)	)	O	O
.	.	O	O
Patients	NNS	O	O
with	IN	O	O
null	JJ	O	O
mutations	NNS	O	O
in	IN	O	O
GRN	NNP	O	O
display	VBP	O	O
very	RB	O	O
low	JJ	O	O
-	:	O	O
plasma	NN	O	O
PGRN	NNP	O	O
levels	NNS	O	O
;	:	O	O
this	DT	O	O
analysis	NN	O	O
is	VBZ	O	O
useful	JJ	O	O
for	IN	O	O
identifying	VBG	O	O
mutation	NN	O	O
carriers	NNS	O	O
,	,	O	O
independent	JJ	O	O
of	IN	O	O
the	DT	O	O
clinical	JJ	O	O
presentation	NN	O	O
,	,	O	O
and	CC	O	O
in	IN	O	O
those	DT	O	O
before	IN	O	O
the	DT	O	O
appearance	NN	O	O
of	IN	O	O
symptoms	NNS	O	O
.	.	O	O

Areas	RB	O	O
covered	VBN	O	O
:	:	O	O
Here	RB	O	O
,	,	O	O
we	PRP	O	O
review	VBP	O	O
the	DT	O	O
current	JJ	O	O
knowledge	NN	O	O
of	IN	O	O
PGRN	NNP	O	B-Protein
physiological	JJ	O	O
functions	NNS	O	O
and	CC	O	O
GRN	NNP	O	B-Protein
mutations	NNS	O	B-Var
associated	VBN	O	B-Reg
with	IN	O	O
FTD	NNP	O	O
;	:	O	O
we	PRP	O	O
also	RB	O	O
summarize	VBP	O	O
state	NN	O	O
of	IN	O	O
the	DT	O	O
art	NN	O	O
clinical	JJ	O	O
trials	NNS	O	O
and	CC	O	O
those	DT	O	O
compounds	NNS	O	O
able	JJ	O	O
to	TO	O	O
replace	VB	O	O
PGRN	NNP	O	B-Protein
loss	NN	O	B-NegReg
in	IN	O	O
preclinical	JJ	O	O
models	NNS	O	O
.	.	O	O

Expert	JJ	O	O
opinion	NN	O	O
:	:	O	O
PGRN	NNP	O	O
represents	VBZ	O	O
a	DT	O	O
promising	JJ	O	O
therapeutic	JJ	O	O
target	NN	O	O
for	IN	O	O
FTD	NNP	O	O
.	.	O	O

Cohorts	NNS	O	O
suitable	JJ	O	O
for	IN	O	O
treatment	NN	O	O
,	,	O	O
ideally	RB	O	O
at	IN	O	O
the	DT	O	O
preclinical	JJ	O	O
stage	NN	O	O
,	,	O	O
where	WRB	O	O
pathogenic	JJ	O	O
mechanisms	NNS	O	O
ongoing	VBG	O	O
in	IN	O	O
the	DT	O	O
brain	NN	O	O
are	VBP	O	O
targeted	VBN	O	O
,	,	O	O
are	VBP	O	O
available	JJ	O	O
.	.	O	O

However	RB	O	O
,	,	O	O
PGRN	NNP	O	O
may	MD	O	O
have	VB	O	O
side	NN	O	O
effects	NNS	O	O
,	,	O	O
such	JJ	O	O
as	IN	O	O
the	DT	O	O
risk	NN	O	O
of	IN	O	O
tumorigenesis	NN	O	O
,	,	O	O
and	CC	O	O
the	DT	O	O
risk	NN	O	O
benefit	VBP	O	O
ratio	NN	O	O
of	IN	O	O
any	DT	O	O
intervention	NN	O	O
cannot	NN	O	O
be	VB	O	O
predicted	VBN	O	O
.	.	O	O

Furthermore	RB	O	O
,	,	O	O
at	IN	O	O
present	JJ	O	O
,	,	O	O
the	DT	O	O
situation	NN	O	O
is	VBZ	O	O
complicated	VBN	O	O
by	IN	O	O
the	DT	O	O
absence	NN	O	O
of	IN	O	O
adequate	JJ	O	O
outcome	NN	O	O
measures	NNS	O	O

and	CC	I-Var	O
malignant	JJ	I-Gene	O
potential	NN	I-PosReg	O
of	IN	I-CPA	O
reprogrammed	JJ	I-NegReg	O
cells	NNS	I-CPA	O
p53	NN	B-Gene	O
deficiency	NN	B-Var	O
enhances	VBZ	B-PosReg	O
somatic	JJ	B-CPA	O
cell	NN	I-CPA	O
reprogramming	VBG	I-CPA	O
mutated	VBD	B-Var	O
forms	NNS	I-Var	O
p53	NN	B-Gene	O
gain	NN	B-PosReg	O
activities	NNS	B-MPA	O
gain	NN	B-PosReg	O
function	NN	B-MPA	O
mut	NN	B-Var	O
-	:	I-Var	O
p53	NN	I-Var	O
enhanced	VBD	B-PosReg	O
reprogramming	VBG	B-CPA	O
process	NN	I-CPA	O
activity	NN	B-MPA	O
mut	NN	B-Var	O
-	:	I-Var	O
p53	NN	I-Var	O
alterations	NNS	B-Reg	O
characteristics	NNS	B-CPA	O
of	IN	I-CPA	O
the	DT	I-CPA	O
reprogrammed	JJ	I-CPA	O
cells	NNS	I-CPA	O
pluripotent	JJ	B-MPA	O
capacity	NN	I-MPA	O
mutant	JJ	B-Var	B-Var
p53	NN	B-Gene	B-Gene
lost	VBD	B-NegReg	B-NegReg
gave	VBD	B-Reg	O
rise	NN	I-Reg	O
malignant	JJ	B-CPA	O
tumors	NNS	I-CPA	O

oncogenic	JJ	B-MPA	B-CPA
activity	NN	I-MPA	I-CPA
overexpression	NN	B-PosReg	O
p53	NN	B-Var	O
KO	NNP	I-Var	O
or	CC	I-Var	O
mut	SYM	I-Var	O
-	:	I-Var	O
p53	NN	I-Var	O
induced	VBD	B-PosReg	O
aggressive	JJ	B-CPA	O
tumors	NNS	I-CPA	O
Overall	JJ	O	O
,	,	O	O
our	PRP$	O	O
data	NNS	O	O
show	VBP	O	O
that	IN	O	O
reprogrammed	VBD	O	O
cells	NNS	O	O
with	IN	O	O
the	DT	O	O
capacity	NN	O	O
to	TO	O	O
differentiate	VB	O	O
into	IN	O	O
the	DT	O	O
three	CD	O	O
germ	NN	O	O
layers	NNS	O	O
in	IN	O	O
vitro	NN	O	O
can	MD	O	O
form	VB	O	O
malignant	JJ	O	O
tumors	NNS	O	O
,	,	O	O
suggesting	VBG	O	O
that	IN	O	O
in	IN	O	O
genetically	RB	O	O
unstable	JJ	O	O
cells	NNS	O	O
,	,	O	O
such	JJ	O	O
as	IN	O	O
those	DT	O	O
in	IN	O	O
which	WDT	O	O
p53	NN	B-Gene	O
is	VBZ	O	O
mutated	VBN	B-Var	O
,	,	O	O
reprogramming	VBG	B-CPA	O
may	MD	O	O
result	VB	B-Reg	O
in	IN	I-Reg	O
the	DT	O	O
generation	NN	O	O
of	IN	O	O
cells	NNS	B-CPA	O
with	IN	I-CPA	O
malignant	JJ	I-CPA	O
tumor	NN	I-CPA	O
-	:	I-CPA	O
forming	VBG	I-CPA	O
potential	JJ	I-CPA	O

-	:	I-PosReg	I-PosReg
of	IN	I-PosReg	I-PosReg
-	:	I-PosReg	I-PosReg
function	NN	I-PosReg	I-PosReg
in	IN	I-Var	O
PTPN11	NNP	B-Gene	O
histiocytic	JJ	B-Disease	O
sarcomas	NN	I-Disease	O

High	JJ	O	O
prevalence	NN	O	O
of	IN	O	O
fatal	JJ	O	O
,	,	O	O
disseminated	VBN	O	O
HS	NNP	O	O
has	VBZ	O	O
been	VBN	O	O
described	VBN	O	O
in	IN	O	O
Bernese	JJ	O	O
Mountain	NNP	O	O
Dogs	NNP	O	O
(	(	O	O
BMDs	NNP	O	O
)	)	O	O
.	.	O	O

Support	NN	O	O
for	IN	O	O
genetic	JJ	O	O
predisposition	NN	O	O
to	TO	O	O
develop	VB	O	O
HS	NNP	O	O
has	VBZ	O	O
been	VBN	O	O
presented	VBN	O	O
in	IN	O	O
several	JJ	O	O
studies	NNS	O	O
,	,	O	O
but	CC	O	O
to	TO	O	O
date	NN	O	O
,	,	O	O
causative	JJ	O	O
genetic	JJ	O	O
events	NNS	O	O
have	VBP	O	O
not	RB	O	O
been	VBN	O	O
reported	VBN	O	O
.	.	O	O

In	IN	O	O
addition	NN	O	O
,	,	O	O
no	DT	O	O
driver	NN	O	O
mutations	NNS	O	O
have	VBP	O	O
been	VBN	O	O
identified	VBN	O	O
in	IN	O	O
tumours	NNS	O	O
.	.	O	O

Recently	RB	O	O
,	,	O	O
E76K	NNP	B-Var	O
gain	VBP	B-PosReg	B-PosReg
-	:	I-PosReg	I-PosReg
of	IN	I-PosReg	I-PosReg
-	:	I-PosReg	I-PosReg
function	NN	I-PosReg	I-PosReg
mutation	NN	O	B-Var
in	IN	O	O
SHP2	NNP	O	O
encoded	VBN	O	O
by	IN	O	O
the	DT	O	O
PTPN11	NNP	B-Gene	O
gene	NN	O	O
has	VBZ	O	O
been	VBN	O	O
described	VBN	O	O
in	IN	O	O
human	JJ	O	O
histiocytic	JJ	B-Disease	O
malignancies	NNS	I-Disease	O
.	.	O	O
In	IN	O	O
our	PRP$	O	O
study	NN	O	O
,	,	O	O
we	PRP	O	O
identified	VBD	O	O
the	DT	O	O
PTPN11E76K	NNP	O	O
in	IN	O	O
HS	NNP	O	O
of	IN	O	O
BMDs	NNP	O	O
.	.	O	O

Amplification	NN	O	O
of	IN	O	O
exon	JJ	O	O
3	CD	O	O
of	IN	O	O
the	DT	O	O
PTPN11	NNP	O	O
gene	NN	O	O
followed	VBN	O	O
by	IN	O	O
Sanger	NNP	O	O
sequencing	NN	O	O
was	VBD	O	O
used	VBN	O	O
to	TO	O	O
detect	VB	O	O
the	DT	O	O
mutation	NN	O	O
and	CC	O	O
estimate	VB	O	O
the	DT	O	O
prevalence	NN	O	O
in	IN	O	O
HS	NNP	O	O
from	IN	O	O
30	CD	O	O
BMDs	NNP	O	O
,	,	O	O
13	CD	O	O
Golden	NNP	O	O
Retrievers	NNPS	O	O
and	CC	O	O
10	CD	O	O
other	JJ	O	O
dog	NN	O	O
breeds	NNS	O	O
.	.	O	O

The	DT	O	O
overall	JJ	O	O
prevalence	NN	O	O
of	IN	O	O
PTPN11E76K	NNP	O	O
in	IN	O	O
HS	NNP	O	O
of	IN	O	O
BMDs	NNP	O	O
was	VBD	O	O
36.67%	CD	O	O
compared	VBN	O	O
with	IN	O	O
8.69%	CD	O	O
in	IN	O	O
other	JJ	O	O
breeds	NNS	O	O
.	.	O	O

No	DT	O	O
mutation	NN	O	O
was	VBD	O	O
identified	VBN	O	O
in	IN	O	O
normal	JJ	O	O
tissues	NNS	O	O
from	IN	O	O
10	CD	O	O
BMDs	NNP	O	O
with	IN	O	O
HS	NNP	O	O
that	WDT	O	O
carried	VBD	O	O
the	DT	O	O
mutation	NN	O	O
and	CC	O	O
12	CD	O	O
control	NN	O	O
dogs	NNS	O	O
with	IN	O	O
no	DT	O	O
neoplastic	JJ	O	O
disease	NN	O	O
,	,	O	O
including	VBG	O	O
6	CD	O	O
BMDs	NNP	O	O
.	.	O	O

Increased	VBN	O	O
immunoreactivity	NN	O	O
for	IN	O	O
AKT	NNP	O	O
,	,	O	O
phosphorylated	VBD	O	O
ERK1	NNP	O	O
2	CD	O	O
and	CC	O	O
phosphorylated	VBD	O	O
AKT	NNP	O	O
in	IN	O	O
a	DT	O	O
small	JJ	O	O
subset	NN	O	O
of	IN	O	O
BMDs	NNP	O	O
with	IN	O	O
PTPN11E76K	NNP	O	O
suggests	VBZ	O	O
that	IN	O	O
a	DT	O	O
gain	NN	O	O
-	:	O	O
of	IN	O	O
-	:	O	O
function	NN	O	O
might	MD	O	O
be	VB	O	O
mediated	VBN	O	O
by	IN	O	O
the	DT	O	O
ERK	NNP	O	O
and	CC	O	O
AKT	NNP	O	O
pathways	NNS	O	O
.	.	O	O

These	DT	O	O
data	NNS	O	O
suggest	VBP	O	O
PTPN11E76K	NNP	O	O
as	IN	O	O
an	DT	O	O
important	JJ	O	O
driver	NN	O	O
mutation	NN	O	O
of	IN	O	O
HS	NNP	O	O
in	IN	O	O
BMDs	NNP	O	O
.	.	O	O

This	DT	O	O
information	NN	O	O
may	MD	O	O
not	RB	O	O
only	RB	O	O
aid	NN	O	O
in	IN	O	O
unravelling	VBG	O	O
the	DT	O	O
tumourigenic	JJ	O	O
events	NNS	O	O
associated	VBN	O	O
with	IN	O	O
HS	NNP	O	O
in	IN	O	O
BMDs	NNP	O	O
,	,	O	O
but	CC	O	O
also	RB	O	O
help	NN	O	O
in	IN	O	O
identifying	VBG	O	O
more	JJR	O	O
promising	JJ	O	O
therapeutic	JJ	O	O
strategies	NNS	O	O

TP53	NNP	B-Gene	B-Disease
tumor	NN	I-Gene	I-Disease
-	:	I-Gene	O
suppressor	NN	I-Gene	O
gene	NN	I-Gene	O
Missense	JJ	B-Var	B-Var
mutations	NNS	I-Var	I-Var
promote	NN	B-PosReg	B-PosReg
tumor	NN	B-CPA	B-CPA
malignancy	NN	I-CPA	I-CPA
mutant	NN	B-Var	B-Var
p53	NN	B-Gene	B-Gene
promotes	NNS	B-PosReg	B-PosReg
tumor	VBP	B-CPA	B-CPA
malignancy	NN	I-CPA	I-CPA
suppressing	VBG	B-NegReg	O
expression	NN	B-MPA	O
of	IN	I-MPA	O
a	DT	I-MPA	O
natural	JJ	I-MPA	O
occurring	VBG	I-MPA	O
anti	JJ	I-MPA	O
-	:	I-MPA	O
inflammatory	NN	I-MPA	O
cytokine	NN	I-MPA	O
We	PRP	O	O
show	VBP	O	O
that	IN	O	O
mutp53	NN	B-Var	O
but	CC	O	O
not	RB	O	O
wild	JJ	O	O
-	:	O	O
type	NN	O	O
(	(	O	O
wt	NN	O	O
)	)	O	O
p53	NN	O	O
suppresses	VBZ	B-NegReg	O
the	DT	O	O
sIL	NN	B-MPA	O
-	:	I-MPA	O
1	CD	I-MPA	O
Ra	NNP	I-MPA	O
production	NN	I-MPA	O
in	IN	O	O
conditioned	JJ	O	O
media	NNS	O	O
of	IN	O	O
cancer	NN	O	O
cells	NNS	O	O
.	.	O	O
Moreover	RB	O	O
,	,	O	O
mutp53	NN	O	O
,	,	O	O
but	CC	O	O
not	RB	O	O
wtp53	VB	O	O
,	,	O	O
binds	VBZ	O	O
physically	RB	O	O
the	DT	O	O
sIL	NN	O	O
-	:	O	O
1	CD	O	O
Ra	NNP	O	O
promoter	NN	O	O
and	CC	O	O
the	DT	O	O
protein	NN	O	O
-	:	O	O
protein	NN	O	O
interaction	NN	O	O
with	IN	O	O
the	DT	O	O
transcriptional	JJ	O	O
co	NN	O	O
-	:	O	O
repressor	NN	O	O
MAFF	NNP	O	O
(	(	O	O
v	SYM	O	O
-	:	O	O
MAF	NNP	O	O
musculoaponeurotic	JJ	O	O
fibrosarcoma	NN	O	O
oncogene	MD	O	O
family	NN	O	O
,	,	O	O
protein	RB	O	O
F	NNP	O	O
)	)	O	O
is	VBZ	O	O
required	VBN	O	O
for	IN	O	O
mutp53	NN	O	O
-	:	O	O
induced	JJ	O	O
sIL	NN	O	O
-	:	O	O
1	CD	O	O
Ra	NNP	O	O
suppression	NN	O	O
.	.	O	O

Remarkably	RB	O	O
,	,	O	O
when	WRB	O	O
exposed	VBN	O	O
to	TO	O	O
IL	NNP	O	O
-	:	O	O
1	CD	O	O
beta	NN	O	O
(	(	O	O
IL	NNP	O	O
-	:	O	O
1	CD	O	O
)	)	O	O
inflammatory	NN	O	O
stimuli	NN	O	O
,	,	O	O
mutp53	NN	O	O
sustains	VBZ	O	O
a	DT	O	O
ready	JJ	O	O
-	:	O	O
to	TO	O	O
-	:	O	O
be	VB	O	O
-	:	O	O
activated	VBN	O	O
in	IN	O	O
vitro	NN	O	O
and	CC	O	O
in	IN	O	O
vivo	JJ	O	O
cancer	NN	O	O
cells	NNS	O	O
response	NN	O	O
through	IN	O	O
the	DT	O	O
sIL	JJ	O	O
-	:	O	O
1	CD	O	O
Ra	NNP	O	O
repression	NN	O	O
.	.	O	O

Taken	VBN	O	O
together	RB	O	O
,	,	O	O
these	DT	O	O
results	NNS	O	O
identify	VBP	O	O
sIL	JJ	O	O
-	:	O	O
1	CD	O	O
Ra	NNP	O	O
as	IN	O	O
a	DT	O	O
novel	JJ	O	O
mutp53	NN	O	O
target	NN	O	O
gene	NN	O	O
,	,	O	O
whose	WP$	O	O
suppression	NN	O	O
might	MD	O	O
be	VB	O	O
required	VBN	O	O
to	TO	O	O
generate	VB	O	O
a	DT	O	O
chronic	JJ	O	O
pro	FW	O	O
-	:	O	O
inflammatory	NN	O	O
tumor	NN	O	O
microenvironment	NN	O	O
through	IN	O	O
which	WDT	O	O
mutp53	NN	O	B-Var
promotes	NNS	O	B-PosReg
tumor	VBP	O	B-CPA
malignancy	NN	O	I-CPA

Previously	RB	O	O
reported	VBN	O	O
pathogenic	JJ	O	O
gain	NN	O	O
-	:	O	O
of	IN	O	O
-	:	O	O
function	NN	O	O
mutations	NNS	O	O
of	IN	O	O
GPCR	NNP	O	O
genes	NNS	O	O
invariably	RB	O	O
encoded	VBD	O	O
aberrant	JJ	O	O
receptors	NNS	O	O
with	IN	O	O
excessive	JJ	O	O
signal	JJ	O	O
transduction	NN	O	O
activity	NN	O	O
.	.	O	O

Although	IN	O	O
in	IN	O	O
vitro	JJ	O	O
assays	NNS	O	O
demonstrated	VBD	O	O
that	IN	O	O
an	DT	O	O
artificially	RB	O	O
created	VBN	O	O
inactive	JJ	O	O
mutant	NN	O	O
of	IN	O	O
PROKR2	NNP	O	O
exerted	VBD	O	O
paradoxical	JJ	O	O
gain	NN	O	O
-	:	O	O
of	IN	O	O
-	:	O	O
function	NN	O	O
effects	NNS	O	O
when	WRB	O	O
co	NN	O	O
-	:	O	O
transfected	VBN	O	O
with	IN	O	O
wild	JJ	O	O
-	:	O	O
type	NN	O	O
proteins	NNS	O	O
,	,	O	O
such	PDT	O	O
a	DT	O	O
phenomenon	NN	O	O
has	VBZ	O	O
not	RB	O	O
been	VBN	O	O
observed	VBN	O	O
in	IN	O	O
vivo	NN	O	O
.	.	O	O

Here	RB	O	O
,	,	O	O
we	PRP	O	O
report	VBP	O	O
a	DT	O	O
heterozygous	JJ	O	O
frameshift	NN	O	B-Var
mutation	NN	O	O
of	IN	O	O
PROKR2	NNP	O	O
identified	VBN	O	O
in	IN	O	O
a	DT	O	O
3.5	CD	O	O
-	:	O	O
year	NN	O	O
-	:	O	O
old	JJ	O	O
girl	NN	O	O
with	IN	O	O
central	JJ	O	O
precocious	JJ	O	O
puberty	NN	O	O
.	.	O	O

The	DT	O	O
mutant	JJ	B-Var	O
mRNA	NN	O	O
escaped	VBD	B-NegReg	O
nonsense	JJ	B-MPA	O
-	:	I-MPA	O
mediated	VBN	I-MPA	O
decay	NN	I-MPA	O
and	CC	O	O
generated	VBD	O	O
a	DT	O	O
GPCR	NNP	O	O
lacking	VBG	B-NegReg	O
two	CD	B-MPA	O
transmembrane	NN	I-MPA	O
domains	NNS	I-MPA	O
and	CC	O	O
the	DT	O	O
carboxyl	NN	O	O
-	:	O	O
terminal	JJ	O	O
tail	NN	O	O
.	.	O	O
The	DT	O	O
mutant	JJ	O	O
protein	NN	O	O
had	VBD	O	O
no	DT	O	O
in	IN	O	O
vitro	JJ	O	O
signal	JJ	O	O
transduction	NN	O	O
activity	NN	O	O
;	:	O	O
however	RB	O	O
,	,	O	O
cells	NNS	O	O
co	VBP	O	O
-	:	O	O
expressing	VBG	O	O
the	DT	O	O
mutant	NN	O	O
and	CC	O	O
wild	JJ	O	O
-	:	O	O
type	NN	O	O
PROKR2	NNP	O	O
exhibited	VBD	O	O
markedly	RB	O	O
exaggerated	JJ	O	O
ligand	NN	O	O
-	:	O	O
induced	VBN	O	O
Ca	NNP	O	O
(	(	O	O
2	CD	O	O
)	)	O	O
responses	NNS	O	O
.	.	O	O

The	DT	O	O
results	NNS	O	O
indicate	VBP	O	O
that	IN	O	O
certain	JJ	O	O
inactive	JJ	O	O
PROKR2	NNP	B-Gene	O
mutants	NNS	B-Var	O
can	MD	O	O
cause	VB	O	O
early	JJ	O	O
puberty	NN	O	O
by	IN	O	O
enhancing	VBG	B-PosReg	O
the	DT	O	O
functional	JJ	B-MPA	O
property	NN	I-MPA	O
of	IN	I-MPA	O
coexisting	VBG	I-MPA	O
wild	JJ	I-MPA	O
-	:	I-MPA	O
type	NN	I-MPA	O
proteins	NNS	I-MPA	O
.	.	O	O
Considering	VBG	O	O
the	DT	O	O
structural	JJ	O	O
similarity	NN	O	O
among	IN	O	O
GPCRs	NNP	O	O
,	,	O	O
this	DT	O	O
paradoxical	JJ	O	O
gain	NN	O	O
-	:	O	O
of	IN	O	O
-	:	O	O
function	NN	O	O
mechanism	NN	O	O
may	MD	O	O
underlie	VB	O	O
various	JJ	O	O
human	JJ	O	O
disorders	NNS	O	O

dilated	VBN	B-Disease	O
cardiomyopathy	NN	I-Disease	O
Nav1	NNP	B-Gene	O
.	.	I-Gene	O
5	CD	I-Gene	O
gain	NN	B-PosReg	O
-	:	I-PosReg	O
of	IN	I-PosReg	O
-	:	I-PosReg	O
function	NN	I-PosReg	O
G213D	NNP	B-Var	O
mutations	NNS	B-Var	B-Var
lead	VB	B-Reg	B-Reg
to	TO	I-Reg	I-Reg
cardiac	JJ	B-Disease	B-Disease
diseases	NNS	I-Disease	I-Disease

Screening	NN	O	O
of	IN	O	O
the	DT	O	O
SCN5A	NNP	B-Gene	B-Gene
gene	NN	O	O
revealed	VBD	O	O
a	DT	O	O
missense	JJ	B-Var	O
mutation	NN	I-Var	O
in	IN	O	O
the	DT	O	O
linker	NN	O	O
between	IN	O	O
segments	NNS	O	O
3	CD	O	O
and	CC	O	O
4	CD	O	O
in	IN	O	O
domain	NN	O	O
1	CD	O	O
of	IN	O	O
the	DT	O	O
Nav1	NNP	O	O
.	.	O	O
5	CD	O	O
protein	NN	O	O
,	,	O	O
resulting	VBG	B-Reg	O
in	IN	I-Reg	O
a	DT	O	O
glycine	NN	O	O
to	TO	O	O
aspartate	VB	O	O
substitution	NN	O	O
at	IN	O	O
position	NN	O	O
213	CD	O	O
(	(	O	O
G213D	NNP	B-Var	O
)	)	O	O
.	.	O	O
The	DT	O	O
phenotype	NN	O	O
co	SYM	O	O
-	:	O	O
segregated	VBN	O	O
with	IN	O	O
the	DT	O	O
missense	NN	O	O
mutation	NN	O	O
.	.	O	O

Electrophysiological	JJ	O	O
studies	NNS	O	O
of	IN	O	O
wild	JJ	O	O
type	NN	O	O
(	(	O	O
WT	NNP	O	O
)	)	O	O
hNav1	NN	O	O
.	.	O	O
5	CD	O	O
and	CC	O	O
hNav1	NN	O	O
.	.	O	O
5	CD	O	O
_	JJ	O	O
G213D	NNP	O	O
expressed	VBD	O	O
in	IN	O	O
CHO	NNP	O	O
-	:	O	O
K	NNP	O	O
cells	NNS	O	O
showed	VBD	O	O
that	IN	O	O
the	DT	O	O
voltage	NN	O	O
of	IN	O	O
half	JJ	O	O
-	:	O	O
maximal	JJ	O	O
activation	NN	O	O
(	(	O	O
V	NNP	O	O
)	)	O	O
was	VBD	O	O
significantly	RB	O	O
more	RBR	O	O
negative	JJ	O	O
for	IN	O	O
hNav1	NN	O	O
.	.	O	O
5	CD	O	O
_	JJ	O	O
G213D	NNP	O	O
compared	VBN	O	O
to	TO	O	O
WT	NNP	O	O
(	(	O	O
V	NNP	O	O
-	:	O	O
38.7	CD	O	O
0.5	CD	O	O
mV	NN	O	O
for	IN	O	O
WT	NNP	O	O
and	CC	O	O
V	NNP	O	O
-	:	O	O
42.4	CD	O	O
0.5	CD	O	O
mV	NN	O	O
for	IN	O	O
G213D	NNP	O	O
;	:	O	O
P	NNP	O	O
0.001	CD	O	O
)	)	O	O
.	.	O	O

This	DT	O	O
suggests	VBZ	O	O
activation	NN	O	O
of	IN	O	O
Nav1	NNP	O	O
.	.	O	O
5	CD	O	O
_	JJ	O	O
G231D	NNP	O	O
at	IN	O	O
more	RBR	O	O
negative	JJ	O	O
potentials	NNS	O	O
.	.	O	O

The	DT	O	O
V	NNP	O	O
of	IN	O	O
steady	JJ	O	O
-	:	O	O
state	NN	O	O
inactivation	NN	O	O
was	VBD	O	O
significantly	RB	O	O
shifted	VBN	O	O
towards	NNS	O	O
more	RBR	O	O
positive	JJ	O	O
values	NNS	O	O
for	IN	O	O
Nav1	NNP	O	O
.	.	O	O
5	CD	O	O
_	JJ	O	O
G213D	NNP	O	O
(	(	O	O
V	NNP	O	O
-	:	O	O
86.7	CD	O	O
0.2	CD	O	O
mV	NN	O	O
for	IN	O	O
WT	NNP	O	O
and	CC	O	O
-	:	O	O
82.2	CD	O	O
0.3	CD	O	O
mV	NN	O	O
for	IN	O	O
G213D	NNP	O	O
;	:	O	O
P	NNP	O	O
0.001	CD	O	O
)	)	O	O
,	,	O	O
also	RB	O	O
contributing	VBG	O	O
to	TO	O	O
a	DT	O	O
gain	NN	O	O
-	:	O	O
of	IN	O	O
-	:	O	O
function	NN	O	O
phenotype	NN	O	O
.	.	O	O

Flecainide	NNP	O	O
and	CC	O	O
amiodarone	RB	O	O
markedly	RB	O	O
reduced	JJ	O	B-NegReg
premature	NN	O	B-MPA
atrial	NN	O	I-MPA
and	CC	O	O
ventricular	JJ	O	O
contractions	NNS	O	O
in	IN	O	O
four	CD	O	O
patients	NNS	O	O
.	.	O	O

CONCLUSION	NN	O	O
:	:	O	O
The	DT	O	O
Nav1	NNP	B-Gene	O
.	.	I-Gene	O
5	CD	I-Gene	O
_	JJ	O	O
G213D	NNP	B-Var	O
mutation	NN	O	O
is	VBZ	O	O
associated	VBN	O	O
with	IN	O	O
a	DT	O	O
gain	NN	B-PosReg	O
-	:	I-PosReg	O
of	IN	I-PosReg	O
-	:	I-PosReg	O
function	NN	I-PosReg	O
phenotype	NN	O	O
,	,	O	O
multifocal	JJ	O	O
atrial	NN	O	O
and	CC	O	O
ventricular	JJ	O	O
ectopy	NN	O	O
and	CC	O	O
dilated	VBD	B-Disease	O
cardiomyopathy	NN	I-Disease	O
.	.	O	O
Since	IN	O	O
patients	NNS	O	O
with	IN	O	O
a	DT	O	O
MEPPC	NNP	O	O
-	:	O	O
like	IN	O	O
phenotype	NN	O	O
may	MD	O	O
specifically	RB	O	O
benefit	VB	O	O
from	IN	O	O
Class	NNP	O	O
-	:	O	O
1	CD	O	O
antiarrhythmic	JJ	O	O
drugs	NNS	O	O
or	CC	O	O
amiodarone	NN	O	O
,	,	O	O
clinical	JJ	O	O
identification	NN	O	O
of	IN	O	O
this	DT	O	O
disease	NN	O	O
entity	NN	O	O
is	VBZ	O	O
important	JJ	O	O

long	JJ	B-Disease	B-Disease
QT	NNP	I-Disease	I-Disease
syndrome	NN	I-Disease	I-Disease

Standard	NNP	O	O
-	:	O	O
of	IN	O	O
-	:	O	O
care	NN	O	O
clinical	JJ	O	O
genetic	JJ	O	O
testing	NN	O	O
for	IN	O	O
this	DT	O	O
and	CC	O	O
other	JJ	O	O
arrhythmia	NN	O	O
susceptibility	NN	O	O
syndromes	VBZ	O	O
improves	VBZ	O	O
the	DT	O	O
identification	NN	O	O
of	IN	O	O
complex	JJ	O	O
genotypes	NNS	O	O
.	.	O	O

Therefore	RB	O	O
,	,	O	O
it	PRP	O	O
is	VBZ	O	O
important	JJ	O	O
to	TO	O	O
distinguish	VB	O	O
between	IN	O	O
pathogenic	JJ	O	O
mutations	NNS	O	O
and	CC	O	O
benign	JJ	O	O
rare	JJ	O	O
variants	NNS	O	O
.	.	O	O

We	PRP	O	O
identified	VBD	O	O
four	CD	O	O
genetic	JJ	O	O
variants	NNS	O	O
(	(	O	O
KCNQ1	NNP	O	O
-	:	O	O
p	NN	O	B-Var
.	.	O	I-Var
R583H	NNP	O	I-Var
,	,	O	O
KCNH2	NNP	O	O
-	:	O	O
p	NN	O	B-Var
.	.	O	I-Var
C108Y	NNP	O	I-Var
,	,	O	O
KCNH2	NNP	O	O
-	:	O	O
p	NN	O	B-Var
.	.	O	I-Var
K897T	NNP	O	I-Var
,	,	O	O
and	CC	O	O
KCNE1	NNP	O	O
-	:	O	O
p	NN	O	B-Var
.	.	O	I-Var
G38S	NNP	O	I-Var
)	)	O	O
in	IN	O	O
an	DT	O	O
LQTS	NNP	O	O
family	NN	O	O
.	.	O	O

On	IN	O	O
the	DT	O	O
basis	NN	O	O
of	IN	O	O
in	IN	O	O
silico	NN	O	O
analysis	NN	O	O
,	,	O	O
clinical	JJ	O	O
data	NNS	O	O
from	IN	O	O
our	PRP$	O	O
family	NN	O	O
,	,	O	O
and	CC	O	O
the	DT	O	O
evidence	NN	O	O
from	IN	O	O
previous	JJ	O	O
studies	NNS	O	O
,	,	O	O
we	PRP	O	O
analyzed	VBD	O	O
two	CD	O	O
mutated	JJ	O	O
channels	NNS	O	O
,	,	O	O
KCNQ1	NNP	O	O
-	:	O	O
p	NN	O	B-Var
.	.	O	I-Var
R583H	NNP	O	I-Var
and	CC	O	O
KCNH2	NNP	O	O
-	:	O	O
p	NN	O	B-Var
.	.	O	I-Var
C108Y	NNP	O	I-Var
,	,	O	O
using	VBG	O	O
the	DT	O	O
whole	JJ	O	O
-	:	O	O
cell	NN	O	O
patch	NN	O	O
clamp	NN	O	O
technique	NN	O	O
.	.	O	O

We	PRP	O	O
found	VBD	O	O
that	IN	O	O
KCNQ1	NNP	O	O
-	:	O	O
p	NN	O	B-Var
.	.	O	I-Var
R583H	NNP	O	I-Var
was	VBD	O	O
not	RB	O	O
associated	VBN	O	O
with	IN	O	O
a	DT	O	O
severe	JJ	O	O
functional	JJ	O	O
impairment	NN	O	O
,	,	O	O
whereas	WP	O	O
KCNH2	NNP	B-Gene	O
-	:	O	O
p	NN	B-Var	B-Var
.	.	I-Var	I-Var
C108Y	NNP	I-Var	I-Var
,	,	O	O
a	DT	O	O
novel	JJ	O	O
variant	NN	O	O
,	,	O	O
encoded	VBD	B-Reg	O
a	DT	O	O
non	JJ	B-Pathway	O
-	:	I-Pathway	O
functional	JJ	I-Pathway	O
channel	NN	I-Pathway	O
that	WDT	O	O
exerts	VBZ	O	O
dominant	JJ	B-NegReg	O
-	:	I-NegReg	O
negative	JJ	I-NegReg	O
effects	NNS	B-MPA	O
on	IN	O	O
the	DT	O	O
wild	JJ	O	O
-	:	O	O
type	NN	O	O
.	.	O	O
Notably	RB	O	O
,	,	O	O
the	DT	O	O
common	JJ	O	O
variants	NNS	O	O
KCNH2	NNP	O	O
-	:	O	O
p	NN	O	B-Var
.	.	O	I-Var
K897T	NNP	O	I-Var
and	CC	O	O
KCNE1	NNP	O	O
-	:	O	O
p	NN	O	B-Var
.	.	O	I-Var
G38S	NNP	O	I-Var
were	VBD	O	O
previously	RB	O	O
reported	VBN	O	O
to	TO	O	O
produce	VB	O	O
more	JJR	O	O
severe	JJ	O	O
phenotypes	NNS	O	O
when	WRB	O	O
combined	VBN	O	O
with	IN	O	O
disease	NN	O	O
-	:	O	O
causing	NN	O	O
alleles	NNS	O	O
.	.	O	O

Our	PRP$	O	O
results	NNS	O	O
indicate	VBP	O	O
that	IN	O	O
the	DT	O	O
novel	NN	O	O
KCNH2	NNP	B-Gene	O
-	:	O	O
C108Y	NNP	B-Var	O
variant	NN	O	O
can	MD	O	O
be	VB	O	O
a	DT	O	O
pathogenic	JJ	B-Reg	O
LQTS	NNP	B-Disease	O
mutation	NN	O	O
,	,	O	O
whereas	WP	O	O
KCNQ1	NNP	O	O
-	:	O	O
p	NN	O	B-Var
.	.	O	I-Var
R583H	NNP	O	I-Var
,	,	O	O
KCNH2	NNP	O	O
-	:	O	O
p	NN	O	B-Var
.	.	O	I-Var
K897T	NNP	O	I-Var
,	,	O	O
and	CC	O	O
KCNE1	NNP	O	O
-	:	O	O
p	NN	O	B-Var
.	.	O	I-Var
G38S	NNP	O	I-Var
could	MD	O	O
be	VB	O	O
LQTS	NNP	O	O
modifiers	NNS	O	O

NR2F2	NNP	B-Gene	B-Gene
loss	NN	B-NegReg	O
-	:	I-NegReg	O
of	IN	I-NegReg	O
-	:	I-NegReg	O
function	NN	I-NegReg	O
to	TO	I-Var	O
congenital	VB	B-Disease	O
heart	NN	I-Disease	O
defect	NN	I-Disease	O

However	RB	O	O
,	,	O	O
the	DT	O	O
genetic	JJ	O	O
basis	NN	O	O
of	IN	O	O
CHD	NNP	O	O
remains	VBZ	O	O
poorly	RB	O	O
understood	JJ	O	O
due	JJ	O	O
to	TO	O	O
substantial	JJ	O	O
genetic	JJ	O	O
heterogeneity	NN	O	O
.	.	O	O

In	IN	O	O
this	DT	O	O
study	NN	O	O
,	,	O	O
the	DT	O	O
coding	NN	O	O
exons	NNS	O	O
and	CC	O	O
splicing	VBG	O	O
boundaries	NNS	O	O
of	IN	O	O
the	DT	O	O
NR2F2	NNP	O	B-Gene
gene	NN	O	O
,	,	O	O
which	WDT	O	O
encodes	VBZ	O	O
a	DT	O	O
pleiotropic	NN	O	O
transcription	NN	O	O
factor	NN	O	O
required	VBN	O	O
for	IN	O	O
normal	JJ	O	O
cardiovascular	JJ	O	O
development	NN	O	O
,	,	O	O
were	VBD	O	O
sequenced	VBN	O	O
in	IN	O	O
168	CD	O	O
unrelated	JJ	O	O
patients	NNS	O	O
with	IN	O	O
CHD	NNP	O	O
,	,	O	O
and	CC	O	O
a	DT	O	O
novel	JJ	O	O
mutation	NN	O	O
(	(	O	O
c	NN	O	B-Var
.	.	O	I-Var
247	CD	O	I-Var
G	NNP	O	I-Var
T	NNP	O	I-Var
,	,	O	O
equivalent	JJ	O	O
to	TO	O	O
p	VB	O	B-Var
.	.	O	I-Var
G83X	NNP	O	I-Var
)	)	O	O
was	VBD	O	O
detected	VBN	O	O
in	IN	O	O
a	DT	O	O
patient	NN	O	O
with	IN	O	O
double	JJ	O	O
outlet	NN	O	O
right	RB	O	O
ventricle	NN	O	O
as	RB	O	O
well	RB	O	O
as	IN	O	O
ventricular	JJ	O	O
septal	JJ	O	O
defect	NN	O	O
.	.	O	O

Genetic	JJ	O	O
scanning	NN	O	O
of	IN	O	O
the	DT	O	O
mutation	NN	O	O
carrier	NN	O	O
's	POS	O	O
relatives	NNS	O	O
available	JJ	O	O
showed	VBD	O	O
that	IN	O	O
the	DT	O	O
mutation	NN	O	O
was	VBD	O	O
present	JJ	O	O
in	IN	O	O
all	DT	O	O
affected	JJ	O	O
family	NN	O	O
members	NNS	O	O
but	CC	O	O
absent	JJ	O	O
in	IN	O	O
unaffected	JJ	O	O
family	NN	O	O
members	NNS	O	O
.	.	O	O

Analysis	NN	O	O
of	IN	O	O
the	DT	O	O
index	NN	O	O
patient	NN	O	O
's	POS	O	O
pedigree	JJ	O	O
displayed	NN	O	O
that	IN	O	O
the	DT	O	O
mutation	NN	O	O
co	SYM	O	O
-	:	O	O
segregated	VBN	O	O
with	IN	O	O
CHD	NNP	O	O
,	,	O	O
which	WDT	O	O
was	VBD	O	O
transmitted	VBN	O	O
as	IN	O	O
an	DT	O	O
autosomal	JJ	O	O
dominant	JJ	O	O
trait	NN	O	O
with	IN	O	O
complete	JJ	O	O
penetrance	NN	O	O
.	.	O	O

The	DT	O	O
nonsense	JJ	O	O
mutation	NN	O	O
was	VBD	O	O
absent	JJ	O	O
in	IN	O	O
230	CD	O	O
unrelated	JJ	O	O
,	,	O	O
ethnically	RB	O	O
-	:	O	O
matched	VBN	O	O
healthy	JJ	O	O
individuals	NNS	O	O
used	VBN	O	O
as	IN	O	O
controls	NNS	O	O
.	.	O	O

Functional	JJ	O	O
deciphers	NNS	O	O
by	IN	O	O
using	VBG	O	O
a	DT	O	O
dual	JJ	O	O
-	:	O	O
luciferase	NN	O	O
reporter	NN	O	O
assay	VBP	O	O
system	NN	O	O
revealed	VBD	O	O
that	IN	O	O
the	DT	O	O
mutant	JJ	B-Var	O
NR2F2	NNP	B-Gene	O
protein	NN	O	O
had	VBD	O	O
no	DT	B-NegReg	O
transcriptional	JJ	B-MPA	O
activity	NN	I-MPA	O
as	IN	O	O
compared	VBN	O	O
with	IN	O	O
its	PRP$	O	O
wild	JJ	O	O
-	:	O	O
type	NN	O	O
counterpart	NN	O	O
.	.	O	O
Furthermore	RB	O	O
,	,	O	O
the	DT	O	O
mutation	NN	B-Var	O
abrogated	VBD	B-NegReg	O
the	DT	O	O
synergistic	JJ	B-MPA	O
transcriptional	JJ	I-MPA	O
activation	NN	I-MPA	O
between	IN	O	O
NR2F2	NNP	B-Gene	O
and	CC	O	O
GATA4	NNP	B-Gene	O
,	,	O	O
another	DT	O	O
core	NN	O	O
cardiac	NN	O	O
transcription	NN	O	O
factor	NN	O	O
associated	VBN	O	O
with	IN	O	O
CHD	NNP	O	O
.	.	O	O
This	DT	O	O
study	NN	O	O
firstly	RB	O	O
associates	VBZ	O	O
NR2F2	NNP	O	O
loss	NN	O	O
-	:	O	O
of	IN	O	O
-	:	O	O
function	NN	O	O
mutation	NN	O	O
with	IN	O	O
an	DT	O	O
increased	VBN	O	O
susceptibility	NN	O	O
to	TO	O	O
double	VB	O	O
outlet	NN	O	O
right	JJ	O	O
ventricle	NN	O	O
in	IN	O	O
humans	NNS	O	O
,	,	O	O
which	WDT	O	O
provides	VBZ	O	O
further	RBR	O	O
significant	JJ	O	O
insight	NN	O	O
into	IN	O	O
the	DT	O	O
molecular	JJ	O	O
mechanisms	NNS	O	O
underpinning	VBG	O	O
CHD	NNP	O	O
,	,	O	O
suggesting	VBG	O	O
potential	JJ	O	O
implications	NNS	O	O
for	IN	O	O
genetic	JJ	O	O
counseling	NN	O	O
of	IN	O	O
CHD	NNP	O	O
families	NNS	O	O
and	CC	O	O
personalized	JJ	O	O
treatment	NN	O	O
of	IN	O	O
CHD	NNP	O	O
patients	NNS	O	O

primary	JJ	B-Disease	B-Disease
immunodeficiencies	NNS	I-Disease	I-Disease
gain	NN	B-PosReg	B-PosReg
-	:	I-PosReg	I-PosReg
of	IN	I-PosReg	I-PosReg
-	:	I-PosReg	I-PosReg
function	NN	I-PosReg	I-PosReg
mutations	NNS	B-Var	B-Var
STAT	NNP	B-Gene	B-Gene
RECENT	JJ	O	O
FINDINGS	NN	O	O
:	:	O	O
GOF	NNP	O	O
mutations	NNS	B-Var	O
affecting	VBG	O	O
STAT1	NNP	B-Gene	O
result	NN	O	O
in	IN	O	O
increased	JJ	B-PosReg	B-PosReg
STAT	NNP	B-MPA	B-MPA
tyrosine	NN	I-MPA	I-MPA
phosphorylation	NN	I-MPA	I-MPA
and	CC	O	O
secondarily	RB	O	O
increased	VBD	B-PosReg	B-PosReg
response	NN	B-MPA	B-MPA
to	TO	I-MPA	I-MPA
STAT1	NNP	I-MPA	I-MPA
-	:	I-MPA	I-MPA
signaling	VBG	I-MPA	I-MPA
cytokines	NNS	I-MPA	I-MPA
,	,	O	O
such	JJ	O	O
as	IN	O	O
interferons	NNS	O	O
.	.	O	O
In	IN	O	O
contrast	NN	O	O
,	,	O	O
STAT3	NNP	O	O
hyperactivity	NN	O	O
is	VBZ	O	O
not	RB	O	O
usually	RB	O	O
related	VBN	O	O
to	TO	O	O
hyperphosphorylation	NN	O	O
but	CC	O	O
rather	RB	O	O
to	TO	O	O
increased	VB	O	O
STAT3	NNP	O	O
-	:	O	O
mediated	VBD	O	O
transcriptional	JJ	O	O
activity	NN	O	O
.	.	O	O

In	IN	O	O
both	DT	O	O
cases	NNS	O	O
,	,	O	O
heterozygous	JJ	O	O
STAT1	NNP	O	O
and	CC	O	O
STAT3	NNP	O	O
GOF	NNP	O	O
mutations	NNS	O	B-Var
trigger	VBP	O	B-Gene
a	DT	O	O
distinct	JJ	O	O
set	NN	O	O
of	IN	O	O
genes	NNS	O	O
in	IN	O	O
target	NN	O	O
cells	NNS	O	O
that	WDT	O	O
lead	VBP	O	O
to	TO	O	O
abnormal	JJ	O	O
functioning	NN	O	O
of	IN	O	O
antimicrobial	JJ	O	O
response	NN	O	O
and	CC	O	O
or	CC	O	O
autoimmunity	NN	O	O
and	CC	O	O
result	NN	O	O
in	IN	O	O
autosomal	JJ	O	O
dominant	JJ	O	O
diseases	NNS	O	O
.	.	O	O

SUMMARY	NN	O	O
:	:	O	O
Clinical	JJ	O	O
manifestations	NNS	O	O
of	IN	O	O
patients	NNS	O	O
with	IN	O	O
STAT1	NNP	O	O
GOF	NNP	O	O
are	VBP	O	O
characterized	VBN	O	O
by	IN	O	O
mucocutaneous	JJ	O	O
candidiasis	NN	O	O
and	CC	O	O
recurrent	NN	O	O
lower	JJR	O	O
tract	NN	O	O
respiratory	JJ	O	O
infections	NNS	O	O
.	.	O	O

In	IN	O	O
addition	NN	O	O
,	,	O	O
many	JJ	O	O
patients	NNS	O	O
have	VBP	O	O
thyroiditis	VBN	O	O
,	,	O	O
type	VBZ	O	O
1	CD	O	O
diabetes	NNS	O	O
mellitus	RB	O	O
,	,	O	O
autoimmune	JJ	O	O
cytopenias	NN	O	O
,	,	O	O
cancer	NN	O	O
or	CC	O	O
aneurysms	NNS	O	O
.	.	O	O

Patients	NNS	O	O
with	IN	O	O
germline	JJ	O	O
STAT3	NNP	O	O
GOF	NNP	O	O
mutations	NNS	O	O
have	VBP	O	O
an	DT	O	O
increased	JJ	O	O
frequency	NN	O	O
of	IN	O	O
early	JJ	O	O
-	:	O	O
onset	NN	O	O
multiorgan	JJ	O	O
autoimmunity	NN	O	O
(	(	O	O
i	JJ	O	O
.	.	O	O
e	NN	O	O
.	.	O	O

autoimmune	NN	O	O
enteropathy	NN	O	O
,	,	O	O
type	NN	O	O
1	CD	O	O
diabetes	NNS	O	O
mellitus	RB	O	O
,	,	O	O
autoimmune	JJ	O	O
interstitial	JJ	O	O
lung	NN	O	O
disease	NN	O	O
and	CC	O	O
autoimmune	JJ	O	O
cytopenias	NN	O	O
)	)	O	O
,	,	O	O
lymphoproliferation	NN	O	O
,	,	O	O
short	JJ	O	O
stature	NN	O	O
and	CC	O	O
,	,	O	O
less	RBR	O	O
frequently	RB	O	O
,	,	O	O
severe	JJ	O	O
recurrent	NN	O	O
infections	NNS	O	O
.	.	O	O

Treatment	NN	O	O
options	NNS	O	O
range	VBP	O	O
from	IN	O	O
antimicrobial	JJ	O	O
therapy	NN	O	O
,	,	O	O
intravenous	JJ	O	O
or	CC	O	O
subcutaneous	JJ	O	O
immunoglobulin	NN	O	O
and	CC	O	O
immunosuppressive	JJ	O	O
drugs	NNS	O	O
.	.	O	O

Some	DT	O	O
patients	NNS	O	O
with	IN	O	O
STAT1	NNP	O	O
GOF	NNP	O	O
disorder	NN	O	O
have	VBP	O	O
undergone	VBN	O	O
hematopoietic	JJ	O	O
stem	NN	O	O
cell	NN	O	O
transplantation	NN	O	O
,	,	O	O
although	IN	O	O
these	DT	O	O
have	VBP	O	O
been	VBN	O	O
difficult	JJ	O	O
because	IN	O	O
of	IN	O	O
the	DT	O	O
underlying	JJ	O	O
proinflammatory	NN	O	O
milieu	NN	O	O
from	IN	O	O
the	DT	O	O
mutation	NN	O	O

cleft	NN	B-Disease	O
palate	NN	I-Disease	O
only	RB	I-Disease	O

Mutations	NNS	O	B-Var
in	IN	O	O
this	DT	O	O
gene	NN	O	O
were	VBD	O	O
also	RB	O	O
reported	VBN	O	O
in	IN	O	O
families	NNS	O	O
with	IN	O	O
Van	NNP	O	O
der	NN	O	O
Woude	NNP	O	O
syndrome	NN	O	O
.	.	O	O

To	TO	O	O
identify	VB	O	O
rare	JJ	O	O
mutations	NNS	O	O
in	IN	O	O
GRHL3	NNP	O	O
that	WDT	O	O
might	MD	O	O
explain	VB	O	O
the	DT	O	O
missing	JJ	O	O
heritability	NN	O	O
for	IN	O	O
CPO	NNP	O	O
,	,	O	O
we	PRP	O	O
sequenced	VBD	O	O
GRHL3	NNP	O	O
in	IN	O	O
cases	NNS	O	O
of	IN	O	O
CPO	NNP	O	O
from	IN	O	O
Africa	NNP	O	O
.	.	O	O

We	PRP	O	O
recruited	VBD	O	O
participants	NNS	O	O
from	IN	O	O
Ghana	NNP	O	O
,	,	O	O
Ethiopia	NNP	O	O
,	,	O	O
and	CC	O	O
Nigeria	NNP	O	O
.	.	O	O

This	DT	O	O
cohort	NN	O	O
included	VBD	O	O
case	NN	O	O
-	:	O	O
parent	NN	O	O
trios	NNS	O	O
,	,	O	O
cases	NNS	O	O
and	CC	O	O
other	JJ	O	O
family	NN	O	O
members	NNS	O	O
,	,	O	O
as	RB	O	O
well	RB	O	O
as	IN	O	O
controls	NNS	O	O
.	.	O	O

We	PRP	O	O
sequenced	VBD	O	O
exons	NNS	O	O
of	IN	O	O
this	DT	O	O
gene	NN	O	O
in	IN	O	O
DNA	NNP	O	O
from	IN	O	O
a	DT	O	O
total	NN	O	O
of	IN	O	O
134	CD	O	O
nonsyndromic	JJ	O	O
cases	NNS	O	O
.	.	O	O

When	WRB	O	O
possible	JJ	O	O
,	,	O	O
we	PRP	O	O
sequenced	VBD	O	O
them	PRP	O	O
in	IN	O	O
parents	NNS	O	O
to	TO	O	O
identify	VB	O	O
de	FW	O	O
novo	FW	O	O
mutations	NNS	O	O
.	.	O	O

Five	CD	O	O
novel	JJ	O	O
mutations	NNS	O	O
were	VBD	O	O
identified	VBN	O	O
:	:	O	O
2	CD	O	O
missense	NN	O	O
(	(	O	O
c	NN	O	O
.	.	O	O
497	CD	O	O
C	NNP	O	O
A	NNP	O	O
;	:	O	O
p	NN	O	B-Var
.	.	O	I-Var
Pro166His	NNP	O	O
and	CC	O	O
c	NN	O	O
.	.	O	O
1229	CD	O	O
A	NNP	O	O
G	NNP	O	O
;	:	O	O
p	NN	O	B-Var
.	.	O	I-Var
Asp410Gly	NNP	O	I-Var
)	)	O	O
,	,	O	O
1	CD	O	O
splice	NN	O	O
site	NN	O	O
(	(	O	O
c	NN	O	O
.	.	O	O
1282	CD	O	O
A	NNP	O	O
C	NNP	O	O
p	NN	O	B-Var
.	.	O	I-Var
Ser428Arg	NNP	O	I-Var
)	)	O	O
,	,	O	O
1	CD	O	O
frameshift	NN	O	O
(	(	O	O
c	NN	O	O
.	.	O	O
470	CD	O	O
delC	NN	O	O
;	:	O	O
p	NN	O	B-Var
.	.	O	I-Var
Gly158Alafster55	NNP	O	I-Var
)	)	O	O
,	,	O	O
and	CC	O	O
1	CD	O	O
nonsense	NN	O	O
(	(	O	O
c	NN	O	O
.	.	O	O
1677	CD	O	O
C	NNP	O	O
A	NNP	O	O
;	:	O	O
p	NN	O	B-Var
.	.	O	I-Var
Tyr559Ter	NNP	O	I-Var
)	)	O	O
.	.	O	O

These	DT	O	O
mutations	NNS	O	O
were	VBD	O	O
absent	JJ	O	O
from	IN	O	O
270	CD	O	O
sequenced	JJ	O	O
controls	NNS	O	O
and	CC	O	O
from	IN	O	O
all	DT	O	O
public	JJ	O	O
exome	NN	O	O
and	CC	O	O
whole	JJ	O	O
genome	NN	O	O
databases	NNS	O	O
,	,	O	O
including	VBG	O	O
the	DT	O	O
1000	CD	O	O
Genomes	NNP	O	O
database	NN	O	O
(	(	O	O
which	WDT	O	O
includes	VBZ	O	O
data	NNS	O	O
from	IN	O	O
Africa	NNP	O	O
)	)	O	O
.	.	O	O

However	RB	O	O
,	,	O	O
4	CD	O	O
of	IN	O	O
the	DT	O	O
5	CD	O	O
mutations	NNS	O	O
were	VBD	O	O
present	JJ	O	O
in	IN	O	O
unaffected	JJ	O	O
mothers	NNS	O	O
,	,	O	O
indicating	VBG	O	O
that	IN	O	O
their	PRP$	O	O
penetrance	NN	O	O
is	VBZ	O	O
incomplete	JJ	O	O
.	.	O	O

Interestingly	RB	O	O
,	,	O	O
1	CD	O	O
mutation	NN	B-Var	O
damaged	VBD	B-NegReg	O
a	DT	O	O
predicted	JJ	O	O
sumoylation	NN	B-MPA	O
site	NN	I-MPA	O
,	,	O	O
and	CC	O	O
another	DT	O	O
disrupted	VBD	B-NegReg	O
a	DT	O	O
predicted	JJ	O	O
CK1	NNP	B-MPA	O
phosphorylation	NN	I-MPA	O
site	NN	O	O
.	.	O	O
Overexpression	NNP	O	O
assays	NNS	O	O
in	IN	O	O
zebrafish	NN	O	O
and	CC	O	O
reporter	NN	O	O
assays	NNS	O	O
in	IN	O	O
vitro	NN	O	O
indicated	VBD	O	O
that	IN	O	O
4	CD	O	O
variants	NNS	O	O
were	VBD	O	O
functionally	RB	O	O
null	JJ	O	O
or	CC	O	O
hypomorphic	JJ	O	O
,	,	O	O
while	IN	O	O
1	CD	O	O
was	VBD	O	O
dominant	JJ	O	O
negative	JJ	O	O
.	.	O	O

This	DT	O	O
study	NN	O	O
provides	VBZ	O	O
evidence	NN	O	O
that	RB	O	O
,	,	O	O
as	IN	O	O
in	IN	O	O
Caucasian	JJ	O	O
populations	NNS	O	O
,	,	O	O
mutations	NNS	B-Var	O
in	IN	O	O
GRHL3	NNP	B-Gene	O
contribute	NN	O	O
to	TO	O	O
the	DT	O	O
risk	NN	B-Reg	O
of	IN	O	O
nonsyndromic	JJ	O	O
CPO	NNP	B-Disease	O
in	IN	O	O
the	DT	O	O
African	JJ	O	O
population	NN	O	O

Peroxidasins	NNS	O	O
are	VBP	O	O
extracellular	JJ	O	O
peroxidases	NNS	O	O
implicated	VBN	O	O
in	IN	O	O
the	DT	O	O
unique	JJ	O	O
sulfilimine	NN	O	O
cross	NN	O	O
-	:	O	O
links	NNS	O	O
between	IN	O	O
type	NN	O	O
IV	NNP	O	O
basement	NN	O	O
membrane	NN	O	O
collagens	NNS	O	O
.	.	O	O

Loss	NNP	B-NegReg	O
of	IN	I-NegReg	O
function	NN	I-NegReg	O
in	IN	O	O
the	DT	O	O
Caenorhabditis	NNP	B-Enzyme	O
elegans	VBZ	I-Enzyme	O
peroxidasin	VBP	I-Enzyme	O
PXN	NNP	I-Enzyme	O
-	:	I-Enzyme	O
2	CD	I-Enzyme	O
results	NNS	O	O
in	IN	O	O
fully	RB	B-CPA	O
penetrant	JJ	I-CPA	O
embryonic	NN	I-CPA	O
or	CC	O	O
larval	JJ	B-CPA	O
lethality	NN	I-CPA	O
.	.	O	O
Using	VBG	O	O
genetic	JJ	O	O
suppressor	NN	O	O
screening	NN	O	O
,	,	O	O
we	PRP	O	O
find	VBP	O	O
that	IN	O	O
the	DT	O	O
requirement	NN	O	O
for	IN	O	O
PXN	NNP	O	O
-	:	O	O
2	CD	O	O
in	IN	O	O
development	NN	O	O
can	MD	O	O
be	VB	O	O
bypassed	VBN	O	O
by	IN	O	O
gain	NN	O	O
of	IN	O	O
function	NN	O	O
in	IN	O	O
multiple	JJ	O	O
genes	NNS	O	O
encoding	VBG	O	O
other	JJ	O	O
basement	JJ	O	O
membrane	NN	O	O
components	NNS	O	O
,	,	O	O
or	CC	O	O
proteins	NNS	O	O
implicated	VBN	O	O
in	IN	O	O
cell	NN	O	O
-	:	O	O
matrix	NN	O	O
attachment	NN	O	O
.	.	O	O

We	PRP	O	O
identify	VBP	O	O
multiple	JJ	O	O
alleles	NNS	O	O
of	IN	O	O
let	NN	O	O
-	:	O	O
805	CD	O	O
,	,	O	O
encoding	VBG	O	O
the	DT	O	O
transmembrane	NN	O	O
protein	NN	O	O
myotactin	NN	O	O
,	,	O	O
which	WDT	O	O
suppress	VBP	O	O
phenotypes	NNS	O	O
of	IN	O	O
pxn	NN	O	O
-	:	O	O
2	CD	O	O
null	JJ	O	O
mutants	NNS	O	O
and	CC	O	O
of	IN	O	O
other	JJ	O	O
basement	NN	O	O
membrane	NN	O	O
mutants	NNS	O	O
such	JJ	O	O
as	IN	O	O
F	NNP	O	O
-	:	O	O
spondin	NN	O	O
spon	SYM	O	O
-	:	O	O
1	CD	O	O
These	DT	O	O
let	VB	B-Gene	O
-	:	I-Gene	O
805	CD	I-Gene	O
suppressor	NN	O	O
alleles	NNS	O	O
cause	VBP	O	O
missense	JJ	B-Var	O
alterations	NNS	I-Var	O
in	IN	O	O
two	CD	O	O
pairs	NNS	O	O
of	IN	O	O
FNIII	NNP	O	O
repeats	NNS	O	O
in	IN	O	O
the	DT	O	O
extracellular	JJ	O	O
domain	NN	O	O
;	:	O	O
they	PRP	O	O
act	VBP	O	O
dominantly	RB	O	O
and	CC	O	O
have	VBP	O	O
no	DT	O	O
detectable	JJ	O	O
phenotypes	NNS	O	O
alone	RB	O	O
,	,	O	O
suggesting	VBG	O	O
they	PRP	O	O
cause	VBP	O	O
gain	NN	B-PosReg	O
of	IN	I-PosReg	O
function	NN	I-PosReg	O
.	.	O	O
We	PRP	O	O
also	RB	O	O
identify	VBP	O	O
suppressor	NN	O	O
missense	NN	O	O
mutations	NNS	O	O
affecting	VBG	O	O
basement	NN	O	O
membrane	NN	O	O
components	NNS	O	O
type	VBP	O	O
IV	NNP	O	O
collagen	NN	O	O
(	(	O	O
emb	JJ	O	O
-	:	O	O
9	CD	O	O
,	,	O	O
let	VB	O	O
-	:	O	O
2	CD	O	O
)	)	O	O
and	CC	O	O
perlecan	JJ	O	O
(	(	O	O
unc	JJ	O	O
-	:	O	O
52	CD	O	O
)	)	O	O
,	,	O	O
as	RB	O	O
well	RB	O	O
as	IN	O	O
a	DT	O	O
mutation	NN	O	O
affecting	VBG	O	O
spectraplakin	NN	O	O
(	(	O	O
vab	JJ	O	O
-	:	O	O
10	CD	O	O
)	)	O	O
,	,	O	O
a	DT	O	O
component	NN	O	O
of	IN	O	O
the	DT	O	O
epidermal	JJ	O	O
cytoskeleton	NN	O	O
.	.	O	O

These	DT	O	O
suppressor	NN	O	O
alleles	NNS	O	O
do	VBP	O	O
not	RB	O	O
bypass	VB	O	O
the	DT	O	O
developmental	JJ	O	O
requirement	NN	O	O
for	IN	O	O
core	NN	O	O
structural	JJ	O	O
proteins	NNS	O	O
of	IN	O	O
the	DT	O	O
basement	NN	O	O
membrane	NN	O	O
such	JJ	O	O
as	IN	O	O
laminin	NN	O	O
or	CC	O	O
type	NN	O	O
IV	NNP	O	O
collagen	NN	O	O
.	.	O	O

In	IN	O	O
conclusion	NN	O	O
,	,	O	O
putative	JJ	O	O
gain	NN	O	O
-	:	O	O
of	IN	O	O
-	:	O	O
function	NN	O	O
alterations	NNS	O	O
in	IN	O	O
matrix	JJ	O	O
proteins	NNS	O	O
or	CC	O	O
in	IN	O	O
cell	NN	O	O
-	:	O	O
matrix	NN	O	O
receptors	NNS	O	O
can	MD	O	O
overcome	VB	O	O
the	DT	O	O
requirement	NN	O	O
for	IN	O	O
certain	JJ	O	O
basement	JJ	O	O
membrane	NN	O	O
proteins	NNS	O	O
in	IN	O	O
embryonic	JJ	O	O
development	NN	O	O
,	,	O	O
revealing	VBG	O	O
previously	RB	O	O
unknown	JJ	O	O
plasticity	NN	O	O
in	IN	O	O
the	DT	O	O
genetic	JJ	O	O
requirements	NNS	O	O
for	IN	O	O
the	DT	O	O
extracellular	JJ	O	O
matrix	NN	O	O

More	RBR	O	O
recently	RB	O	O
,	,	O	O
population	NN	O	O
studies	NNS	O	O
have	VBP	O	O
identified	VBN	O	O
cancer	NN	O	O
-	:	O	O
associated	VBN	O	O
variants	NNS	O	O
in	IN	O	O
the	DT	O	O
blood	NN	O	O
of	IN	O	O
otherwise	RB	O	O
healthy	JJ	O	O
individuals	NNS	O	O
as	IN	O	O
they	PRP	O	O
age	NN	O	O
,	,	O	O
a	DT	O	O
phenomenon	NN	O	O
termed	VBD	O	O
clonal	JJ	O	O
hematopoiesis	NN	O	O
of	IN	O	O
indeterminate	JJ	O	O
potential	NN	O	O
(	(	O	O
CHIP	NNP	O	O
)	)	O	O
.	.	O	O

This	DT	O	O
suggests	VBZ	O	O
that	IN	O	O
these	DT	O	O
mutations	NNS	O	B-Var
may	MD	O	O
occur	VB	O	O
in	IN	O	O
hematopoietic	JJ	O	O
stem	NN	O	O
cells	NNS	O	O
(	(	O	O
HSCs	NNP	O	O
)	)	O	O
long	RB	O	O
before	IN	O	O
any	DT	O	O
clinical	JJ	O	O
presentation	NN	O	O
but	CC	O	O
are	VBP	O	O
not	RB	O	O
necessarily	RB	O	O
harbingers	NNS	O	O
of	IN	O	O
transformation	NN	O	O
because	IN	O	O
only	RB	O	O
a	DT	O	O
fraction	NN	O	O
of	IN	O	O
individuals	NNS	O	O
with	IN	O	O
CHIP	NNP	O	O
develop	VB	O	O
hematopoietic	JJ	O	O
pathologies	NNS	O	O
.	.	O	O

Delineation	NN	O	O
between	IN	O	O
CHIP	NNP	O	O
variants	NNS	O	O
that	WDT	O	O
predispose	VBP	O	O
for	IN	O	O
disease	NN	O	O
versus	NN	O	O
those	DT	O	O
that	WDT	O	O
are	VBP	O	O
more	JJR	O	O
benign	NNS	O	O
could	MD	O	O
be	VB	O	O
used	VBN	O	O
as	IN	O	O
a	DT	O	O
prognostic	JJ	O	O
factor	NN	O	O
to	TO	O	O
identify	VB	O	O
individuals	NNS	O	O
at	IN	O	O
greater	JJR	O	O
risk	NN	O	O
for	IN	O	O
transformation	NN	O	O
.	.	O	O

To	TO	O	O
achieve	VB	O	O
this	DT	O	O
,	,	O	O
the	DT	O	O
biological	JJ	O	O
impact	NN	O	O
of	IN	O	O
CHIP	NNP	O	O
variants	NNS	O	O
on	IN	O	O
HSC	NNP	O	O
function	NN	O	O
must	MD	O	O
be	VB	O	O
validated	VBN	O	O
.	.	O	O

One	CD	O	O
variant	NN	O	O
that	WDT	O	O
has	VBZ	O	O
been	VBN	O	O
identified	VBN	O	O
recurrently	RB	O	O
in	IN	O	O
CHIP	NNP	B-CPA	O
is	VBZ	O	O
a	DT	O	O
gain	NN	B-PosReg	O
-	:	I-PosReg	O
of	IN	I-PosReg	O
-	:	I-PosReg	O
function	NN	I-PosReg	O
missense	NN	B-Var	O
mutation	NN	I-Var	O
in	IN	O	O
the	DT	O	O
imprinted	JJ	O	O
gene	NN	O	O
GNAS	NNP	B-Gene	O
(	(	O	O
Guanine	NNP	O	B-MPA
Nucleotide	NNP	O	I-MPA
Binding	NNP	O	I-MPA
Protein	NNP	O	I-MPA
,	,	O	O
Alpha	NNP	O	O
Stimulating	NNP	O	O
)	)	O	O
.	.	O	O
In	IN	O	O
this	DT	O	O
study	NN	O	O
,	,	O	O
we	PRP	O	O
examined	VBD	O	O
the	DT	O	O
effect	NN	O	O
of	IN	O	O
the	DT	O	O
GNASR201C	NNP	O	O
variant	NN	O	O
on	IN	O	O
HSC	NNP	O	O
function	NN	O	O
.	.	O	O

Ectopic	NNP	O	B-Gene
expression	NN	O	B-MPA
of	IN	O	O
GNASR201C	NNP	B-Gene	O
supported	VBD	I-Gene	O
transplantable	JJ	I-Var	O
HSC	NNP	I-PosReg	O
activity	NN	I-CPA	O
and	CC	O	O
improved	VBN	B-PosReg	O
lymphoid	JJ	B-CPA	O
output	NN	I-CPA	O
in	IN	O	O
secondary	JJ	O	O
recipients	NNS	O	O
.	.	O	O
Because	IN	O	O
declining	VBG	O	O
lymphoid	JJ	O	O
output	NN	O	O
is	VBZ	O	O
a	DT	O	O
hallmark	NN	O	O
of	IN	O	O
aging	VBG	O	O
,	,	O	O
GNASR201C	NNP	O	O
mutations	NNS	O	O
may	MD	O	O
sustain	VB	O	O
lymphoid	JJ	O	O
-	:	O	O
biased	VBN	O	O
HSCs	NNP	O	O
over	IN	O	O
time	NN	O	O
and	CC	O	O
maintain	VB	O	O
them	PRP	O	O
in	IN	O	O
a	DT	O	O
developmental	JJ	O	O
state	NN	O	O
favorable	JJ	O	O
for	IN	O	O
transformation	NN	O	O

p53	NN	B-Gene	B-Gene
missense	NN	B-Var	B-Var
mutations	NNS	I-Var	I-Var
abrogate	VBP	B-NegReg	B-Gene
tumour	JJ	B-CPA	O
suppressive	JJ	I-CPA	O
function	NN	I-CPA	O
gain	NN	B-PosReg	O
-	:	I-PosReg	O
of	IN	I-PosReg	O
-	:	I-PosReg	O
function	NN	I-PosReg	O
promotes	VBZ	B-PosReg	O
cancer	NN	B-Disease	O
Here	RB	O	O
we	PRP	O	O
show	VBP	O	O
that	IN	O	O
p53	NN	B-Gene	O
GOF	NNP	B-PosReg	O
mutants	NNS	B-Var	B-Var
bind	VBP	O	B-Interaction
to	TO	O	O
and	CC	O	O
upregulate	JJ	B-PosReg	O
chromatin	NN	B-Gene	O
regulatory	JJ	I-Gene	O
genes	NNS	I-Gene	O
,	,	O	O
including	VBG	O	O
the	DT	O	O
methyltransferases	NNS	B-Enzyme	O
MLL1	NNP	I-Enzyme	O
(	(	O	O
also	RB	O	O
known	VBN	O	O
as	IN	O	O
KMT2A	NNP	O	O
)	)	O	O
,	,	O	O
MLL2	NNP	B-Enzyme	O
(	(	O	O
also	RB	O	O
known	VBN	O	O
as	IN	O	O
KMT2D	NNP	O	O
)	)	O	O
,	,	O	O
and	CC	O	O
acetyltransferase	NN	B-Enzyme	O
MOZ	NNP	I-Enzyme	O
(	(	O	O
also	RB	O	O
known	VBN	O	O
as	IN	O	O
KAT6A	NNP	O	O
or	CC	O	O
MYST3	NNP	O	O
)	)	O	O
,	,	O	O
resulting	VBG	O	O
in	IN	O	O
genome	JJ	O	O
-	:	O	O
wide	JJ	O	O
increases	NNS	B-PosReg	O
of	IN	O	O
histone	NN	B-MPA	O
methylation	NN	I-MPA	O
and	CC	O	O
acetylation	NN	B-MPA	B-MPA
.	.	O	O
Analysis	NN	O	O
of	IN	O	O
The	DT	O	O
Cancer	NNP	O	O
Genome	NNP	O	O
Atlas	NNP	O	O
shows	VBZ	O	O
specific	JJ	O	O
upregulation	NN	B-PosReg	O
of	IN	O	O
MLL1	NNP	B-Enzyme	O
,	,	O	O
MLL2	NNP	B-Enzyme	O
,	,	O	O
and	CC	O	O
MOZ	NNP	B-Enzyme	O
in	IN	O	O
p53	NN	B-Gene	O
GOF	NNP	B-Var	O
patient	NN	O	O
-	:	O	O
derived	VBN	O	O
tumours	NNS	O	O
,	,	O	O
but	CC	O	O
not	RB	O	O
in	IN	O	O
wild	JJ	O	O
-	:	O	O
type	NN	O	O
p53	NN	O	O
or	CC	O	O
p53	NN	O	O
null	JJ	O	O
tumours	NN	O	O
.	.	O	O
Cancer	NNP	O	O
cell	NN	O	O
proliferation	NN	O	O
is	VBZ	O	O
markedly	RB	O	O
lowered	VBN	O	O
by	IN	O	O
genetic	JJ	O	O
knockdown	NN	O	O
of	IN	O	O
MLL1	NNP	O	O
or	CC	O	O
by	IN	O	O
pharmacological	JJ	O	O
inhibition	NN	O	O
of	IN	O	O
the	DT	O	O
MLL1	NNP	O	O
methyltransferase	NN	O	O
complex	NN	O	O
.	.	O	O

Our	PRP$	O	O
study	NN	O	O
reveals	VBZ	O	O
a	DT	O	O
novel	JJ	O	O
chromatin	NN	O	O
mechanism	NN	O	O
underlying	VBG	O	O
the	DT	O	O
progression	NN	O	O
of	IN	O	O
tumours	NNS	O	O
with	IN	O	O
GOF	NNP	O	O
p53	NN	O	O
,	,	O	O
and	CC	O	O
suggests	VBZ	O	O
new	JJ	O	O
possibilities	NNS	O	O
for	IN	O	O
designing	VBG	O	O
combinatorial	JJ	O	O
chromatin	NN	O	O
-	:	O	O
based	VBN	O	O
therapies	NNS	O	O
for	IN	O	O
treating	VBG	O	O
individual	JJ	O	O
cancers	NNS	O	O
driven	VBN	O	O
by	IN	O	O
prevalent	JJ	O	O
GOF	NNP	O	O
p53	NN	O	O
mutations	NNS	O	O

Spinocerebellar	JJ	B-Disease	O
ataxia	NN	I-Disease	O
type	NN	I-Disease	O
2	CD	I-Disease	O
(	(	O	O
SCA2	NNP	O	O
)	)	O	O
is	VBZ	O	O
an	DT	O	O
autosomal	JJ	O	B-Disease
dominant	JJ	O	I-Disease
neurodegenerative	JJ	O	I-Disease
disease	NN	O	I-Disease
caused	VBN	B-Reg	B-Reg
by	IN	I-Reg	O
CAG	NNP	B-Var	O
repeat	NN	I-Var	O
expansion	NN	I-Var	O
in	IN	O	O
the	DT	O	O
ATXN2	NNP	B-Gene	O
gene	NN	O	O
.	.	O	O
The	DT	O	O
repeat	NN	O	O
resides	NNS	O	O
in	IN	O	O
an	DT	O	O
encoded	JJ	O	O
region	NN	O	O
of	IN	O	O
the	DT	O	O
gene	NN	O	O
resulting	VBG	O	O
in	IN	O	O
polyglutamine	NN	O	O
(	(	O	O
polyQ	NN	O	O
)	)	O	O
expansion	NN	O	O
which	WDT	O	O
has	VBZ	O	O
been	VBN	O	O
assumed	VBN	O	O
to	TO	O	O
result	VB	O	O
in	IN	O	O
gain	NN	O	O
of	IN	O	O
function	NN	O	O
,	,	O	O
predominantly	RB	O	O
,	,	O	O
for	IN	O	O
the	DT	O	O
ATXN2	NNP	O	O
protein	NN	O	O
.	.	O	O

We	PRP	O	O
evaluated	VBD	O	O
temporal	JJ	O	O
cerebellar	JJ	O	O
expression	NN	O	O
profiles	NNS	O	O
by	IN	O	O
RNA	NNP	O	O
sequencing	NN	O	O
of	IN	O	O
ATXN2Q127	NNP	O	O
mice	NNP	O	O
vs	NN	O	O
wildtype	NN	O	O
littermates	NNS	O	O
.	.	O	O

ATXN2Q127	NNP	O	O
mice	NN	O	O
are	VBP	O	O
characterized	VBN	O	O
by	IN	O	O
a	DT	O	O
progressive	JJ	O	O
motor	NN	O	O
phenotype	NN	O	O
onset	NN	O	O
,	,	O	O
and	CC	O	O
have	VBP	O	O
progressive	JJ	O	O
cerebellar	JJ	O	O
molecular	NN	O	O
and	CC	O	O
neurophysiological	JJ	O	O
(	(	O	O
Purkinje	NNP	O	O
cell	NN	O	O
firing	VBG	O	O
frequency	NN	O	O
)	)	O	O
phenotypes	NNS	O	O
.	.	O	O

Our	PRP$	O	O
analysis	NN	O	O
revealed	VBD	O	O
previously	RB	O	O
uncharacterized	VBN	O	O
early	JJ	O	O
and	CC	O	O
progressive	JJ	O	O
abnormal	JJ	O	O
patterning	NN	O	O
of	IN	O	O
cerebellar	JJ	O	O
gene	NN	O	O
expression	NN	O	O
.	.	O	O

Weighted	VBN	O	O
Gene	NNP	O	O
Coexpression	NNP	O	O
Network	NNP	O	O
Analysis	NNP	O	O
(	(	O	O
WGCNA	NNP	O	O
)	)	O	O
revealed	VBD	O	O
four	CD	O	O
gene	NN	O	O
modules	NNS	O	O
that	WDT	O	O
were	VBD	O	O
significantly	RB	O	O
correlated	VBN	O	O
with	IN	O	O
disease	NN	O	O
status	NN	O	O
,	,	O	O
composed	VBD	O	O
primarily	RB	O	O
of	IN	O	O
genes	NNS	O	O
associated	VBN	O	O
with	IN	O	O
GTPase	NNP	O	O
signaling	VBG	O	O
,	,	O	O
calcium	NN	O	O
signaling	NN	O	O
,	,	O	O
and	CC	O	O
cell	NN	O	B-CPA
death	NN	O	I-CPA
.	.	O	O

Of	IN	O	O
these	DT	O	O
genes	NNS	O	O
,	,	O	O
few	JJ	O	O
overlapped	VBD	O	O
with	IN	O	O
differentially	RB	O	O
expressed	VBN	O	O
cerebellar	JJ	O	O
genes	NNS	O	O
that	IN	O	O
we	PRP	O	O
identified	VBD	O	O
in	IN	O	O
Atxn2	NNP	O	O
-	:	O	O
-	:	O	O
knockout	NN	O	O
mice	NN	O	O
vs	NN	O	O
wildtype	NN	O	O
littermates	VBZ	O	O
,	,	O	O
suggesting	VBG	O	O
that	IN	O	O
loss	NN	O	O
-	:	O	O
of	IN	O	O
-	:	O	O
function	NN	O	O
is	VBZ	O	O
not	RB	O	O
a	DT	O	O
significant	JJ	O	O
component	NN	O	O
of	IN	O	O
disease	NN	O	O
pathology	NN	O	O
.	.	O	O

We	PRP	O	O
conclude	VBP	O	O
that	DT	O	O
SCA2	NNP	O	O
is	VBZ	O	O
a	DT	O	O
disease	NN	O	O
characterized	VBN	O	O
by	IN	O	O
gain	NN	O	O
of	IN	O	O
function	NN	O	O
for	IN	O	O
ATXN2	NNP	O	O

Mutant	JJ	B-Var	B-Var
p53	NN	B-Protein	B-Gene
gain	VBP	B-PosReg	B-PosReg
new	JJ	I-PosReg	I-PosReg
activities	NNS	I-PosReg	B-MPA
promoting	VBG	B-CPA	I-MPA
tumorigenesis	NN	I-CPA	I-MPA
Mutp53	NNP	O	B-Var
can	MD	O	O
accumulate	VB	O	O
to	TO	O	O
high	JJ	O	O
levels	NNS	O	O
in	IN	O	O
tumours	NN	O	O
,	,	O	O
which	WDT	O	O
promotes	VBZ	O	O
mutp53	NN	B-Var	O
GOF	NNP	B-PosReg	O
in	IN	O	O
tumorigenesis	NN	B-CPA	O
.	.	O	O
The	DT	O	O
mechanism	NN	O	O
of	IN	O	O
mutp53	NN	O	O
accumulation	NN	O	O
is	VBZ	O	O
poorly	RB	O	O
understood	JJ	O	O
.	.	O	O

Here	RB	O	O
we	PRP	O	O
find	VBP	O	O
that	IN	O	O
MDM2	NNP	O	O
isoforms	NNS	O	O
promote	VBP	O	B-PosReg
mutp53	JJ	O	B-Var
accumulation	NN	O	B-PosReg
in	IN	O	O
tumours	NNS	O	O
.	.	O	O

MDM2	NNP	O	O
isoform	NN	O	O
B	NNP	O	O
(	(	O	O
MDM2	NNP	O	O
-	:	O	O
B	NN	O	O
)	)	O	O
,	,	O	O
the	DT	O	O
MDM2	NNP	O	O
isoform	NN	O	O
most	RBS	O	O
frequently	RB	O	O
over	IN	O	O
-	:	O	O
expressed	VBN	O	O
in	IN	O	O
human	JJ	O	O
tumours	NNS	O	O
,	,	O	O
interacts	NNS	O	O
with	IN	O	O
full	JJ	O	O
-	:	O	O
length	NN	O	O
MDM2	NNP	O	O
to	TO	O	O
inhibit	VB	O	O
MDM2	NNP	O	O
-	:	O	O
mediated	VBD	O	O
mutp53	JJ	O	O
degradation	NN	O	O
,	,	O	O
promoting	VBG	O	O
mutp53	NN	O	O
accumulation	NN	O	O
and	CC	O	O
GOF	NNP	O	O
in	IN	O	O
tumorigenesis	NN	O	O
.	.	O	O

Furthermore	RB	O	O
,	,	O	O
MDM2	NNP	O	O
-	:	O	O
B	NNP	O	O
overexpression	NN	O	O
correlates	NNS	O	O
with	IN	O	O
mutp53	JJ	O	O
accumulation	NN	O	O
in	IN	O	O
human	JJ	O	O
tumours	NNS	O	O
.	.	O	O

In	IN	O	O
mutp53	NN	O	O
knock	NN	O	O
-	:	O	O
in	IN	O	O
mice	NN	O	O
,	,	O	O
a	DT	O	O
MDM2	NNP	O	O
isoform	NN	O	O
similar	JJ	O	O
to	TO	O	O
human	JJ	O	O
MDM2	NNP	O	O
-	:	O	O
B	NN	O	O
is	VBZ	O	O
overexpressed	VBN	O	O
in	IN	O	O
the	DT	O	O
majority	NN	O	O
of	IN	O	O
tumours	NNS	O	O
,	,	O	O
which	WDT	O	O
promotes	VBZ	O	O
mutp53	NN	O	O
accumulation	NN	O	O
and	CC	O	O
tumorigenesis	NN	O	O
.	.	O	O

Thus	RB	O	O
,	,	O	O
overexpression	NN	O	O
of	IN	O	O
MDM2	NNP	O	O
isoforms	NNS	O	O
promotes	VBZ	O	O
mutp53	JJ	O	O
accumulation	NN	O	O
in	IN	O	O
tumours	NNS	O	O
,	,	O	O
contributing	VBG	O	O
to	TO	O	O
mutp53	VB	B-Var	O
GOF	NNP	B-PosReg	O
in	IN	O	O
tumorigenesis	NN	B-CPA	O
.	.	O	O
This	DT	O	O
may	MD	O	O
be	VB	O	O
an	DT	O	O
important	JJ	O	O
mechanism	NN	O	O
by	IN	O	O
which	WDT	O	O
MDM2	NNP	O	O
isoforms	NNS	O	O
promote	VBP	O	B-PosReg
tumorigenesis	NN	O	B-CPA

inactivating	VBG	I-Var	O
variants	NNS	I-Var	O
GTPBP2	NNP	B-Gene	O
disorder	NN	I-Reg	O
with	IN	I-Disease	O

We	PRP	O	O
present	VBP	O	O
three	CD	O	O
unrelated	JJ	O	O
families	NNS	O	O
in	IN	O	O
which	WDT	O	O
whole	JJ	O	O
-	:	O	O
exome	NN	O	O
sequencing	NN	O	O
identified	VBD	O	O
the	DT	O	O
homozygous	JJ	O	O
non	SYM	O	O
-	:	O	O
sense	NN	O	O
variants	NNS	O	B-Var
c	VBP	B-Var	B-Var
.	.	I-Var	I-Var
430	CD	I-Var	I-Var
[	JJ	I-Var	I-Gene
C	NNP	I-Var	I-Var
T	NNP	I-Var	I-Var
]	NNP	I-Var	O
;	:	I-Var	O
[	NNP	I-Var	O
C	NNP	I-Var	O
T	NNP	I-Var	O
]	NNP	I-Var	O
p	NN	I-Var	B-Var
.	.	I-Var	I-Var

(	(	I-Var	O
Arg144	NNP	I-Var	O
)	)	I-Var	O
,	,	O	O
c	RB	B-Var	B-Var
.	.	I-Var	I-Var
1219	CD	I-Var	I-Var
[	JJ	I-Var	I-Gene
C	NNP	I-Var	I-Var
T	NNP	I-Var	I-Var
]	NNP	I-Var	O
;	:	I-Var	O
[	NNP	I-Var	O
C	NNP	I-Var	O
T	NNP	I-Var	O
]	NNP	I-Var	O
p	NN	I-Var	B-Var
.	.	I-Var	I-Var

(	(	I-Var	O
Gln407	NNP	I-Var	O
)	)	I-Var	O
and	CC	O	O
c	$	B-Var	B-Var
.	.	I-Var	I-Var
1408	CD	I-Var	I-Var
[	JJ	I-Var	I-Gene
C	NNP	I-Var	I-Var
T	NNP	I-Var	I-Var
]	NNP	I-Var	O
;	:	I-Var	O
[	NNP	I-Var	O
C	NNP	I-Var	O
T	NNP	I-Var	O
]	NNP	I-Var	O
p	NN	I-Var	B-Var
.	.	I-Var	I-Var

(	(	I-Var	O
Arg470	NNP	I-Var	O
)	)	I-Var	O
in	IN	O	O
GTPBP2	NNP	B-Gene	O
.	.	O	O
Their	PRP$	O	O
clinical	JJ	O	O
presentations	NNS	O	O
include	VBP	O	O
early	JJ	O	O
onset	NN	O	O
and	CC	O	O
apparently	RB	O	O
non	JJ	B-CPA	O
-	:	I-CPA	O
progressive	JJ	I-CPA	O
motor	NN	I-CPA	O
and	CC	I-CPA	O
cognitive	JJ	I-CPA	O
impairment	NN	I-CPA	O
,	,	O	O
and	CC	O	O
thereby	RB	O	O
overlap	VB	O	O
with	IN	O	O
findings	NNS	O	O
in	IN	O	O
a	DT	O	O
recently	RB	O	O
described	VBN	O	O
family	NN	O	O
harbouring	VBG	O	O
a	DT	O	O
homozygous	JJ	O	O
GTPBP2	NNP	O	O
splice	NN	O	O
site	NN	O	O
variant	NN	O	O
.	.	O	O
Notable	JJ	O	O
differences	NNS	O	O
include	VBP	O	O
structural	JJ	B-CPA	O
brain	NN	I-CPA	O
abnormalities	NNS	I-CPA	O
(	(	O	O
e	NN	O	O
.	.	O	O
g	NN	O	O
.	.	O	O
,	,	O	O
agenesis	NN	B-CPA	O
of	IN	I-CPA	O
the	DT	I-CPA	O
corpus	NN	I-CPA	O
callosum	NN	I-CPA	O
,	,	O	O
exclusive	JJ	O	O
to	TO	O	O
our	PRP$	O	O
patients	NNS	O	O
)	)	O	O
,	,	O	O
and	CC	O	O
evidence	NN	O	O
for	IN	O	O
brain	NN	B-CPA	O
iron	NN	I-CPA	O
accumulation	NN	I-CPA	O
(	(	O	O
exclusive	JJ	O	O
to	TO	O	O
the	DT	O	O
previously	RB	O	O
described	VBN	O	O
family	NN	O	O
)	)	O	O
.	.	O	O
This	DT	O	O
report	NN	O	O
confirms	VBZ	O	O
pathogenicity	NN	O	O
of	IN	O	O
biallelic	JJ	O	O
GTPBP2	NNP	O	O
inactivation	NN	O	O
and	CC	O	O
broadens	VBZ	O	O
the	DT	O	O
phenotypic	NN	O	O
spectrum	NN	O	O
.	.	O	O

It	PRP	O	O
also	RB	O	O
underlines	VBZ	O	O
that	IN	O	O
a	DT	O	O
potential	JJ	O	O
involvement	NN	O	O
of	IN	O	O
brain	NN	O	O
iron	NN	O	O
accumulation	NN	O	O
needs	VBZ	O	O
clarification	NN	O	O
.	.	O	O

Further	JJ	O	O
patients	NNS	O	O
will	MD	O	O
have	VB	O	O
to	TO	O	O
be	VB	O	O
identified	VBN	O	O
and	CC	O	O
characterised	VBN	O	O
in	IN	O	O
order	NN	O	O
to	TO	O	O
fully	RB	O	O
define	VB	O	O
the	DT	O	O
core	NN	O	O
features	NNS	O	O
of	IN	O	O
GTPBP2	NNP	O	O
-	:	O	O
associated	JJ	O	O
neurological	JJ	O	O
disorder	NN	O	O
,	,	O	O
but	CC	O	O
future	JJ	O	O
approaches	NNS	O	O
to	TO	O	O
molecular	JJ	O	O
diagnosis	NN	O	O
of	IN	O	O
neurodevelopmental	JJ	O	O
disorders	NNS	O	O
should	MD	O	O
implement	VB	O	O
GTPBP2	NNP	O	O

Familial	JJ	B-Disease	B-Disease
erythrocytosis	NN	I-Disease	I-Disease
caused	VBN	B-Reg	B-Reg
mutations	NNS	B-Var	B-Var
EPO	NNP	B-Gene	B-Gene
We	PRP	O	O
identified	VBD	O	O
a	DT	O	O
mutation	NN	O	O
in	IN	O	O
EPO	NNP	O	O
that	WDT	O	O
cosegregated	VBD	O	O
with	IN	O	O
disease	NN	O	O
with	IN	O	O
a	DT	O	O
logarithm	NN	O	O
of	IN	O	O
the	DT	O	O
odds	NNS	O	O
(	(	O	O
LOD	NNP	O	O
)	)	O	O
score	NN	O	O
of	IN	O	O
3.3	CD	O	O
in	IN	O	O
a	DT	O	O
family	NN	O	O
with	IN	O	O
autosomal	JJ	O	B-Disease
dominant	JJ	O	I-Disease
erythrocytosis	NN	O	I-Disease
.	.	O	O

This	DT	O	O
mutation	NN	B-Var	O
,	,	O	O
a	DT	O	O
single	JJ	O	O
-	:	O	O
nucleotide	JJ	O	B-Var
deletion	NN	O	I-Var
(	(	O	O
c	NN	O	B-Var
.	.	O	I-Var
32	CD	O	I-Var
delG	NN	O	O
)	)	O	O
,	,	O	O
introduces	VBZ	O	O
a	DT	O	O
frameshift	NN	O	O
in	IN	O	O
exon	CC	O	O
2	CD	O	O
that	WDT	O	O
interrupts	JJ	B-NegReg	O
translation	NN	O	O
of	IN	O	O
the	DT	O	O
main	JJ	B-MPA	O
EPO	NNP	I-MPA	O
messenger	NN	I-MPA	O
RNA	NNP	I-MPA	O
(	(	I-MPA	O
mRNA	NN	I-MPA	O
)	)	I-MPA	O
transcript	NN	I-MPA	O
but	CC	O	O
initiates	VBZ	O	O
excess	JJ	O	O
production	NN	O	O
of	IN	O	O
erythropoietin	NN	O	O
from	IN	O	O
what	WP	O	O
is	VBZ	O	O
normally	RB	O	O
a	DT	O	O
noncoding	JJ	O	O
EPO	NNP	O	O
mRNA	NN	O	O
transcribed	VBD	O	O
from	IN	O	O
an	DT	O	O
alternative	JJ	O	O
promoter	NN	O	O
located	VBN	O	O
in	IN	O	O
intron	NN	O	O
1	CD	O	O
.	.	O	O
(	(	O	O
Funded	VBN	O	O
by	IN	O	O
the	DT	O	O
Gebert	NNP	O	O
R	NNP	O	O
f	POS	O	O
Foundation	NNP	O	O
and	CC	O	O
others	NNS	O	O
.	.	O	O

)	)	O	O

loss	NN	B-NegReg	B-NegReg
-	:	I-NegReg	I-NegReg
of	IN	I-NegReg	I-NegReg
-	:	I-NegReg	I-NegReg
function	NN	I-NegReg	I-NegReg
mutation	NN	B-Var	B-Var
IGF1R	NNP	B-Gene	O
crosstalk	NN	B-Reg	O
IGF1R	NNP	B-Gene	O
Wnt	NNP	B-Pathway	O
-	:	I-Pathway	O
catenin	NN	I-Pathway	O
signaling	VBG	I-Pathway	O
pathways	NNS	I-Pathway	O
IGF1R	NNP	O	O
is	VBZ	O	O
a	DT	O	O
ubiquitous	JJ	O	O
receptor	NN	O	O
tyrosine	NN	O	O
kinase	NN	O	O
that	WDT	O	O
plays	VBZ	O	O
critical	JJ	O	O
roles	NNS	O	O
in	IN	O	O
cell	NN	O	O
proliferation	NN	O	O
,	,	O	O
growth	NN	O	O
and	CC	O	O
survival	NN	O	O
.	.	O	O

Clinical	JJ	O	O
studies	NNS	O	O
have	VBP	O	O
demonstrated	VBN	O	O
upregulation	NN	O	O
of	IN	O	O
IGF1R	NNP	O	O
mediated	VBD	O	O
signaling	VBG	O	O
in	IN	O	O
a	DT	O	O
number	NN	O	O
of	IN	O	O
malignancies	NNS	O	O
including	VBG	O	O
colon	NN	O	O
,	,	O	O
breast	NN	O	O
,	,	O	O
and	CC	O	O
lung	NN	O	O
cancers	NNS	O	O
.	.	O	O

Overexpression	NN	O	O
of	IN	O	O
the	DT	O	O
IGF1R	NNP	O	O
in	IN	O	O
these	DT	O	O
malignancies	NNS	O	O
is	VBZ	O	O
associated	VBN	O	O
with	IN	O	O
a	DT	O	O
poor	JJ	O	O
prognosis	NN	O	O
and	CC	O	O
overall	JJ	O	O
survival	NN	O	O
.	.	O	O

IGF1R	NNP	O	O
specific	JJ	O	O
kinase	NN	O	O
inhibitors	NNS	O	O
have	VBP	O	O
failed	VBN	O	O
in	IN	O	O
multiple	JJ	O	O
clinical	JJ	O	O
trials	NNS	O	O
partly	RB	O	O
because	IN	O	O
of	IN	O	O
the	DT	O	O
complex	JJ	O	O
nature	NN	O	O
of	IN	O	O
IGF1R	NNP	O	O
signaling	VBG	O	O
.	.	O	O

Thus	RB	O	O
identifying	VBG	O	O
new	JJ	O	O
binding	VBG	O	O
partners	NNS	O	O
and	CC	O	O
allosteric	JJ	O	O
sites	NNS	O	O
on	IN	O	O
IGF1R	NNP	O	O
are	VBP	O	O
emerging	VBG	O	O
areas	NNS	O	O
of	IN	O	O
research	NN	O	O
.	.	O	O

More	RBR	O	O
recently	RB	O	O
,	,	O	O
IGF1R	NNP	O	O
has	VBZ	O	O
been	VBN	O	O
shown	VBN	O	O
to	TO	O	O
translocate	VB	O	O
into	IN	O	O
the	DT	O	O
nucleus	NN	O	O
and	CC	O	O
perform	VB	O	O
many	JJ	O	O
functions	NNS	O	O
.	.	O	O

In	IN	O	O
this	DT	O	O
study	NN	O	O
,	,	O	O
we	PRP	O	O
generated	VBD	O	O
a	DT	O	O
library	NN	O	O
of	IN	O	O
IGF1R	NNP	O	O
deletion	NN	O	O
and	CC	O	O
point	NN	O	O
mutants	NNS	O	O
to	TO	O	O
examine	VB	O	O
IGF1R	NNP	O	O
subcellular	JJ	O	O
localization	NN	O	O
and	CC	O	O
activation	NN	O	O
of	IN	O	O
downstream	NN	O	O
signaling	VBG	O	O
pathways	NNS	O	O
.	.	O	O

We	PRP	O	O
show	VBP	O	O
that	IN	O	O
the	DT	O	O
nuclear	JJ	O	O
localization	NN	O	O
of	IN	O	O
IGF1R	NNP	O	O
is	VBZ	O	O
primarily	RB	O	O
defined	VBN	O	O
by	IN	O	O
its	PRP$	O	O
cytoplasmic	JJ	O	O
domain	NN	O	O
.	.	O	O

We	PRP	O	O
identified	VBD	O	O
a	DT	O	O
cross	NN	O	O
-	:	O	O
talk	NN	O	O
between	IN	O	O
IGF1R	NNP	O	O
and	CC	O	O
Wnt	NNP	O	O
-	:	O	O
catenin	NN	O	O
signaling	VBG	O	O
pathways	NNS	O	O
and	CC	O	O
showed	VBD	O	O
,	,	O	O
for	IN	O	O
the	DT	O	O
first	JJ	O	O
time	NN	O	O
,	,	O	O
that	IN	O	O
IGF1R	NNP	O	O
is	VBZ	O	O
associated	VBN	O	O
with	IN	O	O
upregulation	NN	O	O
of	IN	O	O
TCF	NNP	O	O
-	:	O	O
mediated	VBD	O	O
-	:	O	O
catenin	NN	O	O
transcriptional	JJ	O	O
activity	NN	O	O
.	.	O	O

Using	VBG	O	O
loss	NN	O	O
-	:	O	O
of	IN	O	O
-	:	O	O
function	NN	O	O
mutants	NNS	O	O
,	,	O	O
deletion	NN	O	O
analysis	NN	O	O
and	CC	O	O
IGF1R	NNP	O	O
specific	JJ	O	O
inhibitor	NN	O	O
(	(	O	O
s	NN	O	O
)	)	O	O
,	,	O	O
we	PRP	O	O
show	VBP	O	O
that	IN	O	O
cytoplasmic	JJ	O	O
and	CC	O	O
nuclear	JJ	O	O
activities	NNS	O	O
are	VBP	O	O
two	CD	O	O
independent	JJ	O	O
functions	NNS	O	O
of	IN	O	O
IGF1R	NNP	O	O
.	.	O	O

Furthermore	RB	O	O
,	,	O	O
we	PRP	O	O
identified	VBD	O	O
a	DT	O	O
unique	JJ	O	O
loss	NN	O	O
-	:	O	O
of	IN	O	O
-	:	O	O
function	NN	O	O
mutation	NN	O	O
in	IN	O	O
IGF1R	NNP	O	O
.	.	O	O

This	DT	O	O
unique	JJ	O	O
loss	NN	O	O
-	:	O	O
of	IN	O	O
-	:	O	O
function	NN	O	O
mutant	NN	O	O
retains	VBZ	O	O
only	RB	O	O
nuclear	JJ	O	O
functions	NNS	O	O
and	CC	O	O
sits	NNS	O	O
in	IN	O	O
a	DT	O	O
pocket	NN	O	O
,	,	O	O
outside	JJ	O	O
ATP	NNP	O	O
and	CC	O	O
substrate	VB	O	B-MPA
binding	JJ	O	I-MPA
region	NN	O	I-MPA
,	,	O	O
that	WDT	O	O
is	VBZ	O	O
suited	VBN	O	O
for	IN	O	O
designing	VBG	O	O
allosteric	JJ	O	O
inhibitors	NNS	O	O
of	IN	O	O
IGF1R	NNP	O	O

mutations	NNS	B-Var	B-Var
p53	NN	B-Gene	B-Gene
inactivation	NN	B-PosReg	B-Var
wildtype	JJ	B-MPA	O
functions	NNS	I-MPA	O
elicits	VBZ	B-Reg	O
interactions	NNS	B-Interaction	B-Interaction
promote	VBP	B-PosReg	B-PosReg
malignancy	NN	B-Disease	B-Var
mutant	JJ	B-Var	B-Var
p53	NN	B-Gene	B-Gene
gain	NN	B-PosReg	B-PosReg
-	:	I-PosReg	I-PosReg
of	IN	I-PosReg	I-PosReg
-	:	I-PosReg	I-PosReg
function	NN	I-PosReg	I-PosReg
R273C	NNP	B-Var	B-Var
R175H	NNP	B-Var	O
p53	NN	B-Gene	O
exhibited	VBD	B-Reg	O
structural	JJ	B-Var	O
distortion	NN	I-Var	O
reduced	JJ	B-NegReg	O
flexibility	NN	B-MPA	O
In	IN	O	O
addition	NN	O	O
,	,	O	O
surface	NN	O	O
analysis	NN	O	O
revealed	VBD	O	O
an	DT	O	O
increase	NN	O	O
in	IN	O	O
the	DT	O	O
accessible	JJ	O	O
surface	NN	O	O
area	NN	O	O
in	IN	O	O
the	DT	O	O
p53	NN	O	O
mutants	NNS	O	O
.	.	O	O

This	DT	O	O
suggests	VBZ	O	O
that	IN	O	O
the	DT	O	O
GOF	NNP	O	O
transition	NN	O	O
involves	VBZ	O	O
protein	JJ	O	O
unfolding	NN	O	O
and	CC	O	O
exposure	NN	O	O
of	IN	O	O
buried	VBN	O	O
hydrophobic	JJ	O	O
surface	NN	O	O
essential	JJ	O	O
for	IN	O	O
interaction	NN	O	O
with	IN	O	O
HSF	NNP	O	O
-	:	O	O
1	CD	O	O
oncogenic	JJ	O	O
partner	NN	O	O
and	CC	O	O
wildtype	NN	O	O
p63	NN	O	O
,	,	O	O
and	CC	O	O
p73	JJ	O	O
homologs	NNS	O	O
.	.	O	O

Further	JJ	O	O
validation	NN	O	O
revealed	VBD	O	O
binding	NN	O	O
cavities	NNS	O	O
,	,	O	O
similar	JJ	O	O
in	IN	O	O
the	DT	O	O
mutants	NNS	O	O
but	CC	O	O
dissimilar	JJ	O	O
to	TO	O	O
the	DT	O	O
WT	NNP	O	O
.	.	O	O

Taken	VBN	O	O
together	RB	O	O
,	,	O	O
this	DT	O	O
study	NN	O	O
complements	VBZ	O	O
experimental	JJ	O	O
findings	NNS	O	O
and	CC	O	O
reveals	VBZ	O	O
the	DT	O	O
interplay	NN	O	O
between	IN	O	O
mutation	NN	B-Var	O
-	:	O	O
induced	JJ	B-Reg	O
structural	JJ	B-Var	O
distortion	NN	I-Var	O
,	,	O	O
loss	NN	B-NegReg	B-NegReg
of	IN	O	O
flexibility	NN	B-MPA	O
,	,	O	O
rigidity	NN	B-MPA	O
,	,	O	O
enhanced	VBN	B-PosReg	B-PosReg
stability	NN	B-MPA	B-MPA
,	,	O	O
protein	NN	O	O
unfolding	NN	O	O
and	CC	O	O
ultimately	RB	O	O
,	,	O	O
exposure	NN	O	O
of	IN	O	O
binding	VBG	O	O
surfaces	NNS	O	O
as	IN	O	O
conformational	JJ	O	O
attributes	NNS	O	O
that	IN	O	O
characterize	VBP	O	O
mutP53	JJ	O	O
structure	NN	O	O
-	:	O	O
GOF	NNP	O	O
activities	NNS	O	O
.	.	O	O
This	DT	O	O
insight	NN	O	O
is	VBZ	O	O
,	,	O	O
therefore	RB	O	O
,	,	O	O
of	IN	O	O
great	JJ	O	O
importance	NN	O	O
as	IN	O	O
it	PRP	O	O
opens	VBZ	O	O
up	RP	O	O
a	DT	O	O
novel	JJ	O	O
therapeutic	JJ	O	O
approach	NN	O	O
toward	IN	O	O
the	DT	O	O
structure	NN	O	O
based	VBN	O	O
targeting	NN	O	O
of	IN	O	O
mutP53	NN	O	O
oncogenic	JJ	O	O
involvement	NN	O	O
beyond	IN	O	O
wildtype	JJ	O	O
inactivation	NN	O	O
.	.	O	O

Furthermore	RB	O	O
,	,	O	O
"	NNS	O	O
exposed	VBD	O	O
"	JJ	O	O
binding	NN	O	O
site	NN	O	O
information	NN	O	O
obtained	VBN	O	O
from	IN	O	O
this	DT	O	O
study	NN	O	O
can	MD	O	O
be	VB	O	O
explored	VBN	O	O
for	IN	O	O
structure	NN	O	O
-	:	O	O
based	VBN	O	O
design	NN	O	O
of	IN	O	O
substances	NNS	O	O
best	RB	O	O
described	VBN	O	O
as	IN	O	O
"	JJ	O	O
destabilizers	NNS	O	O
"	VBP	O	O
to	TO	O	O
disrupt	VB	O	O
the	DT	O	O
GOF	NNP	O	O
interaction	NN	O	O
of	IN	O	O
mutp53	NN	O	B-Var

Certain	NNP	O	B-Disease
tumor	NN	O	I-Disease
associated	VBN	O	B-Reg
p53	NN	B-Gene	B-Disease
missense	NN	B-Var	O
mutants	NNS	I-Var	O
acquire	VB	O	O
gain	NN	B-PosReg	O
-	:	I-PosReg	O
of	IN	I-PosReg	O
-	:	I-PosReg	O
function	NN	I-PosReg	O
(	(	O	O
GOF	NNP	O	O
)	)	O	O
properties	NNS	O	O
and	CC	O	O
confer	VB	O	O
oncogenic	JJ	O	O
phenotypes	NNS	O	O
including	VBG	O	O
enhanced	JJ	B-PosReg	B-PosReg
chemoresistance	NN	B-CPA	B-MPA
.	.	O	O
The	DT	O	O
colorectal	NN	O	O
cancers	NNS	O	O
(	(	O	O
CRC	NNP	O	O
)	)	O	O
harboring	VBG	O	O
mutant	JJ	O	B-Var
p53	NN	O	B-Gene
are	VBP	O	O
generally	RB	O	O
aggressive	JJ	O	O
in	IN	O	O
nature	NN	O	O
and	CC	O	O
difficult	JJ	O	O
to	TO	O	O
treat	VB	O	O
.	.	O	O

To	TO	O	O
identify	VB	O	O
a	DT	O	O
potential	JJ	O	O
gene	NN	O	O
expression	NN	O	O
signature	NN	O	O
of	IN	O	O
GOF	NNP	O	O
mutant	NN	O	O
p53	NN	O	O
-	:	O	O
driven	NN	O	O
acquired	VBD	O	O
chemoresistance	NN	O	O
in	IN	O	O
CRC	NNP	O	O
,	,	O	O
we	PRP	O	O
performed	VBD	O	O
transcriptome	JJ	O	O
profiling	NN	O	O
of	IN	O	O
floxuridine	NN	O	O
(	(	O	O
FUdR	NNP	O	O
)	)	O	O
treated	VBD	O	O
SW480	NNP	O	O
cells	NNS	O	O
expressing	VBG	O	O
mutant	JJ	O	O
p53	NN	O	O
(	(	O	O
R273H	NNP	O	O
)	)	O	O
(	(	O	O
GEO	NNP	O	O
:	:	O	O
GSE77533	NNP	O	O
)	)	O	O
.	.	O	O

We	PRP	O	O
obtained	VBD	O	O
several	JJ	O	O
genes	NNS	O	O
differentially	RB	O	O
regulated	VBD	O	O
between	IN	O	O
FUdR	NNP	O	O
treated	VBD	O	O
and	CC	O	O
untreated	JJ	O	O
cells	NNS	O	O
.	.	O	O

Further	RB	O	O
,	,	O	O
functional	JJ	O	O
characterization	NN	O	O
and	CC	O	O
pathway	NN	O	O
analysis	NN	O	O
revealed	VBD	O	O
significant	JJ	O	O
enrichment	NN	O	O
of	IN	O	O
crucial	JJ	O	O
biological	JJ	O	O
processes	NNS	O	O
and	CC	O	O
pathways	NNS	O	O
upon	IN	O	O
FUdR	NNP	O	O
treatment	NN	O	O
in	IN	O	O
SW480	NNP	O	O
cells	NNS	O	O
.	.	O	O

Our	PRP$	O	O
data	NNS	O	O
suggest	VBP	O	O
that	IN	O	O
in	IN	O	O
response	NN	O	O
to	TO	O	O
chemotherapeutics	VB	O	O
treatment	NN	O	O
,	,	O	O
cancer	NN	O	O
cells	NNS	O	O
with	IN	O	O
GOF	NNP	B-PosReg	O
mutant	JJ	B-Var	B-Var
p53	NN	B-Gene	B-Gene
can	MD	O	O
modulate	VB	B-Reg	O
key	JJ	B-Pathway	O
cellular	JJ	I-Pathway	O
pathways	NNS	I-Pathway	O
to	TO	O	O
withstand	VB	B-CPA	O
the	DT	I-CPA	O
cytotoxic	JJ	I-CPA	O
effect	NN	I-CPA	O
of	IN	I-CPA	O
the	DT	I-CPA	O
drugs	NNS	I-CPA	O
.	.	O	O
The	DT	O	O
genes	NNS	O	O
and	CC	O	O
pathways	NNS	O	O
identified	VBN	O	O
in	IN	O	O
the	DT	O	O
present	JJ	O	O
study	NN	O	O
can	MD	O	O
be	VB	O	O
further	RB	O	O
validated	VBN	O	O
and	CC	O	O
targeted	VBN	O	O
for	IN	O	O
better	JJR	O	O
chemotherapy	NN	O	O
response	NN	O	O
in	IN	O	O
colorectal	JJ	O	O
cancer	NN	O	O
patients	NNS	O	O
harboring	VBG	O	O
mutant	JJ	O	O
p53	NN	O	O

